A randomized trial for adults with newly diagnosed acute lymphoblastic leukaemia

Trial Sponsor: University College London
Trial Sponsor no: UCL/08/0167
Trial funder: Cancer Research UK
Funder reference: C27995/A9609
Clinicaltrials.gov no: NCT01085617
EUDRACT no: 2009-012717-22
CTA ref: 20363/0273/001
REC ref: 09/H0711/90

Protocol version & date: Version 5.0 20.07.12

Protocol Version 5.0 (date 20.07.2012) authorised by:

Chief Investigator: Dr Adele Fielding
Senior Lecturer in Haematology

For the Sponsor: Professor Jonathan Ledermann
Director Cancer Research UK & UCL Cancer Trials Centre
FILE NOTE

Re: UKALL14 Protocol v5.0 erratum
Date: 04.02.2014

UKALL14: Updated guidance on hepatitis B screening.

Roche Products Ltd have issued the following recommendations on hepatitis B virus (HBV) screening prior to treatment with Rituximab:

- Screen all patients for HBV before starting treatment with rituximab
- Patients with active hepatitis B disease should not be treated with rituximab
- Refer patients with positive hepatitis B serology (but no active disease) to a liver disease expert before starting treatment with Rituximab. These patients should be monitored and managed following local medical standards to prevent HBV reactivation.

This information will be integrated into section 5.1 (pre-registration and pre-1st-randomisation evaluation (study entry)) of the UKALL14 protocol at the next substantial amendment. In the meantime, sites are expected to adhere to the manufacturer’s recommendations as listed above.

A copy of this file note should be filed with each copy of the protocol held at site.

Signature: 

Date: 04.02.2013
Name: Simon Purnell
Title: Trial Coordinator
**Introduction:**

Cancer Research UK is supporting central coordination through the Cancer Research UK & UCL Cancer Trials Centre (UCL CTC) - the coordinating centre for the trial. Problems relating to this trial should be referred, in the first instance, to the UCL CTC.

This trial will adhere to the principles of ICH Harmonised Tripartite Guideline for Good Clinical Practice (CPMP/ICH/135/95) as set out in Schedule 1 of the Medicines for Human Use (Clinical Trials) Regulations 2004 and the GCP Directive 2005/28/EC, and any amendments thereto. It will be conducted in compliance with the protocol, the Data Protection Act 1998, the Medicines for Human Use (clinical trials) regulations 2004, as amended from time to time, and other regulatory requirements as appropriate.

**Trial contacts:**

Chief Investigator: Dr Adele Fielding  
Address: University College London Medical School  
Royal Free Campus  
Rowland Hill St, London, NW3 2PF  
Phone 0207 830 2833  
Fax 0207 830 2092  
Email a.fielding@ucl.ac.uk

**Trial Management Group (TMG):**

Susan M Richards  
Statistician  
CTSU, Oxford  
David Marks  
Professor of Haematology (UKALL14 Transplant Coordinator)  
Bristol  
Andrew McMillan  
Consultant Haematologist  
Nottingham  
Adele Fielding  
Scientific Correlative studies and Minimal residual disease  
UCL  
Anthony Goldstone  
Professor of Haematology  
UCLH  
Anthony Moorman  
Scientific Correlative studies and Cytogenetics  
Newcastle University  
Clare Rowntree  
Consultant Haematologist  
University Hospital, Wales  
Tobias Menne  
Consultant Haematologist  
The Freeman Hospital  
Anna Osadcow  
Pharmacist  
Royal Free Hospital  
Nia Evans  
Lead Haematology Pharmacist  
University Hospital, Wales  
Paul Smith  
Tumour Group Lead  
UCL CTC  
Jo Gambell  
Senior Trial Coordinator  
UCL CTC  
Simon Purnell  
Trial Coordinator  
UCL CTC  
Bella Patel  
Scientific Correlative studies and Minimal residual disease  
UCL  
William Townsend  
Lymphoma Clinical Fellow  
UCL CTC
**Additional Clinical Coordinators:**

In addition to the Chief Investigator, clinical advice may be obtained from:

- Prof David Marks    Bristol (UKALL14 Transplant Co-ordinator)
- Dr Andrew McMillan   Nottingham
- Dr Clare Rowntree   Cardiff
**Coordinating Centre:**

For general queries, supply of trial documentation and collection of data:

UKALL14 Trial Coordinator  
Cancer Research UK & UCL Cancer Trials Centre  
90 Tottenham Court Road, London, W1T 4TJ  
Tel: +44 (0) 20 7679 9860  
Fax: +44 (0) 20 7679 9861  
Email: ctc.ukall14@ucl.ac.uk

**Sponsor:**

**Name:** University College London  
**Address:** Gower street  
London  
WC1E 6BT

**Sponsor contact:**

**Name:** Senior Clinical Trials Manager or Divisional Manager  
**Position:** Divisional Manager  
**Tel:** 020 7380 9995/6978 (unit admin)  
**Fax:** 020 7380 9937  
**Postal Address:** Joint UCLH and UCL Biomedical Research Unit (1st floor, Maple House)  
Ground Floor, Rosenheim Wing  
25 Grafton Way  
London  
WC1E 5DB
Table of Contents

Introduction: ................................................................................................................ 2
Trial contacts: ............................................................................................................... 2
Trial Management Group (TMG): .................................................................................... 2
Coordinating Centre: ..................................................................................................... 4
Sponsor:....................................................................................................................... 4
Table of Contents .......................................................................................................... 5
1.0 Protocol Summary ........................................................................................... 10
  1.1 Summary of Trial Design ............................................................................. 10
  1.2 Trial schema: .............................................................................................. 13
2.0 Background ........................................................................................................ 14
  2.1 Introduction ................................................................................................ 14
  2.2 Induction therapy for ALL ............................................................................ 14
  2.3 Steroid for induction of ALL ......................................................................... 14
  2.4 Monoclonal antibodies in induction of precursor B lineage ALL ....................... 15
    2.4.1 Anti CD20 antibody: Rituximab ............................................................ 15
  2.5 Nalarabine for induction of T-cell ALL ........................................................... 15
  2.6 Role of L-asparaginase ................................................................................ 16
  2.7 Prophylaxis against Central Nervous System Disease in ALL ...................... 17
  2.8 Role of Haematopoietic Stem Cell Transplantation (HSCT) in adult ALL .......... 18
    2.8.1 Myeloablative conditioning regimen....................................................... 18
    2.8.2 Prevention of oral mucositis – the role of Palifermin .............................. 18
    2.8.3 Reduced intensity conditioning regimens in ALL .................................... 19
    2.8.4 The use of unrelated donors ................................................................ 20
    2.8.5 The source of stem cells ...................................................................... 20
  2.9 Measurement of Minimal Residual Disease (MRD) ......................................... 20
  2.10 Summary of study aims ............................................................................... 22
3.0 Selection of Trial Sites/Site Investigators .......................................................... 23
  3.1 Trial Site selection ....................................................................................... 23
  3.2 Selection of Principal Investigator and other investigators at sites .................. 23
    3.2.1 Training requirements for site staff .............................................................. 23
  3.3 Site set up .................................................................................................. 23
    3.3.1 Site initiation ...................................................................................... 24
    3.3.2 Site activation (UCL CTC responsibility) .............................................. 24
4.0 Informed consent............................................................................................ 25
5.0 Selection of Patients........................................................................................ 26
  5.1 Pre-registration & pre-1st-randomisation evaluation (study entry) .................. 26
  5.2 Patient Eligibility for Study Entry ............................................................... 27
    5.2.1 Patient Inclusion Criteria (study entry) .................................................. 27
    5.2.2 Patient Exclusion Criteria (study entry) ............................................... 27
5.2.3 Management of patients with poor organ function at study entry .......... 27
5.2.4 Pregnancy, Lactation & Birth Control ................................................ 28
5.3 UKALL14 Registration & Randomisation Procedures................................ 29
5.4 Registration & Randomisations (B & T) at study entry .......................... 30
5.5 Pre-transplant evaluation........................................................................ 31
5.6 Patient eligibility for transplant .............................................................. 32
  5.6.1 Inclusion criteria (transplant) ........................................................... 32
  5.6.2 Eligibility for high-risk arm - unrelated donor stem cell transplantation: 32
  5.6.3 Exclusion criteria (transplant) ......................................................... 32
5.7 Procedure for Registration to either maintenance/consolidation or transplant (and Palifermin Randomisation of transplant patients aged ≤ 40 years at study entry) .................. 33
6.0 Initial trial drug supply ........................................................................... 34
7.0 Trial Treatments ..................................................................................... 35
  7.1 Summary of IMPs to be evaluated ...................................................... 35
  7.2 Treatment Schedule ........................................................................... 35
    7.2.1 Recommended supportive care: ................................................... 35
    7.2.2 Steroid pre-phase ......................................................................... 38
    7.2.3 Phase 1 induction ......................................................................... 38
    7.2.4 End of phase 1 induction ............................................................... 41
    7.2.5 Phase 2 induction ......................................................................... 42
    7.2.6 End of phase 2 induction ............................................................... 44
    7.2.7 Intensification/Central nervous system prophylaxis ....................... 45
    7.2.8 Consolidation therapy .................................................................. 47
    7.2.9 Maintenance therapy (non-transplant patients only) ..................... 52
    7.2.10 Transplant conditioning regimens .............................................. 53
    7.2.11 Post-transplant Intrathecal therapy: ........................................... 59
  7.3 Management after treatment withdrawal ............................................. 59
  7.4 Out-of-hours medical care .................................................................... 59
8.0 Assessments ............................................................................................ 60
  8.1 Assessment time points ....................................................................... 60
  8.2 Routine Clinical and Laboratory Assessments during treatment ........... 60
    8.2.1 Schedule of testing for MRD and correlative science testing .......... 61
  8.3 Assessments during follow up ............................................................... 62
9.0 Correlative Science .................................................................................. 63
  9.1 Aim 1. To determine the relationship between CD20 on ALL blasts and response to monoclonal antibody therapy ............................................................... 63
    9.1.1 Background .................................................................................. 63
    9.1.2 Plan of investigation .................................................................... 63
9.2 Aim 2. To determine whether the administration of an anti-B cell monoclonal antibody as part of induction therapy for ALL limits the extent of anti-asparaginase antibody formation and promotes asparagine depletion. ................................................................. 64

9.2.1 Background .................................................................................. 64
9.2.2 Plan of Investigation ...................................................................... 64

9.3 Aim 3. To perform genomic profiling in order to discover and characterise novel prognostic markers and to identify known copy number alterations (CNA). ........................................ 64

9.3.1 Background .................................................................................. 64
9.3.2 Plan of Investigation ...................................................................... 65

9.4 Aim 4. To determine whether the speed at which full donor chimerism is achieved in the T –cell compartment correlates with the level of molecularly determined minimal residual disease. 66

9.4.1 Background .................................................................................. 66
9.4.2 Planned Investigation .................................................................... 66

9.5 Aim 5. Assessment of late effects................................................... 66

9.5.1 Aims .............................................................................................. 66
9.5.2 Background & Planned Investigations ........................................... 66

9.6 Schedule of testing for correlative science studies .............................. 67

10.0 Data Collection & Management .......................................................... 68

10.1 Completing Forms ........................................................................... 68
10.2 Corrections ......................................................................................... 68
10.3 Missing Data .................................................................................... 68
10.4 Queries ............................................................................................... 68
10.5 Submission Timelines ...................................................................... 68
10.6 Archiving of Trial Documentation ..................................................... 68

11.0 Pharmacy .......................................................................................... 69

11.1 Pharmacy responsibilities ................................................................. 69
11.2 Drug accountability .......................................................................... 69

12.0 Pharmacovigilance ........................................................................... 70

12.1 Definitions of Adverse Events ............................................................ 70
12.2 Reporting Procedures ....................................................................... 70
12.2.1 All Adverse Events (AEs) ............................................................... 71
12.2.2 Serious Adverse Events (SAEs) .................................................... 72

12.3 SUSARs ........................................................................................... 75
12.4 Safety Monitoring ............................................................................ 76
12.5 Pregnancy ......................................................................................... 76

12.5.1 Pregnancy Follow-Up Reports ..................................................... 76
12.5.2 SAEs During Pregnancy ............................................................... 76
12.5.3 Pregnancy Report Processing at the UCL CTC .......................... 76

12.6 Development Safety Update Reports (DSURs) ................................. 77
UCL CTC will provide Medac GmbH, Roche, Glaxosmithkline and Swedish Orphan Biovitrum with DSURs that include information regarding the products they supply for the trial. 

13.0 Incident Reporting and Serious Breaches ........................................................................ 78
13.1 Incident Reporting ........................................................................................................ 78
13.2 Serious Breaches ........................................................................................................... 78
14.0 Withdrawal of patients .................................................................................................. 79
15.0 Discontinuation/End of the Trial .................................................................................. 80
  15.1 Trial closure ................................................................................................................ 80
  15.3 Early discontinuation of trial ...................................................................................... 80
  15.4 Withdrawal from trial participation by sites ............................................................... 80
16.0 Trial Monitoring and oversight ..................................................................................... 81
17.0 Statistics ....................................................................................................................... 83
  17.1 Population for analysis .............................................................................................. 83
  17.2 Analysis of the primary objective(s) ......................................................................... 83
  17.3 Analysis of secondary objectives .............................................................................. 84
    17.3.1 Efficacy (secondary) ........................................................................................... 84
    17.3.2 Safety ............................................................................................................... 85
  17.4 Sample size calculations ............................................................................................ 85
  17.5 Power for analysis of critical secondary variables .................................................... 85
  17.6 Interim analysis .......................................................................................................... 86
18.0 Ethical and Regulatory Approvals ................................................................................ 87
  18.1 Ethical Approval .......................................................................................................... 87
  18.2 Regulatory Approval ................................................................................................. 87
  18.3 Site Approvals ........................................................................................................... 87
  18.4 Protocol Amendments ............................................................................................... 88
  18.5 Patient Confidentiality & DPA .................................................................................. 88
  19.1 Sponsor Details: ......................................................................................................... 89
  19.2 Indemnity: .................................................................................................................. 89
20.0 Publication Policy ........................................................................................................... 90
21.0 References .................................................................................................................... 91

Appendix 1: Abbreviations ................................................................................................. 95
Appendix 2: IMP Information ............................................................................................. 98
Appendix 3: Non-IMP General Drug information ............................................................... 103
Appendix 4: Dose modifications for toxicity ..................................................................... 110
Appendix 5: Assessment of GVHD .................................................................................... 113
Appendix 6: Cytogenetic Definitions and Detection Strategy ............................................ 115
Appendix 7: Adult ALL MRD Laboratory and trial schedule ........................................... 117
Appendix 8: Donor Peripheral Blood Stem Cell Collection & Return ................................ 120
Appendix 9: Haematopoietic Cell Transplantation-Specific Comorbidity Index ............... 121
Appendix 10: ECOG performance status .......................................................................... 122
Appendix 11: Schedule of Assessments (including testing for MRD & Correlative Science) 123
Appendix 12: General Health Questionnaire (GHQ-12) ................................................. 125
Appendix 13: Oral Mucositis Daily Questionnaire ................................................................. 127
Appendix 14: Guidance on Use of Erwinia Asparaginase (Erwinase®) in patients with systemic reactions to Pegylated-Asparaginase........................................................................................................ 128
Appendix 15: Guideline for the administration of Intravenous High-Dose Methotrexate 130
Appendix 16: Karnofsky Performance Status ......................................................................... 133
Appendix 17: Protocol Version History .................................................................................. 134
1.0 Protocol Summary

1.1 Summary of Trial Design

<table>
<thead>
<tr>
<th>Title:</th>
<th>A randomized trial for adults with newly diagnosed acute lymphoblastic leukaemia</th>
</tr>
</thead>
<tbody>
<tr>
<td>Short Title:</td>
<td>UKALL14</td>
</tr>
<tr>
<td>EuDRACT No.:</td>
<td>2009-012717-22</td>
</tr>
<tr>
<td>MREC No:</td>
<td>09/H0711/90</td>
</tr>
<tr>
<td>Clinicaltrials.gov No.:</td>
<td>NCT01085617</td>
</tr>
<tr>
<td>UK Sponsor &amp; No:</td>
<td>University College London Cancer Research UK &amp; UCL Cancer Trials Centre 90 Tottenham Court Road, London, W1T 4 TJ, UK tel – +44207 679 9869 email – <a href="mailto:bnli@ctc.ucl.ac.uk">bnli@ctc.ucl.ac.uk</a></td>
</tr>
<tr>
<td>UK Funder &amp; No:</td>
<td>Cancer Research UK 61 Lincoln's Inn Fields, London, WC2A 3PX, UK C27995/A9609</td>
</tr>
<tr>
<td>Design:</td>
<td>Multisite, randomized controlled trial</td>
</tr>
</tbody>
</table>
| Aims: | Aim 1B. (precursor-B lineage) To determine if the addition of Rituximab to standard induction chemotherapy results in improved EFS in patients with precursor B-cell lineage ALL.  
Aim 1T (T lineage) To determine if the addition of nelarabine following standard induction therapy (arms T 1 and T2) improves outcome for patients with T cell ALL.  
Aim 2 To determine the tolerability of pegylated asparaginase in induction (for all patients) and to compare anti-asparaginase antibody levels between patients in the 2 randomisation groups from aim 1B.  
Aim 3 To determine whether risk-adapted introduction of unrelated donor HSCT (myeloablative conditioning in patients aged up to and including 40 years at time of study entry and non-myeloablative conditioning in patients aged greater than 40 years, ie having reached their 41st birthday at time of study entry) result in greater EFS for patients at highest risk of relapse.  
Aim 4 To compare 2 schedules of administration (standard P1 vs., ‘collapsed’ P2) of keratinocyte growth factor (palifermin) for efficacy in preventing the severe mucosal toxicity of etoposide/TBI HSCT conditioning regimen. |
| Primary endpoint: | Event free survival (applies to all interventions)  
Toxicity related to pegylated asparaginase (applies to asparaginase evaluation only)  
Mucositis score by Oral Daily Mucositis Score (ODMQ) (applies to palifermin randomisation only) |
| Secondary endpoints: | Anti-asparaginase antibodies (induction randomisation only)  
Overall Survival  
Complete remission rate  
Minimal residual disease quantification after 1st phase of induction (applies to all patients) and MRD quantification post transplant (applies to the reduced intensity conditioned transplant randomisation only)  
Grade 3/4 graft versus host diseases (applies to transplant patients only)  
Death in complete remission |
**Patients:**

The target overall recruitment is 720 patients with newly diagnosed, untreated acute lymphoblastic leukaemia with or without evidence of Philadelphia chromosome. 20% of patients are expected to be T lineage, so out of a total of 720 patients 144 will be T-lineage and 576 precursor-B-lineage.

**Planned number of sites:**

100

**Target countries:**

United Kingdom and Eire

**Treatment Summary:**

(see also trial schema)

**PHASE 1 & 2**

Treatment for all patients will consist of a steroid pre-phase followed by 2 phases of induction therapy during which novel agents will be tested (precursor-B-lineage: 2 randomisation arms termed B1 and B2 and T lineage ALL 2 randomisation arms termed T1 and T2), as indicated in study aims, above.

**After PHASE 2**

A risk assessment will be carried out for each patient based on presenting characteristics, cytogenetics and minimal residual disease analysis

Patients achieving CR & aged up to and including 40 years at time of study entry with an HLA-matched sibling identified move directly to allogeneic SCT*

For all other patients further therapy depends on risk:

- **Standard Risk:** Continuing chemotherapy based on a modified UKALL12/ECOG2993 schedule (4 cycles of combination chemotherapy and then standard maintenance therapy).
- **High Risk and aged up to and including 40 years at time of study entry** will be allocated to allogeneic SCT with a matched unrelated donor and receive a myeloablative conditioning regimen* (Etoposide-TBI is preferred but Cyclophosphamide can be used.)
- **High risk and aged greater than 40 years (ie having reached 41st birthday at time of study entry)** will be allocated to allogeneic SCT with a matched unrelated donor and receive a reduced intensity conditioning regimen (fludarabine-melphalan +/- alemtuzumab). Intensification with high-dose methotrexate and PEG-ASP similar to the UKALL12/ECOG2993 trial will be given in the reduced intensity conditioned setting.

*All Patients receiving the myeloablative regimen will be randomized between 2 dose schedules of palifermin as detailed in study aims, above.

**Anticipated duration of recruitment:**

Six years

**Duration of patient follow up:**

Until death

**Definition of end of trial:**

Recruitment: 6 years
Active treatment: 2.5 years when maintenance chemotherapy is given
Follow-up: 2 years after the last patient has completed maintenance therapy
The end of the follow-up phase signifies the end of the trial.
| **Correlative Science:** | 1. To determine the relationship between CD20 expression on ALL blasts and response to monoclonal antibody therapy  
2. To determine whether the administration of an anti-B cell monoclonal antibody as part of induction therapy for ALL limits the extent anti-asparaginase antibodies formation and promotes asparagine depletion.  
3. To perform genomic profiling in order to discover and characterise novel prognostic markers and to identify known sub-microscopic copy number alterations (CNA) beyond the resolution of standard diagnostic testing (i.e. cytogenetics and FISH).  
4. To determine whether the speed at which full donor chimerism is achieved in the T-cell compartment correlates with the level of molecularly determined minimal residual disease.  
5. To formally assess the late effects of ALL therapy for all patients on the trial, whether they have received chemotherapy alone or an allograft. |
| **Drug Supply:** | 1. Rituximab – Supplied free of charge from Roche until Rituximab comes off patent at the end of Nov 2013 after which it will be provided from hospital commercial stock.  
2. Nelarabine – Supplied free of charge from Glaxo SmithKline  
3. Palifermin – Supplied free of charge from Biovitrum  
4. Pegylated Asparaginase – Supplied from MEDAC UK (not free of charge)  
All other drugs specified in the protocol must be provided from pharmacy stock at participating sites, see UKALL14 drug supply guidelines for more information. |
1.2 Trial schema:

**UKALL14 TRIAL SCHEMA**

*Phase 1 Induction (4 weeks):* precursor B cell & T cell patients (Philadelphia –ve patients only) to receive Pegylated-Asparaginase plus standard phase 1 induction therapy

- **Pre B-cell ALL**
  - B1: Standard Phase 1 Therapy Alone
  - B2: Standard Phase 1 Therapy + CD20 (Rituximab)

- **T-cell ALL**
  - Standard Phase 1 Therapy

*Phase 2 Induction (4 weeks):* precursor B cell & T cell patients to receive standard phase 2 induction therapy

- **Pre B-cell ALL**
- **T-cell ALL**
  - T1: Standard Phase 2 Therapy
  - T2: Standard Phase 2 Therapy + Nelarabine

**PATIENTS IN COMPLETE REMISSION (CR) – Risk Assessment performed on all patients at this time point**

- **SIBLING DONOR**
  - Over 40 years old
    - Intensification with HD-Methotrexate + PEG-ASP
    - Myeloablative: Conditioning with Etopside-TBI or Cyclophosphamide TBI
    - To receive allo SCT (sibling)

- **40 years and under**
  - Myeloablative: Conditioning with Etopside-TBI or Cyclophosphamide TBI
  - To receive allo SCT (sibling)

- **NO SIBLING DONOR**
  - Over 40 years old
    - Intensification with HD-Methotrexate + PEG-ASP
    - Conditioning regimen with fludarabine-melphalan and Alemtuzumab
    - To receive allo SCT (MUD)

- **40 years and under**
  - Myeloablative: Conditioning with Etopside-TBI or Cyclophosphamide TBI
  - Conditioning regimen with fludarabine-melphalan and Alemtuzumab
  - To receive allo SCT (MUD)

**Randomisation to Palifermin Dose**

- **P1: Standard**
- **P2: Collapsed**

*Age at study entry*
2.0 Background

2.1 Introduction
The treatment of children with acute lymphoblastic leukaemia (ALL) is a shining example of the success of combination chemotherapy in curing malignancy. Results of recent trials suggest that up to 90% of children may be cured of their disease. Adult patients with ALL now have a 90% chance of entering first complete remission (CR) with modern chemotherapy. However, most patients still relapse, and leukaemia-free survival with three to seven years of follow-up is only 30-40%. The poor outcome of chemotherapy in adults with ALL as compared to children relates to multiple factors, some of which are known (e.g. adults have a higher incidence of poor prognostic subtypes such as Ph+ /t(9;22)/BCR-ABL ALL and a lower incidence of favourable subtypes such as t(12;21)(p13;q22)/ETV6-RUNX1 and high hyperdiploidy) but others, are unknown.

2.2 Induction therapy for ALL
The primary goal of induction therapy is a complete eradication of ALL cells from blood, bone marrow and CNS or other extramedullary sites (when initially involved). This should be achieved in as many patients and as early as possible, and with as few toxic side effects as possible, in order to start rapidly the postremission consolidation. For Ph- ALL, induction therapy involve three sequential, connected steps, a pre-phase, induction I and induction II with the latter applied regardless of CR after induction I. Many examples of highly effective induction protocols have been reported with CR rates of 90% or more. Because of the complexity of existing induction regimens and the fact that it is already possible to obtain a CR in 90% or more of unselected patients, the evaluation of any new treatment element will also have to evaluate alternative endpoints as early surrogate marker of long-term response. The induction regimen used in this protocol is based on that used in UKALLXII/ECOG2993 with some modifications some of which are rooted in changes in practice since the design of UKALLXII and some of which comprise the questions to be asked.

2.3 Steroid for induction of ALL
Corticosteroids are one of the most important drugs in the treatment of ALL, and recent trials in paediatric ALL patients have suggested that the use of dexamethasone, as opposed to prednisolone may improve outcome. This is based on data suggesting that dexamethasone has greater in vitro anti-leukaemia activity than prednisolone, better penetration of the CNS and causes fewer thromboembolic events. Randomized trials have demonstrated improved survival in children receiving dexamethasone as opposed to prednisolone, although this has not been shown in every study. Based on these data this trial will substitute a discontinuous schedule of dexamethasone for prednisolone during induction.
2.4 Monoclonal antibodies in induction of precursor B lineage ALL

2.4.1 Anti CD20 antibody: Rituximab

Rituximab, a chimeric IgG-1 anti-CD20 monoclonal antibody, has found ever expanding uses since its approval by the FDA in 1997. When combined with CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma, the combination of chemotherapy with rituximab was shown to have an overall survival advantage.66

Rituximab has been combined with chemotherapy in a wide range of schedules of Lymphoma therapy without any evidence of increased toxicity.

CD20 is expressed on nearly 70% of pre-B ALL cells, although at lower intensity than in non-Hodgkin lymphoma or chronic lymphocytic leukaemia (E. Paietta, personal communication). The ability to combine rituximab with chemotherapy in the treatment of lymphoma and the expression of CD20 in ALL of B cell precursor-cell type has led to the use of rituximab in the treatment of B cell precursor ALL in case reports and smaller case series 5,6.

A recent report of 28 patients with adult-Burkitt-type lymphoma and ALL (B-ALL) suggested an advantage with a Hyper-CVAD plus rituximab compared to historical controls treated with hyper CVAD alone. Hyper-CVAD and rituximab have also been combined for treatment of B cell precursor-ALL patients. The addition of rituximab to Hyper-CVAD appeared to improve disease-free survival in CD20-positive patients compared to historical controls treated with Hyper-CVAD alone 7. These data are encouraging enough to warrant a randomized trial comparing chemotherapy with or without rituximab in induction for newly diagnosed patients with bcr-abl negative B cell precursor-ALL. This data has recently been updated with longer follow up at the American Society of Haematology meeting December 2008.

The expression of CD20 and CD22 on ALL blasts varies widely (E. Paietta, personal communication) CD20 is less commonly or less highly expressed on B-ALL blasts than some other B cell antigens. However, there is accumulating evidence that it is of prognostic significance. No data in ALL - or other tumour types - are available to define the relationship between antigen expression and response and suggest a threshold level for response. Particularly intriguing in this regard is a recent demonstration that the relatively modest expression level of CD20 at diagnosis was often dramatically up-regulated, both in numbers of cells expressing the antigen and levels of expression per cell, following induction chemotherapy. This was shown in vitro to occur on exposure to glucocorticoids, and correlated well with in-vitro rituximab-induced killing9.

We propose to compare the efficacy and toxicity of induction chemotherapy in ALL alone or in combination with Rituximab.

2.5 Nelarabine for induction of T-cell ALL

Guanine arabinoside (ara-G) was first synthesized in 1964 and subsequently shown to have pre-clinical activity against human T cell lymphoid malignancies. A pro-drug with increased solubility, known as compound 506U78, was developed. A phase I study was carried out in 93 patients with refractory haematologic malignancies utilizing a daily one-hour intravenous infusion schedule of administration for five days. Doses ranging from 5 to 75 mg/kg/day were given with dose-limiting neurotoxicity encountered at the dose of 75 mg/kg/day. One patient each had grade 3 neurotoxicity at doses of 20 and 60 mg/kg/day. Maximum tolerated doses were defined as 40
mg/kg/day in adults and 60 mg/kg/day in children. To facilitate future phase II studies, dosing was converted to doses given per m² of body surface area during the study and it was projected that 1.2 grams/m²/day (approximately 30 mg/kg/day in adults and 40 mg/kg/day in children) would be a reasonable phase II dose. Both central and peripheral neurotoxicity were the main toxicities seen and were largely reversible. A subsequent phase II study of nelarabine conducted by the Children's Oncology Group (COG) in patients with refractory T cell malignancies treated four groups of patients: first bone marrow (BM) relapse, second or greater BM relapse, central nervous system (CNS) relapse and extramedullary (EM) relapse. An initial dose of 1.2 grams/m²/day for five days was chosen, but was de-escalated to 900 mg/m²/day and then to 650 mg/m²/day because of severe neurotoxicity. The third and fourth groups with CNS and EM relapse were treated with 400 mg/m²/day to obtain pilot response data with the anticipation that this dose might be utilized in combination with chemotherapy in future trials. Complete plus partial response rates in the four groups were 55% (first BM relapse), 27% (second BM relapse), 33% (CNS relapse) and 14% (EM relapse). Neurological events of grade 3 or greater were seen in 18% of patients. The COG has recently reported the safety and feasibility of combining nelarabine at a doses of both 650 and 400 mg/m²/day for five days with an intensive modified BFM regimen in children with T cell precursor ALL. A cohort of patients on the study was treated without nelarabine. Neurological and non-neurological toxicities were similar between the two dose levels of nelarabine and those treated without nelarabine. A phase III trial of nelarabine in combination with augmented BFM chemotherapy in consolidation therapy in newly diagnosed intermediate and high-risk children and young adults with T-ALL has recently opened in COG (AALL0434). A study in adults showed approximately 30% response in relapsed and resistant ALL with neurotoxicity being minimal and haematological toxicity being the most common. In the present trial we propose to add a course of nelarabine to induction in a randomized fashion following phase II of induction therapy in patients with T-ALL.

2.6 Role of L-asparaginase

L-asparaginase is arguably one of the most valuable drugs in the treatment of ALL. However, it is associated with numerous toxicities including hepatic dysfunction, pancreatitis and thrombohaemorrhagic complications related to depletion of coagulation factors. An additional complicating feature of the use of L-asparaginase clinically is the development of antibodies to the enzyme that can either result in hypersensitivity reactions (IgE) or via neutralising antibodies (IgG) decrease in enzyme activity with loss of therapeutic efficacy. Neutralizing antibodies developing in the absence of a clinical reaction is known as silent inactivation. When toxicity occurs early in treatment, therapeutic delays are often generated which can compromise the aims of therapy. The appropriate dose, preparation and formulation of L-asp remain unresolved. In paediatric practice, pegylated L-asp (peg-asp) is less immunogenic and gives the most appropriate pharmacokinetic and pharmacodynamics but evidence that this agent could be properly used in adults was lacking until a recent CALGB phase II study used peg-asp as part of a multi-agent regimen. Effective asp depletion was achieved in some adults although increasing age was associated with significantly decreased peg-asp doses and less asparagine depletion. Furthermore, there was still a significant number of patients who developed anti-asparaginase antibodies; this correlated with a less successful asparagine depletion. Within the associated clinical study UKALL14, peg-asp will be administered to adults for the first time in a large phase 3 setting.

L-asparaginase is prepared from bacterial sources of either Escherichia coli or Erwinia chrysanthemi. E Coli asparaginase is available either as a native asparaginase or conjugated to polyethylene glycol (peg-asp). Pegylation
extends the half-life and lessens the frequency of injections. The use of PEG-ASP has been compared to the Ecolab native asparaginase preparation in two randomized trials. In the DFCI 91-01 study, patients were randomized to receive PEG-ASP 2500 IU/m² every other week for 15 doses or E. coli asparaginase 25,000 IU/m² every week for 30 doses in intensification. Event-free survival and toxicities were similar between the two asparaginase arms. A CCG trial compared PEG-ASP 2500 IU/m² on day 3 of induction to nine doses of native E. coli asparaginase, 6000 IU/m² every 3 days in induction and found a lower rate of high titre antibody formation with PEG-ASP, but similar rates of adverse events and similar EFS. Recent data from the CALGB has shown that effective asparagine depletion with PEG-ASP results in improved outcomes compared with patients not achieving effective asparagine depletion.

Based on these and other data, we propose to evaluate the treatment of patients in this study with PEG-ASP and ask specific questions about the toxicity and some scientific questions about asparagine depletion and anti-asparaginase antibody formation. Because of regulatory restrictions two different forms of PEG-ASP will be used in this study, the Medac product in the United Kingdom and the Enzon product in the United States. The precise relative efficacy of the two products is not known so doses will be chosen based on published reports of the use of each respective product.

In the case of hypersensitivity to peg-asp, Erwina asparaginase should be substituted at a dose of 20,000 units/m² IM (x6 doses) as a replacement for each scheduled dose of PEG-asparaginase. Please see appendix 14 for further guidance.

2.7 Prophylaxis against Central Nervous System Disease in ALL

The presence of leukaemic blasts in the central nervous system (CNS) is a more frequent occurrence in patients with ALL than AML and the importance of prophylactic treatment to prevent the development of progression to the CNS has long been recognized. The results of therapy in patients with CNS involvement at diagnosis in the current MRC UK ALL XII/ECOG E2993 trial have recently been published. Seventy-seven of 1508 (5%) patients had CNS involvement at diagnosis. The incidence is higher in patients with T cell ALL. Of these 77 patients, 69 (90%) achieved complete remission. This study has demonstrated that, while long-term disease-free survival is attainable in patients who present with CNS involvement, overall survival at five years was inferior at 29% compared to 38% for patients without CNS involvement (p=0.03).

The role of prophylactic cranial irradiation in the era of combined intrathecal and high-dose systemic therapy has been questioned in recent studies with the stated intent of reducing the risk of late sequelae. This has been of particular interest to paediatricians and trials in children have demonstrated that CNS irradiation can be eliminated without worsening overall outcome. In adults several trials have reported CNS recurrence rates less than 10% with the combined use of high dose systemic and intrathecal chemotherapy without the use of cranial irradiation. In the UKALL XII/E2993 the risk of CNS recurrence was 4%. We propose to discontinue the use of cranial irradiation in the trial proposed here, but will plan to perform interim analyses to detect any increase in CNS recurrence rate.
2.8 Role of Haematopoietic Stem Cell Transplantation (HSCT) in adult ALL

Numerous trials have been conducted incorporating autologous and allogeneic SCT into the treatment algorithm. These trials, while varying in design, have generally demonstrated that allogeneic transplant is more effective than autologous transplant or chemotherapy in either high-risk patients or in all patients treated.

One of the most important analyses was the comparison of the outcome of Ph- patients assigned to HLA-matched sibling SCT compared to patients randomized to autologous SCT or chemotherapy (so-called donor vs. no donor analysis) in UKALLXI/E 2993. In a comparison of 389 patients with a donor to 530 patients without a donor, the donor groups had superior EFS (50% versus 41%, p=0.009) and OS (53% versus 45%, p=0.02). A similar statistically significant benefit was seen when the no donor group was restricted to those who were randomized to the chemotherapy arm only. Of importance, this benefit was primarily seen in the standard risk patients (OS 63% for donor versus 51% for no donor patients, p=0.01), but not in high-risk patients (OS 40% versus 36%, p=0.6). The lack of difference in outcomes between donor and no donor patients in the high-risk group were related to a high non-relapse mortality of 39% at two years (20% at two years for the standard risk patients) which in large part was seen in older patients. An additional justification for considering allogeneic SCT in first CR is the dismal outcome of patients who relapse from first CR in the current UKALLXI/E2993 trial with an overall survival at 5 years of 7%.

Hence allogeneic transplant is currently the treatment of choice for eligible adults in first complete remission (CR1). At present, a group of adults with ALL in whom the risk of relapse is less than the risk of sibling allogeneic SCT cannot be defined. Accordingly, this study continues to propose sibling allogeneic SCT for every eligible patient where a sibling donor is available.

2.8.1 Myeloablative conditioning regimen

The “Stanford” conditioning regimen of high dose etoposide and total body irradiation (TBI) was originally chosen for UKALLXI/E2993 as it offered the best published results in SCT for ALL. There are no randomized controlled studies comparing conditioning regimens. Best available evidence is a retrospective analysis of IBMTR data. This suggests no difference in relapse risk or OS between conditioning regimens containing cyclophosphamide and etoposide when patients are transplanted in CR1, while there was an advantage to etoposide and higher doses of TBI in patients transplanted in CR2. There is now considerable experience with the use of the etoposide/TBI regimen among centres carrying out allogeneic SCT for ALL, the appropriate course of action is to continue to use the etoposide-TBI conditioning regimen for this study in patients under the age of 40. Since the major acute toxicity of this regimen is severe mucositis, attempts to reduce the incidence of mucositis are warranted and this will be a study question – aim 4.

2.8.2 Prevention of oral mucositis - the role of Palifermin

The development of palifermin and demonstration of its efficacy in reducing the incidence and severity of oral mucositis following a TBI-containing conditioning regimen in the autologous setting has generated considerable interest in the BMT community. However, the schedule of administration of palifermin is cumbersome in that it mandates administration of three doses prior to initiation of the conditioning regimen. Palifermin has been tested in the setting of allogeneic BMT in a phase I/II study and shown to be safe. The etoposide-TBI regimen to be
utilized in this study has considerable anti-leukaemic efficacy, but is associated with a 100% incidence of grade 3-4 mucositis. This toxicity has an important consequence for GVHD prophylaxis as most patients cannot receive all 4 planned methotrexate (MTX) doses required for the standard cyclosporin and short course MTX GVHD prophylaxis regimen. Two major studies confirm the importance of MTX dose delivery \(^{34,35}\), in preventing severe acute GVHD, which is an important cause of mortality that can affect transplant outcome. Preliminary data suggest that a ‘collapsed dose’ of Palifermin is as effective as the standard administration schedule. There are some phase 2 data and data from murine models, which also suggest the hypothesis that a collapsed schedule may be more effective. A randomized comparison of standard (6 doses) versus ‘collapsed’ (4 doses) will be incorporated into the current trial in combination with the etoposide-TBI-containing regimen in an attempt to reduce the morbidity and mortality of this intensive regimen.

2.8.3 Reduced intensity conditioning regimens in ALL

The current UKALLXII/E2993 trial confirmed the benefit of allogeneic SCT in inducing a potent GVL effect, but was associated with unacceptable toxicity in older patients. Reduced intensity conditioning SCT (RIC-SCT) has allowed the extension of the use of allogeneic SCT to older and infirm patients. There is a paucity of data on the use of RIC-SCT in the treatment of patients with ALL \(^{37,38}\). These small studies have, however, demonstrated the feasibility of this approach with preservation of a GVL effect.

Most RIC-SCT conditioning regimens combine a purine nucleoside analogue (most commonly fludarabine) to induce potent T cell immunosuppression with low dose TBI or an alkylating agent such as cyclophosphamide or melphalan with additional immunosuppression with antithymocyte globulin or alemtuzumab \(^{39}\). The fludarabine-melphalan regimen has been extensively used for RIC-SCT for both myeloid and lymphoid malignancies and shown antitumor activity with acceptable toxicity \(^{40-42}\). Recent data from the City of Hope National Medical Centre reported on 21 patients primarily consisting of patients with high risk ALL in first or more advanced stages of remission who were not eligible for conventional BMT and received a conditioning regimen of fludarabine and melphalan combined with a matched related (33%) or unrelated (67%) donor allograft. With 17 months of follow-up, the one year cumulative probability of overall or disease-free survival and relapse were 77%, 71% and 8%, respectively. The incidence of acute GVHD, grades II-IV and III-IV, were 50% and 15%, respectively. The 100-day non-relapse mortality was 10%. In the United Kingdom, alemtuzumab has been combined with fludarabine and melphalan to help ensure engraftment of donor cells and reduce the risk of GVHD. These studies have shown low rates of 100 day non-relapse mortality (<15%) with low rates of acute GVHD, grades III-IV, of <10%), but a significant incidence of viral and fungal infections \(^{40-42}\). This trial will include a phase II sub-study of a fludarabine-melphalan-alemtuzumab regimen for RIC-SCT with either related or unrelated donors for patients over the age of 40 to determine if we can retain a GVL effect in older adults while reducing non-relapse mortality. The cut-off age of 40 years was based on a combination of data from UKALLXII/ECOG2993 and informed opinion from the transplant communities in the UK and the USA.

Please note that as patients receiving reduced intensity Conditioning regimens DO NOT receive TBI there is a need to maintain appropriate CNS directed therapy. These patients will therefore receive 8 x 3 monthly intrathecal methotexate injections at a dose of 12 mg (total dose) for 2 years post transplant starting at 3 months post transplant - see section 7.2.11.
2.8.4 The use of unrelated donors

Evidence has accumulated to suggest that risk of MUD allogeneic SCT for patients with ALL is now not much greater than risk of sibling allogeneic SCT\(^45,\)\(^38\). The outcome for patients at high risk of relapse is sufficiently poor that an evaluation of MUD allogeneic SCT is proposed for those patients deemed to be at the highest risk of relapse. In the UKALLXII/E2993 trial, only those patients with Ph- ALL were deemed to be at high enough risk for relapse to warrant the risk of MUD allogeneic SCT. In the current study, other high-risk factors confirmed both by data from UKALLXII/E2993\(^46,\)\(^47\) and from other published studies have been introduced. Patients older than age 40, those with precursor B cell disease with WBC >30 \(\times 10^9/L\) or T cell precursor disease with WBC>100 \(\times 10^9/L\) or the presence of high-risk cytogenetic abnormalities; Philadelphia chromosome/t(9;22)(q34;q11)/BCR-ABL1, t(4;11), low hypodiploidy/near triploidy and complex karyotype, will each confer “high-risk”.

2.8.5 The source of stem cells

Peripheral blood stem cells have a number of advantages compared to bone marrow in the setting of related donor allogeneic SCT. They result in faster haematopoietic recovery and shorter length of hospitalization but may also result in a higher incidence of chronic graft versus host disease\(^48,\)\(^49\). Larger patients (>80 kg) should certainly receive peripheral blood stem cells as first preference. There is no evidence that for patients in first remission that peripheral blood stem cells result in superior survival to bone marrow and therefore no recommendation can be made with regard to stem cell source in the sibling donor setting. When peripheral blood stem cells are used a more prolonged period of immunosuppression for GVHD prophylaxis should be considered and careful monitoring for chronic graft versus host disease should occur.

Controversy exists over the preferred source of stem cells for matched unrelated donor (MUD) allogeneic SCT for ALL due to a retrospective analysis of European registry data, which suggested that survival after MUD allogeneic SCT for ALL may be reduced by the use of PBSC as compared to BM\(^50\). The survival advantage for BM in this study related to both procedure related mortality and relapse risk. The preferred source of stem cell for MUD allogeneic SCT may be BM, but in the absence of confirmatory prospective data, PBSC remain acceptable.

2.9 Measurement of Minimal Residual Disease (MRD)

Despite the identification of the risk factors described above, many patients with ALL with or without high-risk features still relapse. These relapses presumably occur as a result of minimal residual disease (MRD) not detected by conventional methods of assessing remission status. The introduction of more sensitive molecular techniques to detect MRD in ALL patients and predict their risk of relapse utilizing clonal immunoglobulin or T-cell receptor gene rearrangements have been very effective. In paediatric ALL, the presence of residual disease at the end of induction chemotherapy or at later time points was a powerful predictor of relapse independent of other risk factors\(^52\). In adult ALL, the use of these molecular markers has been introduced more recently and also shown to be of prognostic significance. The German Multi-Centre Study Group for adult ALL has recently published data indicating that patients who have a rapid decline in their minimal residual disease within the first month of therapy had a three-year relapse rate of 0%. Another subset of patients who had MRD detectable until week 16 of therapy had a three-year relapse rate of 94%. Patients in between these two groups had an intermediate risk of 47% Measurement of MRD in a subset of patients in the on-going MRC/ECOG UKALLXII/E2993 trial has also shown evidence of prognostic significance, especially in the pre-B ALL group. The detection of MRD at the end of the
second month of induction therapy appeared to be the most sensitive time point (Patel et al, submitted). Measurement of MRD will be incorporated into the trial presented here to help stratify patients with low risk clinical prognostic features into those who are MRD positive at the end of induction therapy and therefore, re-categorized as high risk and now eligible for allogeneic SCT, and those who are MRD negative who will be treated with consolidation and maintenance chemotherapy and not be allocated to allogeneic SCT. Measurement of MRD will be performed in all patients and correlated with outcome.
2.10 Summary of study aims

Primary
To determine if the addition of monoclonal antibody to standard induction chemotherapy results in improved EFS in patients with precursor B-cell ALL (aim 1B).
To determine if the addition of nelarabine improves outcome for patients with T cell ALL (aim 1T).

Secondary
To determine the tolerability of pegylated asparaginase in induction treatment of all patients (aim 2) and to compare anti-asparaginase antibody levels between patients in the 2 randomisation groups from aim 1B (patients with B lineage ALL only).
To determine whether risk-adapted introduction of unrelated donor HSCT (myeloablative conditioning in patients ≤40 years old and non-myeloablative conditioning in patients >40 years old) results in greater EFS for patients at highest risk of relapse (aim 3).
To compare 2 schedules of administration (standard vs., ‘collapsed’) of keratinocyte growth factor (palifermin) for efficacy in preventing the severe mucosal toxicity of etoposide/TBI HSCT conditioning regimen (aim 4).
To formally assess the late effects of ALL therapy for all patients on the trial, whether they have received chemotherapy alone or an allograft. To identify and describe some of the adverse physical and psychosocial consequences of the disease and its treatment.
3.0 Selection of Trial Sites/ Site Investigators

3.1 Trial Site selection
In this protocol trial ‘site’ refers to the hospital where trial-related activities are conducted.
Sites should be able to comply with:

- Trial treatments, sample collection procedures and follow up schedules
- Research Governance Framework and the Medicines for Human Use (clinical trials) Act (SI 2004/1031)
- The trial protocol
- Data collection requirements.

Each site should also have:

- Haematology Multidisciplinary Team (MDT), which must include a leukaemia specialist
- Transplant centre or a relationship with a referring transplant centre to whom they are prepared to refer every patient for a donor search at diagnosis.
- Transplant centres must be JACIE accredited or working towards JACIE accreditation

3.2 Selection of Principal Investigator and other investigators at sites
Each site must have an appropriate Principal Investigator (PI) ie a health care professional authorised by the site, ethics committee and regulatory authority to lead and coordinate the work of the trial on behalf of the site. Other investigators at site wishing to participate in the trial must be trained and approved by the PI. All investigators must be medical doctors and have experience of treating acute lymphoblastic leukaemia.

3.2.1 Training requirements for site staff
All site staff must be appropriately qualified by education, training and experience to perform the trial related duties allocated to them, which must be recorded on the site delegation log.

CVs for all staff must be kept up-to-date, signed and dated and copies held in the Investigator Site File (ISF). An up-to-date, signed copy of the CV for the PI must be forwarded to UCL CTC upon request.

GCP training is required for all staff responsible for trial activities. The frequency of repeat training may be dictated by the requirements of their employing institution, or 2 yearly where the institution has no policy, and more frequently when there have been updates to the legal or regulatory requirements for the conduct of clinical trials.

3.3 Site set up
The following documentation must be submitted by the site to UCL CTC prior to a site being activated by the UCL CTC trial team:

- All relevant institution approvals (including local NHS permission)
- UKALL14 Site Registration Form and Investigator Registration Forms
- A completed Site Delegation Log that is signed and dated by the PI
• A copy of the PI’s current CV that is signed and dated

Please note: Non-transplant sites will not be activated by UCL CTC until their referring transplant centre has approval.

The UCL CTC trial team will ensure that, for UK sites:
• If the site was not included in the original CSP application, the Part C is updated and the R&D form is resubmitted to CSP (who will notify the lead CLRN of the new site)
• An SSI form is transferred to the site via IRAS
• If the site was not included on the original REC application, a substantial amendment is submitted to and approved by the REC
• If the site was not included on the original CTA application, the CTA is updated and the MHRA notified at the next substantial amendment to the MHRA

In addition, the following agreements must be in place:
• For UK sites: a signed Clinical Trial Site Agreement (CTSA) between the Sponsor and the relevant institution (usually a NHS Trust)
• For non-UK sites: a signed International Clinical Trials Site Agreement (ICTSA).
• For countries with a country coordinating centre (CCC):
  o a signed International Country Coordinating Centre Agreement
  o a signed clinical trial agreement between the CCC and the relevant institution

### 3.3.1 Site initiation

All sites will be required to have a site initiation session before recruitment can begin. Site initiation will take the form of either a site visit or a teleconference involving the trial coordinator and site staff involved in the trial. The exact nature of the site initiation will be agreed between the CTC and site staff.

### 3.3.2 Site activation (UCL CTC responsibility)

Once the UCL CTC trial team has received all required documentation and the site has been initiated, a site activation letter will be issued to the PI, at which point the site may start to approach patients.

Once the site has been activated by UCL CTC, the PI is responsible for ensuring:

• adherence to the most recent version of the protocol;
• all relevant site staff are trained in the protocol requirements;
• appropriate recruitment and medical care of patients in the trial;
• timely completion and return of CRFs (including assessment of all adverse events);
• prompt notification and assessment of all serious adverse events;
• that the site has facilities to provide 24 hour medical advice for trial patients.

Please note: Non-transplant sites will not be activated by UCL CTC until their referring transplant centre has approval.
4.0 Informed consent

Sites are responsible for assessing a patient’s capability to give informed consent.

Sites must ensure that all patients have been given the current approved version of the patient information sheet, are fully informed about the trial and have confirmed their willingness to take part in the trial by signing the current approved consent form. The PI, or, where delegated by the PI, other appropriately trained site staff, are required to provide a full explanation of the trial and all relevant treatment options to each patient prior to trial entry. During these discussions the current approved patient information sheet for the trial should be discussed with the patient. A minimum of twenty four hours must be allowed for the patient to consider and discuss participation in the trial. Written informed consent on the current approved version of the consent form for the trial must be obtained before any trial-specific procedures are conducted. The discussion and consent process must be documented in the patient notes.

Non-UK sites will need to consent patients to the trial according to local practice and regulatory and/or ethical requirements.

Site staff are responsible for:

- checking that the current (current approved) version of the patient information sheet and consent form are used
- checking information on the consent form is complete and legible
- checking that the patient has completed/initialled all relevant sections and signed and dated the form
- checking that an appropriate member of staff has countersigned and dated the consent form to confirm that they provided information to the patient
- checking that an appropriate member of staff has made dated entries in the patient’s medical notes relating to the informed consent process (i.e. information given, consent signed, etc.)
- giving the patient a copy of their signed consent form, patient information sheet, patient diary and patient contact card
- adding details of all consented patients to the informed consent form log
- following registration/randomisation: adding the patient trial number to all copied of the consent forms, which should be filed in the patient’s medical notes and investigator site file

The right of the patient to refuse to participate in the trial without giving reasons must be respected. All patients are free to withdraw at any time from the protocol treatment without giving reasons and without prejudicing further treatment. Any patient’s withdrawal of consent from the trial must be explicitly documented in the source documents and UCL CTC informed. Also refer to section 14 (Withdrawal of Patients).
5.0 Selection of Patients

5.1 Pre-registration & pre-1st-randomisation evaluation (study entry)

All patients will undergo their first randomisation upon registration for the trial and the following assessments and procedures are required prior to registration (please note that there are further assessments & procedures required prior to transplant – see section 5.4)

- Full medical history & physical examination
  - Including cardiac history, any history of mental health issues and employment status pre-ALL diagnosis
    (baseline measurements for the late effects assessment at 2 years follow up in section 8.3)
- Height, Weight & BSA
- Assessment of performance status (ECOG)
- Full blood counts & biochemistry
- Bone marrow aspirate & trephine
- Pregnancy test for all women of childbearing age
- Confirmation of disease diagnosis from bone marrow aspirate (or peripheral blood where there is high presenting WCC) using Immunophenotyping/Flow Cytometry
- Cytogenetic, FISH and molecular genetic analysis on a pre-treatment bone marrow is essential to
  - (a) confirm the presence or absence of the Philadelphia (Ph) chromosome \( t(9;22)(q34;q11) \) \( BCR-ABL1 \). Where patient is Ph pos, imatinib will be administered with the therapy.
  - (b) identify the following high risk abnormalities (refer to Appendix 6 for cytogenetic definitions and detection strategy;
    - Philadelphia chromosome \( t(9;22)(q34;q11) \) \( BCR-ABL1 \)
      - These patients will need imatinib added to therapy
    - \( t(4;11)(q21;q23) \) \( MLL-AF4 \)
      - NB AFF1 was previously known as AF4 and MLLT2
    - low hypodiploidy / near-triploidy (Ho-Tr)
    - complex karyotype (five or more chromosomal abnormalities)
  - These tests are to be performed by the local or regional cytogenetic/genetic laboratory and a copy of the report of all diagnostic and relapse cytogenetic, FISH and genetic testing must be sent to the cytogenetic coordinating centre - the Leukaemia Research Cytogenetics Group (LRCG). See Appendix 6 for contact details.
- The cytogenetic co-ordinating centre (LRCG) may request left-over fixed cell suspension, DNA, RNA or other material from the local genetics laboratory or the treating clinician to undertake further cytogenetic, molecular cytogenetic and genetic testing (including but not restricted to FISH, array CGH and RT-PCR) to refine the definition of known abnormalities and characterise novel subgroups. All these additional tests will be performed with the full knowledge of the CI and clinical coordinators.
- Lumbar puncture is not required at diagnosis except in the case of suspected central nervous system involvement. Otherwise, it should be avoided (in case of traumatic puncture and CNS seeding) until the first dose of intrathecal methotrexate is due, at which time blasts should have been cleared from the peripheral blood. The first lumbar puncture should always be given by the most experienced operator available, to reduce the incidence of traumatic taps.
Please note, as detailed in section 8.2.1 and Appendix 7:

<table>
<thead>
<tr>
<th>Specimens for local assessment</th>
<th>Specimens for correlative studies to be sent to central laboratory (see app 7)*</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>At Diagnosis</strong></td>
<td>Bone marrow 3-5ml in EDTA (OR peripheral blood 30-50ml in EDTA if WCC &gt; 30x 10^9/l). BCR-ABL status will also be checked.</td>
</tr>
<tr>
<td>Cytogenetics/molecular assessment of BCR-ABL and MLL on bone marrow. A copy of the results should be sent to the Leukaemia Research Cytogenetics Group (LRCG) at Newcastle University. (Please refer to Appendix 6 for details of the LRCG) Tissue typing of patient and any siblings to be carried out. Donor search to be initiated if no matched sibling donor available.</td>
<td></td>
</tr>
</tbody>
</table>

5.2 Patient Eligibility for Study Entry

For eligibility for transplantation, see section 5.5

5.2.1 Patient Inclusion Criteria (study entry)

a) Subjects must be aged ≥ 25 and ≤ 65 years old with acute lymphoblastic leukaemia OR ≥ 19 and ≤ 65 years old with Philadelphia Chromosome.

b) Newly diagnosed, previously untreated ALL (a steroid pre-phase of 5-7 days is required and can be started prior to registration)

c) Written informed consent

5.2.2 Patient Exclusion Criteria (study entry)

a) Known HIV infection

b) Pregnant or lactating women

c) Blast transformation of CML

d) Mature B-cell leukemia i.e. Burkitt’s lymphoma t(8;14)(q24;q32) and variant c-myc translocations e.g. t(2;8)(p12 ;q24), t(8;22)(q24;q11)

5.2.3 Management of patients with poor organ function at study entry

In order for the protocol to reflect ‘real-life’ management of ALL, patients with poor organ function at diagnosis are not excluded, but extra care should be taken with their management. If patients present with poor renal or hepatic function, relationship to the presenting condition should be sought; imaging should be performed and liver biopsy could be considered, to seek involvement by ALL. A steroid pre-phase is particularly necessary in such patients to gain clinical improvement and normalisation of renal and/or liver function prior to starting study chemotherapy. In the case of persistently abnormal renal or hepatic function at start of protocol therapy, dose adjustments to the non-IMP chemotherapy drugs should be made according to appendix 4 and in conjunction with local network guidelines. Dose modifications should be recorded on the CRF. Dose modification for IMPs, where necessary, are also indicated in appendix 4. If a patient presents with prior history of poor cardiac function, clinically indicated tests should be performed at site and UCL CTC should be contacted to discuss treatment options within the trial.
5.2.4 Pregnancy, Lactation & Birth Control

Pegylateral Asparaginase
The risks to an embryo or foetus from exposure to Pegylated Asparaginase are currently unknown.

Rituximab
The risks to the human embryo or foetus from exposure to Rituximab are currently unknown. Developmental toxicity studies performed in cynomolgus monkeys revealed no evidence of embryotoxicity in utero. New born offspring of maternal animals exposed to Rituximab were noted to have depleted B-Cell populations during the postnatal phase.

Nelarabine
The risks to the human embryo or foetus from exposure to Nelarabine are currently unknown. Studies in animals have shown reproductive toxicity including malformations (see section 5.3). The potential risk in humans is unknown, however, exposure during pregnancy will likely lead to anomalies and malformations of the foetus.

Palifermin
The risks to the human embryo or foetus from exposure to Palifermin are currently unknown. There are no adequate data from the use of Kepivance in pregnant women. Studies in animals have shown reproductive and developmental toxicity. The potential risk to the human embryo or foetus is unknown. Kepivance should not be used during pregnancy unless clearly necessary.

Pregnancy Testing
All women of childbearing potential who are at risk of becoming pregnant must undergo a pregnancy test before study entry.

A woman of childbearing potential is a sexually mature woman (i.e. any female who has experienced menstrual bleeding) who has not:

- undergone a hysterectomy or bilateral oophorectomy/salpingectomy
- been postmenopausal for 24 consecutive months (i.e. who has had menses at any time in the preceding 24 consecutive months without an alternative medical cause)

Contraceptive Advice
Due to insufficient data the effects of trial treatment during pregnancy and lactation, patients must consent to use one of the following acceptable methods of contraception whilst on trial treatment and for 12 months following the trial.

Acceptable methods of effective contraception for this trial are:

- Established use of oral, injected or implanted hormonal methods of contraception.
- Placement of an intrauterine device (IUD) or intrauterine system (IUS).
- Barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository). The use of barrier contraceptives should always be supplemented with the use of a spermicide. The following should be noted:
  - Failure rates indicate that, when used alone, the diaphragm or condom are not highly effective forms of contraception. Therefore the use of additional spermicides does confer additional theoretical contraceptive protection.
- However, spermicides alone are inefficient at preventing pregnancy when the whole ejaculate is spilled. Therefore, spermicides are not a barrier method of contraception and must not be used alone.

- Male sterilisation (with appropriate post-vasectomy documentation of the absence of sperm in the ejaculate). For female patients, the vasectomised male partners must be the sole partner for that patient. Please note that sterilisation is not usually regarded as completely reliable enough on its own to ensure that pregnancy can never occur.

- Absolute and continuous abstinence: When this is in line with the preferred and usual lifestyle of the patient. Please note that periodic abstinence (e.g. calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.

The method(s) of contraception used must be stated in the patient medical notes.

If a patient or the partner of a male trial patient becomes pregnant during the trial UCL CTC must be informed immediately (See section 12.0 for details on the reporting procedure).

5.3 UKALL14 Registration & Randomisation Procedures

Patients will be registered to the trial at study entry and there are 3 randomisations at different timepoints in the trial, each patient will undergo at least one but no more than 2 randomisations.

All randomisations will be performed at the appropriate timepoint at UCL CTC upon submission of the relevant form by sites.

Sites will be informed by UCL CTC of the randomisation group as follows:

<table>
<thead>
<tr>
<th>Randomisation</th>
<th>Randomisation Timepoint (protocol section)</th>
<th>Patient Group</th>
<th>Randomisation group</th>
<th>Treatment involved</th>
<th>Treatment timepoint</th>
<th>Treatment Protocol section</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>B</strong></td>
<td>Study entry (5.3.1)</td>
<td>Precursor B lineage</td>
<td>B1</td>
<td>Standard Phase 1 induction therapy alone</td>
<td>To be given alongside phase 1 induction therapy</td>
<td>7.2.3b</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>B2</td>
<td>+ Rituximab</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>T</strong></td>
<td>Study entry (5.3.1)</td>
<td>T lineage</td>
<td>T1</td>
<td>Standard Phase 2 induction therapy alone</td>
<td>To be given following Phase 2 induction therapy <em>(withhold randomised drug if current evidence of grade 2 or higher neurotoxicity)</em></td>
<td>7.2.4b</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>T2</td>
<td>+ Nelarabine</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>P</strong></td>
<td>Pre-transplant (5.6)</td>
<td>Patients aged ≤40 at study entry proceeding to transplant</td>
<td>P1</td>
<td>Standard dose Palifermin</td>
<td>To be given prior to &amp; post infusion of donor cells according to schedules provided</td>
<td>7.2.10 (c &amp; d)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>P2</td>
<td>Collapsed dose Palifermin</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Neurological adverse events with the use of NELARABINE*
Severe neurological events have been reported with the use of Nelarabine. These events have included altered mental states including severe somnolence, central nervous system effects including convulsions, and peripheral neuropathy ranging from numbness and paresthesias to motor weakness and paralysis. There have also been reports of events associated with demyelination, and ascending peripheral neuropathies similar in appearance to Guillain-Barr Syndrome. Full recovery from these events has not always occurred with cessation of Nelarabine. Therefore, close monitoring for neurological events is strongly recommended, and Nelarabine must be discontinued at the first sign of neurological events of NCI common Toxicity Grade 2 or greater.

5.4 Registration & Randomisations (B & T) at study entry

a. Please see section 5.7 for the registration to transplant and for randomisation procedure for high risk transplant patients (Randomisation P).

b. Patient registration & randomisation will be performed centrally at the UCL CTC and must be performed prior to commencement of any trial treatment (a steroid pre-phase of 5-7 days is required and can be started prior to study entry).

c. Pre-treatment evaluations should be carried out at sites as detailed in section 5.1.

d. A registration form must be fully completed and faxed to UCL CTC and will be used to confirm patient eligibility at UCL CTC.

e. Initial randomisations (performed via minimisation) (B and T) will be stratified on gender, age (≤40, >40 years old) and WBC ≥30 x 10^9/L (precursor-B), WBC ≥100 x 10^9/L (T-lineage)

f. A trial number and treatment allocation will be assigned and details added to the form. UCL CTC will fax confirmation of the patient’s inclusion in the trial, their trial number and treatment allocation (either B1 or B2, T1 or T2, see table 5.3) to the main contact.

g. Patient specific Case Report Forms (CRFs) to cover phase I and 2 induction therapy will be emailed to the main contact at site.

Registration & Randomisation fax number: +44 (0)20 7679 9861
Office hours: 09:00 to 17:00 (UK Time) Monday to Friday

Once a patient has been registered onto the trial they must be provided with the following:

- A copy of their signed consent form (if not given at time of consent).
- A patient contact card. Site on call contact details for out of hours medical care must be added to this card and patients informed to carry this with them at all times while on the trial.
5.5 Pre-transplant evaluation

Please contact the Transplant co-ordinator (see front of protocol) if you have any queries about the eligibility of a patient for transplant or any other transplant queries.

1. Medical history including allergies, previous chemotherapy, prior radiotherapy, hormonal or immunotherapy and response to treatment, end-organ toxicity and infections.
2. Physical examination.
3. ECOG performance status (Appendix 10).
5. Comorbidity Index (Appendix 9).
6. Full blood count with differential
7. Biochemistry. (to include LDH) Liver and renal function should be assessed as per local practice.
8. Urinalysis.
9. Clotting screen including PT/APTT.
10. Pregnancy test (urine) as clinically indicated.
11. Microbial titers (CMV, HIV I+2, HBsAg, HBcAb, HC, HTLV 1+2, EBV, VZV, TPHA, toxoplasma +/- HSV). Syphilis serology also required.
12. Bone marrow aspirate and trephine biopsy (The bone marrow sample taken at the end of Phase II will be acceptable here as long as there are no significant delays. Please discuss with the transplant co-ordinator for advice if you anticipate a delay.)
13. Cardiac function (to be assessed as per local practice).
14. Pulmonary function (to be assessed as per local practice).
15. DNA specimen from patient and donor should be screened for informative markers for subsequent lineage-specific chimerism studies. Residual DNA should be stored indefinitely.

Please note – as detailed in section 8.2.1 and Appendix 7:

<table>
<thead>
<tr>
<th>Specimens for local assessment</th>
<th>Specimens for correlative studies to be sent to central laboratory (see app 8)*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pre-transplant</td>
<td>20ml Blood in EDTA from donor and recipient for assessment of mini-satellite regions</td>
</tr>
</tbody>
</table>
5.6 Patient eligibility for transplant

5.6.1 Inclusion criteria (transplant)

a. Completion of Phase 1 and Phase 2 treatment within the trial
b. HLA-compatible sibling or unrelated donor (8/8 molecular match at A,B,C and DR. DQ mismatch is permitted.
c. Two subgroups of patients will proceed to transplant:
   i. Any patient with an HLA-compatible sibling donor.
   ii. High Risk patients with a molecularly matched donor at HLA-A,B,C and DR (see 5.5.2)

5.6.2 Eligibility for high-risk arm - unrelated donor stem cell transplantation:

Any one of the factors below makes the patient high-risk

a. Age over 40 years
b. WBC ≥30 x 10^9/L (precursor-B), ≥100 x 10^9/L (T-lineage)
c. Cytogenetics – any one or more of the abnormalities below
   i. t(4;11)(q21;q23)/MLL-AF4
   ii. Low hypodiploidy/near triploidy (30-39 chromosomes / 60-78 chromosomes
   iii. Complex karyotype (five or more chromosomal abnormalities)
   iv. Philadelphia chromosome t(9;22) (q34;q11)/BCR-ABL1 (detected by cytogenetic or molecular methods)

NB. Patients age >40 at time of study entry will be given non-myeloablative conditioning and patients age ≤40 at study entry will be given myeloablative conditioning.

5.6.3 Exclusion criteria (transplant)

a. Relapsed disease
b. Standard risk patients without a sibling donor (these patients will continue chemotherapy consolidation and maintenance)
5.7 **Procedure for Registration to either maintenance/consolidation or transplant (and Palifermin Randomisation of transplant patients aged ≤ 40 years at study entry)**

- Registration to either maintenance/consolidation or transplant (& Palifermin (P) randomisation for the patients aged 40 years and under at time of study entry) will be performed centrally at the UCL CTC and must be performed prior to commencement of any transplant activity.

- Pre-transplant evaluations should be carried out as detailed in section 5.5.

- A maintenance/consolidation registration form or transplant registration form must be fully completed and faxed to UCL CTC and will be used to confirm transplant eligibility at UCL CTC.

- UCL CTC will fax confirmation to the main contact at site of either:
  - Patient not eligible to proceed to transplant and will be treated using consolidation and maintenance as detailed in sections 7.2.8 and 7.2.9.
  - Patient may proceed to transplant (and for those patients receiving a myeloablative transplant, Palifermin treatment allocation: P1 or P2, see table 5.3) as detailed in section 7.2.10.

- Randomisation (performed using minimisation) of myeloablative transplant patients aged 40 years or under at study entry into either P1 or P2 will be stratified by gender, sibling/MUD donor and precursor B lineage/T-lineage.

- Patient specific Case Report Forms (CRFs) will be sent to the main contact at site.

<table>
<thead>
<tr>
<th>Registration &amp; Randomisation fax number:</th>
<th>+44 (0)20 7679 9861</th>
</tr>
</thead>
<tbody>
<tr>
<td>Office hours:</td>
<td>09:00 to 17:00</td>
</tr>
<tr>
<td></td>
<td>(UK Time)</td>
</tr>
<tr>
<td></td>
<td>Monday to Friday</td>
</tr>
</tbody>
</table>
6.0 Initial trial drug supply

For full instructions for drug ordering, delivery and labelling for the UKALL14 trial, please consult the UKALL14 Drug Supply Guidelines.
7.0 Trial Treatments

7.1 Summary of IMPs to be evaluated

For the purpose of this protocol, the IMPs are:

1. Rituximab (supplied by Roche, free of charge, until the patent for Rituximab expires in November 2013, after which this will be supplied from hospital stock.)
2. Pegylated asparaginase (made available for the trial by MEDAC UK via UDG, at sites own cost)
3. Nelarabine (supplied by GlaxoSmithKline, free of charge)
4. Palifermin (supplied by Biovitrum, free of charge)

These drugs will be supplied free of charge except Pegylated asparaginase. All other drugs specified in the protocol are standard treatment for this disease and are not IMP’s and must be provided from pharmacy stock at the participating sites.

Full details of all IMPs and supporting medications are supplied in Appendix 2.

For full instructions for drug ordering, delivery and labelling for the UKALL14 trial, please consult the UKALL14 Drug Supply Guidelines.

7.2 Treatment Schedule

7.2.1 Recommended supportive care:

Allopurinol should be started 24 hours prior to induction chemotherapy and should be continued for a minimum of 5 days. Rasburicase should be considered as an alternative to allopurinol if the white cell count is high i.e. > 100 x 10^9/L or the patient has bulky disease eg. large mediastinal mass or elevated urate at diagnosis.

All patients need prophylaxis against HSV and VZV reactivation. It is recommended that patients are given aciclovir 200mg bd throughout therapy although local policies may be followed.

All patients need prophylaxis against PCP from day zero of induction. The recommended PCP prophylaxis is Co-trimoxazole 960mg bd for 2 days each week, avoiding the day that methotrexate is given when the patient is on maintenance therapy. In the event of the patient being allergic to co-trimoxazole, local policies should be followed but alternative prophylactic agents include nebulised pentamidine or dapsone.

Antifungal prophylaxis is mandatory for all patients on ALL therapy from the time of induction. Azoles must be avoided when the patient is on vincristine. There is no clear evidence to suggest which anti-fungal prophylaxis regimen should be used in this situation but one option is to give AmBisome® 7mg/kg weekly. Local policies may be followed. Azoles can be used safely after phase 1 of induction.

Antifungal prophylaxis is not generally required when a patient is on maintenance therapy unless that patient is deemed to be high risk for fungal disease.

The use of granulocyte colony stimulating factor (G-CSF) is strongly recommended for all patients to hasten neutrophil recovery following induction phases 1 and 2. It can be given as per local policy.
Chugai Pharma UK will provide a 25% retrospective reimbursement in stock for rHuG-CSF (Lenograstim) used within the study period. Please contact medicalaffairs@chugai-pharm.co.uk with regards to making a claim.

Granocyte is available at NHS contract prices through AAH Hospital Service Telephone 0845 607 6699.

Management of thrombosis and haemostasis during L-asparaginase therapy
The coagulation screen will inevitably be deranged during L-asp therapy, but as bleeding is rarely a clinical problem there is no need to treat these changes. There is poor understanding of the coagulation abnormalities associated with the use of L-asp. Previous studies have shown that fresh frozen plasma administration does not improve abnormal coagulation parameters.

Fibrinogen levels are often low. Emerging -as yet unpublished- evidence suggests that administration of fibrinogen concentrates to correct the low fibrinogen can enhance the risk of thrombosis in non-bleeding states. In summary, as per any other abnormal coagulation screen in a patient without bleeding, there is no indication to give any plasma products to correct the changes.

The main clinical problem in patients on L-asp is the high risk of venous thromboembolism (VTE). As per NICE thromboprophylaxis guidelines 92, we recommend the use of thromboprophylaxis - usually low molecular weight heparin- to unwell hospitalised adults who have reduced mobility, provided the platelet count is > 50 x 10⁹/l.

Prophylactic LMWH should be stopped at least 12 hours prior to an invasive procedure.

There is some evidence that maintaining AT levels above 60% is associated with fewer venous thromboses related to L-asp therapy and possibly a better clinical outcome. (54) Antithrombin supplementation is usually achieved by giving antithrombin (AT) concentrates, which are expensive. Currently there is insufficient evidence to make it a requirement within the protocol for thromboprophylaxis, but evidence is stronger for administration in the presence of acute VTE (see below).

Management of thrombosis
VTE occurs in 10-15% of patients receiving L-asp treatment. Acute VTE should be treated with full dose low molecular weight heparin (LMWH) (or unfractionated heparin in those with renal failure or where fast reversal is required e.g. high risk of bleeding or pre-procedure) and the platelet count can be maintained over 50 x 10⁹/l with platelet infusions.

Treatment doses of LMWH should be stopped 24 hours prior to a procedure (4 hours for un-fractionated ). Unfractionated heparin requires regular APTT monitoring to maintain APTT of 2-2.5. LMWH does not require monitoring as it has predictable pharmacokinetics.
Since heparin works as an anticoagulant by potentiating AT 10,000 fold, some patients will be relatively resistant to heparin due to reduced plasma levels of AT caused by L-asp. Ideally AT levels should be monitored and supplemented in those being treated for acute VTE, to obtain maximal effect of the heparin in this critical situation.

We do not recommend that future L-asp must be withheld in those with acute VTE as long as appropriate anticoagulation and AT supplementation can be given.

If expert haemostatic advice is required for an individual patient on protocol, it can be obtained from Professor Beverly Hunt who can be contacted via the trials office or beverley.hunt@dstt.nhs.uk.

All VTEs should be reported as SAEs.

**Methotrexate encephalopathy management:**

- Methotrexate encephalopathy presents with fits, focal neurological deficit or impaired consciousness and occurs within one day to about 3 weeks of exposure to Intrathecal methotrexate. Full recovery is usual.
- Other causes of CNS events should be considered such as sagittal sinus thrombosis or central nervous system involvement with ALL.
- Methotrexate should be discontinued whilst the patient is also receiving cytarabine systemically.
- Re-challenge is possible without recurrence but if recurrence happens, the intrathecal regimen should be changed to cytarabine 50mg in association with 12.5mg hydrocortisone. Local policy may be followed for the hydrocortisone dose if necessary.
7.2.2 Steroid pre-phase
All patients should be treated with a steroid pre-phase of 5-7 days. Study entry is still permissible if the steroid pre-phase has started prior to study registration. The steroid pre-phase consists of Dexamethasone 6mg/m²/d, PO for 5 to 7 days.

7.2.3 Phase 1 induction
Phase 1 induction, weeks 1-4
To be given to all patients regardless of phenotype. Patients with B precursor lineage disease will be randomised to receive either, Rituximab or no antibody (randomisation groups B1 and B2, see table 5.3).
Patients with Philadelphia positive disease should also receive continuous daily Imatinib, PO, starting at 400mg, aiming to escalate to 600mg within 2 weeks, if tolerated.
For schedules see Tables 7.2.3a & 7.2.3b over page
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Daunorubicin</td>
<td>30 mg/ m²</td>
<td>IV</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td>8</td>
<td></td>
<td>15</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vincristine***</td>
<td>1.4mg/ m²</td>
<td>Max 2mg</td>
<td>IV</td>
<td>1</td>
<td></td>
<td>8</td>
<td>15</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dexamethasone**</td>
<td>10mg/ m²</td>
<td>PO</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
<td>8</td>
<td>9</td>
<td>10</td>
<td>11</td>
<td>15</td>
<td>16</td>
<td>17</td>
<td>18</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PEG- asparaginase Philadelphia Positive patients</td>
<td>1000I U/ m²</td>
<td>iv</td>
<td>4*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methotrexate#</td>
<td>12.5mg</td>
<td>Intrathecal</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Methotrexate - Patients with Philadelphia positive disease should also receive continuous daily Methotrexate, PO, starting at 400mg, aiming to escalate to 600mg within 2 weeks, if tolerated. This should be continued until transplant wherever possible.

Notes on lumbar puncture and treatment of established CNS disease:

**Omit Day 4 Pegylated Asparaginase for Philadelphia Negative patients OVER 40. These patients should only receive Day 18 Pegylated Asparaginase.

**Dexamethasone should be capped at 20mg for larger patients

***Do not give azoles as antifungal prophylaxis within 72 hours before or after vincristine.

Notes on lumbar puncture and treatment of established CNS disease:

# Timing of Intrathecal therapy can be moved +/- 3 days to allow administration on specified lists as per local and national guidance.

In the case of traumatic lumbar puncture (> 10 red blood cells per microlitre), patients should be treated as having CNS disease IF they still have blasts within the peripheral blood at the time of occurrence or have blasts in the CSF. In this case and in the case where there is existing evidence of established
CNS disease, intrathecal therapy with methotrexate should be escalated to twice per week and given at this frequency until the cytospin is clear of blasts. Such patients should also receive cranial irradiation, prior to consolidation, if they are not going to receive myeloablative allogeneic transplant.

Table 7.2.3b - B lineage antibody randomisation during Phase I induction

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Rituximab plus phase 1; Arm B2</td>
<td>Rituximab*</td>
<td>375mg/m²</td>
<td>IV</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Rituximab to be given to patients with precursor-B Lineage ALL according to randomisation after chemotherapy.

Please note as detailed in section 8.2.1 and Appendix 7:

During Phase 1 therapy

- Specimens for local assessment
  - 5ml peripheral blood in a serum tube (for Asparaginase activity assay and anti-Asparaginase antibodies) taken on d3 or d4 and d18 (immediately prior to doses 1 and 2 of peg-asp). **Not applicable to Philadelphia positive patients**

  - On the same day (d3 or d4), a 4.5 ml sodium citrate tube should be filled (to the line) to collect plasma. Spin the tube @ 2000G for 5 mins, aliquot serum into 5 eppendorfs and store locally at -80°C if possible or if not, -20°C.

- Specimens for correlative studies to be sent to central laboratory (see app 8)*

  - 5ml peripheral blood in a serum tube (for Asparaginase activity assay and anti-Asparaginase antibodies) taken on d3 or d4 and d18 (immediately prior to doses 1 and 2 of peg-asp). **Not applicable to Philadelphia positive patients**
7.2.4 End of phase 1 induction

Following recovery from phase 1 therapy (neutrophils $0.75 \times 10^9/l$ and platelets to $75 \times 10^9/l$), remission should be confirmed by morphological bone marrow examination (please don’t forget to send a specimen centrally for MRD examination - see section 8.2.1 and Appendix 7 for full details). This is the absolute minimum count recovery needed for adequate assessment of response and of MRD. Hence the bone marrow aspirate to assess MRD may be postponed for a few more days after reaching this level and can be carried out once the patient has been admitted to begin the next course of therapy, to make sure there is adequate cellularity for the end of phase assessment in order to confirm CR with count recovery. **The bone marrow aspirate must be done by day 35 at the latest.** Please indicate the peripheral blood counts on the form when you submit specimens for central analysis.

However, progression to phase 2 should not be delayed more than a few days once haematopoietic recovery has occurred.

If the patient is not in CR at the end of phase 1, swift progression to phase 2 treatment is indicated.

Please note as detailed in section 8.2.1 and Appendix 7:

<table>
<thead>
<tr>
<th>At recovery post Phase 1</th>
<th>Specimens for local assessment</th>
<th>Specimens for correlative studies to be sent to central laboratory (see app 8)*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Bone marrow aspirate for remission assessment locally. Same day local FBC to determine peripheral count.</td>
<td>Bone marrow from biopsy: 3-5ml in EDTA for MRD assessment (IgH/TCR rearrangements for Ph-ALL, BCR-ABL for Ph+ALL)</td>
</tr>
</tbody>
</table>

*If CR has not been achieved by day 35 the bone marrow aspirate should still be done to check that non recovery isn’t due to residual disease.
7.2.5 Phase 2 induction

Phase 2 induction, weeks 5-8 (please see section 7.2.4 for recovery pre-phase 2)

To be given to all patients regardless of phenotype. Patients with T-lineage ALL will be randomised to receive either Nelarabine as an additional course, following phase 2 or no additional treatment.

Patients with Philadelphia positive ALL should also receive continuous daily Imatinib, PO, starting at 400mg, aiming to escalate to 600mg within 2 weeks, if tolerated.

Table 7.2.5a – Phase 2 Induction

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Cyclophosphamide*</td>
<td>1000 mg/ m²</td>
<td>IV</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cytarabine#</td>
<td>75mg/ m²</td>
<td>IV</td>
<td>2</td>
<td>3</td>
<td>4</td>
<td>5</td>
<td>9</td>
<td>10</td>
<td>11</td>
<td>12</td>
<td>16</td>
<td>17</td>
<td>18</td>
<td>19</td>
<td>23</td>
<td>24</td>
<td>25</td>
<td>26</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mercaptopurine</td>
<td>60mg/ m²</td>
<td>PO</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
<td>5</td>
<td>6</td>
<td>7</td>
<td>8</td>
<td>9</td>
<td>10</td>
<td>11</td>
<td>12</td>
<td>13</td>
<td>14</td>
<td>15</td>
<td>16</td>
<td>17</td>
<td>18</td>
<td>19</td>
<td>20</td>
<td>21</td>
<td>22</td>
<td>23</td>
<td>24</td>
<td>25</td>
<td>26</td>
</tr>
<tr>
<td>Methotrexate#</td>
<td>12.5mg</td>
<td>Intrathecal</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

# Timing of Intrathecal therapy can be moved +/- 3 days to allow administration on specified lists as per local and national guidance. Likewise, timing of the cytarabine blocks can be scheduled so that they can take place during the week as long as the full doses are given.

* Cyclophosphamide 1000mg/m² IV over 20-30 minutes on days 1 and 15. Give 125 mls/m²/hour of Dextrose/ Saline for 30 minutes before cyclophosphamide and for 3.5 hours afterwards ie 4 hours in total. Do not add potassium. Mesna is not needed.
Table 7.2.5b - Nelarabine schedule for T lineage patients following phase 2 induction

- Only for patients with T lineage disease randomised to Nelarabine
- Day 1 of Nelarabine treatment should follow immediately on from day 28 of Phase 2 induction. (effectively Day 29 of Phase 2 Induction)
- If patients have current grade 2 or greater neurotoxicity, nelarabine should not be given as randomised and patients should continue to whatever treatment is next scheduled
- If no significant neurotoxicity present as detailed above then Day 1 of Nelarabine Administration should be given the day after Phase 2 Induction has been completed (Day 28).

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Phase II plus Nelarabine: Arm T2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nelarabine</td>
<td>1.5 g/m²</td>
<td>IV</td>
<td>1</td>
<td>3</td>
<td>5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Neurological adverse events**

Severe neurological events have been reported with the use of Nelarabine. These events have included altered mental states including severe somnolence, central nervous system effects including convulsions, and peripheral neuropathy ranging from numbness and paresthesias to motor weakness and paralysis. There have also been reports of events associated with demyelination, and ascending peripheral neuropathies similar in appearance to Guillain-Barr Syndrome. Full recovery from these events has not always occurred with cessation of Nelarabine. Therefore, close monitoring for neurological events is strongly recommended, and Nelarabine must be discontinued at the first sign of neurological events of NCI common Toxicity Grade 2 or greater.
7.2.6 End of phase 2 induction

Following recovery from phase 2 therapy (neutrophils $0.75 \times 10^9$/l and platelets to $75 \times 10^9$/l), remission should be confirmed by morphological bone marrow examination (please don't forget to send a specimen centrally for MRD examination - see section 8.2.1 and Appendix 7 for full details). This is the absolute minimum count recovery needed for adequate assessment of response and of MRD. Hence the bone marrow aspirate to assess MRD may be postponed for a few more days after reaching this level and can be carried out once the patient has been admitted to begin the next course of therapy, to make sure there is adequate cellularity for the end of phase assessment in order to confirm CR with count recovery. Please indicate the peripheral blood counts on the form when you submit specimens for central analysis.

However, progression to intensification or bone marrow transplant should be as swift as possible.

If the patient is not in CR at the end of phase 2, protocol therapy ceases. Please refer to Section 13.0. Advice on non-protocol therapy can be obtained from the CI or one of the clinical coordinators.

Please note as detailed in section 8.2.1 and Appendix 7:

<table>
<thead>
<tr>
<th>Specimens for local assessment</th>
<th>Specimens for correlative studies to be sent to central laboratory (see app 8)*</th>
</tr>
</thead>
<tbody>
<tr>
<td>At recovery post Phase 2</td>
<td>Bone marrow aspirate for remission assessment locally. Same day local FBC to determine peripheral count.</td>
</tr>
</tbody>
</table>
7.2.7 Intensification/ Central nervous system prophylaxis

N.B This may be omitted if a myeloablative transplant is to be carried out but if there are delays in transplant start (> 3 weeks following recovery from phase 2 induction), the patient should continue with per-protocol intensification. If there are still delays in donor procurement following intensification, the patient should not be left without any anti-leukaemia therapy. Depending on the projected duration of delay, either 2 monthly cycles of interim maintenance therapy should be given (as per maintenance phase of this protocol, with vincristine and steroid and an intrathecal MTX given each month) OR if anticipated delay is longer than 2 months, patients should instead receive the first cycle of consolidation therapy.

The initial Creatinine Clearance before starting methotrexate should ideally be > 100 mls/minute. Dose reductions must be made if the Cr Cl is < 80 mls /min. Treatment to begin upon recovery from induction phase 2.

Patients with Philadelphia positive disease should also receive continuous daily Imatinib, PO, starting at 400mg, aiming to escalate to 600mg within 2 weeks, if tolerated.

For schedule see Tables 7.2.7 overpage
Table 7.2.7 - Intensification/ CNS prophylaxis

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Methotrexate*</td>
<td>3 g/m²</td>
<td>IV</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PEG- asparaginase**</td>
<td>1000IU/m²</td>
<td>IV</td>
<td>2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Imatinib - Patients with Philadelphia positive disease should also receive continuous daily Imatinib, PO, starting at 400mg, aiming to escalate to 600mg within 2 weeks, if tolerated. This should be continued until transplant wherever possible</td>
<td>1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Please consult appendix 15 for full guidance on administration of High Dose MTX - (please note: after treatment with methotrexate, folinic acid rescue must be given. Please see Appendix 15 for details).

**Please note as detailed in section 8.2.1 and Appendix 7:

<table>
<thead>
<tr>
<th>Specimens for local assessment</th>
<th>Specimens for correlative studies to be sent to central laboratory (see app 8)*</th>
</tr>
</thead>
<tbody>
<tr>
<td>During intensification:</td>
<td>5ml peripheral blood in a serum tube (for Asparaginase activity assay and anti-Asparaginase antibodies) taken on d2 and d16 of intensification (immediately prior to doses 3 and 4 of peg-asp)</td>
</tr>
<tr>
<td></td>
<td>On the same day (d3 or d4), a 4.5 ml sodium citrate tube should be filled (to the line) to collect plasma. Spin the tube @ 2000G for 5 mins, aliquot serum into 5 eppendorfs and store locally at −80°C if possible or if not, -20°C.</td>
</tr>
</tbody>
</table>
7.2.8 Consolidation therapy

To be given to patients not eligible for transplantation. The first cycle of consolidation therapy should begin after intensification, when neutrophils > 0.75 x 10^9/L and platelet > 75 x 10^9/L (Please see tables 7.2.8 a-d for details). For patients with central nervous system involvement, cranial irradiation will be given before consolidation begins. Maintenance therapy with 6-Mercaptopurine should be given throughout the period of CNS irradiation. In the event of cytopenias, 6-Mercaptopurine therapy should be reduced or omitted rather than radiotherapy being delayed. The dose of thiopurine should not be increased as per the maintenance protocol but should be continued at 75mg/m² in the absence of cytopenias.

Table 7.2.8a - Cycle 1 Consolidation – to begin after intensification, when neutrophils > 0.75 x 10^9/L and platelet > 75 x 10^9/L.

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dose</th>
<th>Route of administration</th>
<th>Day 1</th>
<th>Day 2</th>
<th>Day 3</th>
<th>Day 4</th>
<th>Day 5</th>
<th>Day 6</th>
<th>Day 7</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cytarabine</td>
<td>75mg/m²</td>
<td>IV</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
<td>5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Etoposide</td>
<td>100mg/m²</td>
<td>IV</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
<td>5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PEG- asparaginase</td>
<td>1000 IU/m²</td>
<td>IV</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
<td>5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methotrexate#</td>
<td>12.5 mg</td>
<td>Intrathecal</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

# Timing of Intrathecal therapy can be moved +/- 3 days to allow administration on specified lists as per local and national guidance. Likewise, timing of the cytarabine blocks can be scheduled so that they can take place during the week as long as the full doses are given.
Table 7.2.8b - Cycle 2 Consolidation - to commence 3 weeks from day one cycle 1 or when neturophils are >0.75 x 10^9/l and platelets >75 x 10^9/l

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dose</th>
<th>Route of administration</th>
<th>Day 1</th>
<th>Day 2</th>
<th>Day 3</th>
<th>Day 4</th>
<th>Day 5</th>
<th>Day 6</th>
<th>Day 7</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cytarabine</td>
<td>75mg/ m²</td>
<td>IV</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
<td>5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Etoposide</td>
<td>100mg/ m²</td>
<td>IV</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
<td>5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methotrexate</td>
<td>12.5 mg</td>
<td>Intrathecal</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1</td>
<td></td>
</tr>
</tbody>
</table>

Imatinib - Patients with Philadelphia positive disease should also receive continuous daily Imatinib, PO, starting at 400mg, aiming to escalate to 600mg within 2 weeks, if tolerated. This should be continued until transplant wherever possible.

<table>
<thead>
<tr>
<th></th>
<th>Day 1</th>
<th>Day 2</th>
<th>Day 3</th>
<th>Day 4</th>
<th>Day 5</th>
<th>Day 6</th>
<th>Day 7</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
<td>5</td>
<td></td>
<td>6</td>
</tr>
</tbody>
</table>
Table 7.2.8ci – Cycle 3 (DAYS 1-28) - Consolidation/Delayed intensification - to commence 3 weeks from day one cycle 2 or when neutrophil count> 0.75 x 10^9/L and platelets > 75 x 10^9/L

### DAYS 1-28

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Daunorubicin</td>
<td>25mg/m²</td>
<td>IV</td>
<td>1</td>
<td>8</td>
<td>15</td>
<td>22</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vincristine</td>
<td>1.4mg/m² (Max 2mg)</td>
<td>IV</td>
<td>1</td>
<td>8</td>
<td>15</td>
<td>22</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Peg-asparaginase</td>
<td>1,000 IU/m²</td>
<td>IV</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td>4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dexamethasone*</td>
<td>10mg/m²</td>
<td>PO</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
<td>8</td>
<td>9</td>
<td>10</td>
<td>11</td>
<td>15</td>
<td>16</td>
<td>17</td>
<td>18</td>
<td>22</td>
<td>23</td>
<td>24</td>
<td>25</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methotrexate</td>
<td>12.5mg</td>
<td>Intrathecal</td>
<td>2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>17</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Imatinib - Patients with Philadelphia positive disease should also receive continuous daily Imatinib, PO, starting at 400mg, aiming to escalate to 600mg within 2 weeks, if tolerated. This should be continued until transplant wherever possible</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Dexamethasone should be capped at 20mg for larger patients.

This phase runs from day 1 to day 42 inclusive (i.e. 6 weeks). Patients should have ANC >0.75x10^9/L and platelets of >75x10^9/L to start and have recovered again to this level from before the 29th day of therapy is started. Once begun, therapy is not interrupted for myelosuppression alone. Any serious infection, such as Varicella, pneumocystis pneumonia, or neutropenia with fever, and presumed or proven infection, warrants chemotherapy interruption at any time during this block. Before the patient completes day 29-42 (table 7.2.8cii), i.e. before the d29 cyclophosphamide, the counts should be ANC >0.75x10^9/L and platelets of >75x10^9/L.
Table 7.2.8cii - Cycle 3 (DAYS 29-42) - Consolidation/Delayed intensification - to commence 3 weeks and 29 days from day one cycle 2 or when neutrophil count > 0.75 x 10^9/L and platelets > 75 x 10^9/L

**DAYS 29-42**

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dose</th>
<th>Route of administration</th>
<th>Day 29</th>
<th>Day 30</th>
<th>Day 31</th>
<th>Day 32</th>
<th>Day 33</th>
<th>Day 34</th>
<th>Day 35</th>
<th>Day 36</th>
<th>Day 37</th>
<th>Day 38</th>
<th>Day 39</th>
<th>Day 40</th>
<th>Day 41</th>
<th>Day 42</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cyclophosphamide</td>
<td>1000 mg/m²</td>
<td>IV</td>
<td>29</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cytarabine</td>
<td>75mg/m²</td>
<td>IV</td>
<td>30</td>
<td>31</td>
<td>32</td>
<td>33</td>
<td>34</td>
<td>35</td>
<td>36</td>
<td>37</td>
<td>38</td>
<td>39</td>
<td>40</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mercaptopurine</td>
<td>60mg/m²</td>
<td>PO</td>
<td>29</td>
<td>30</td>
<td>31</td>
<td>32</td>
<td>33</td>
<td>34</td>
<td>35</td>
<td>36</td>
<td>37</td>
<td>38</td>
<td>39</td>
<td>40</td>
<td>41</td>
<td>42</td>
</tr>
</tbody>
</table>

Imatinib - Patients with Philadelphia positive disease should also receive continuous daily Imatinib, PO, starting at 400mg, aiming to escalate to 600mg within 2 weeks, if tolerated. This should be continued until transplant wherever possible.

This phase runs from day 1 to day 42 inclusive (i.e. 6 weeks). Patients should have ANC >0.75x10^9/L and platelets of >75x10^9/L to start and have recovered again to this level from before the 29th day of therapy is started. Once begun, therapy is not interrupted for myelosuppression alone. Any serious infection, such as Varicella, pneumocystis pneumonia, or neutropenia with fever, and presumed or proven infection, warrants chemotherapy interruption at any time during this block. Before the patient completes day 29-42 (table 7.2.8cii), i.e. before the d29 cyclophosphamide, the counts should be ANC >0.75x10^9/L and platelets of >75x10^9/L.
Table 7.2.8d - Cycle 4 - Consolidation: Identical to Cycle 2, and will begin when neutrophils > 0.75 x 10^9/L and platelets > 75 x 10^9/l

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dose</th>
<th>Route of administration</th>
<th>Day -1</th>
<th>Day 1</th>
<th>Day 2</th>
<th>Day 3</th>
<th>Day 4</th>
<th>Day 5</th>
<th>Day 6</th>
<th>Day 7</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cytarabine</td>
<td>75mg/m²</td>
<td>IV</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
<td>5</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Etoposide</td>
<td>100mg/m²</td>
<td>IV</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
<td>5</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methotrexate</td>
<td>12.5mg</td>
<td>Intrathecal</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Imatinib</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patients with Philadelphia positive disease should also receive continuous daily Imatinib, PO, starting at 400mg, aiming to escalate to 600mg within 2 weeks, if tolerated. This should be continued until transplant wherever possible.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
<td>5</td>
<td>6</td>
<td>7</td>
<td></td>
</tr>
</tbody>
</table>
7.2.9 Maintenance therapy (non-transplant patients only)

To start as soon as neutrophils are $0.75 \times 10^9/l$ and platelets are $75 \times 10^9/l$ following consolidation 4 and to continue for 2 full years.

*Patients with Philadelphia positive disease should continue with daily Imatinib throughout maintenance.*

**Table 7.2.9 – Maintenance therapy**

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dose</th>
<th>Route of administration</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vincristine</td>
<td>1.4 mg/m²</td>
<td>IV</td>
<td>every 3 months</td>
</tr>
<tr>
<td></td>
<td>(max 2 mg/dose)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prednisolone</td>
<td>60 mg/m²</td>
<td>PO</td>
<td>5 days every 3 months</td>
</tr>
<tr>
<td>Mercaptopurine*</td>
<td>75 mg/m²</td>
<td>PO</td>
<td>Daily</td>
</tr>
<tr>
<td>Methotrexate*</td>
<td>20 mg/m²</td>
<td>PO or IV</td>
<td>once per week (not to be given on the same day at the Co-trimoxazole)</td>
</tr>
<tr>
<td>Intrathecal therapy during maintenance</td>
<td>Methotrexate 12.5mg Intrathecal Every 3 months</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Dosing of maintenance therapy should be adjusted to maintain the neutrophil count between 0.75 and $1.5 \times 10^9/l$ and platelet count between 75 and $150 \times 10^9/l$.

*Dose of MP and MTX should be altered in 25% increments or decrements to achieve the above counts. eg if neutrophils $> 1.5 \times 10^9/l$, increase 6-MP dose by 25%. If neutrophils remain $> 1.5 \times 10^9/l$ after 4 weeks, increase MTX by 25% etc. There are no maximum doses of MP and MTX. If neutrophils fall below $0.75 \times 10^9/l$, reduce both drugs by 50%, if neutrophils fall below $0.5 \times 10^9/l$, stop maintenance and restart at 100% when neutrophils $> 0.75 \times 10^9/l$. Similar adjustments need to be made for the platelet count to maintain above counts.*

Maintenance should not be interrupted unnecessarily but if doses are omitted for cytopaenias or infectious complications, they do not need to be made up with additional doses later.

Co-trimoxazole (960mg bd, twice per week, not on the same day as the weekly oral MTX) and aciclovir (200mg bd) prophylaxis against PCP and HSV/VZV reactivation should be given throughout maintenance. Local practice may be followed regarding the aciclovir dose if necessary.

If cytopaenias occur and maintenance is halted, consideration should be given to stopping the co-trimoxazole if blood counts do not recover within 2-3 weeks. Doses of mercaptopurine and MTX should not be compromised in order to permit continuation of co-trimoxazole.

Alternative prophylaxis against PCP should be given, for example monthly nebulised pentamindine, or oral dapsone.
7.2.10 Transplant conditioning regimens

Please see appendix 8 for Donor Peripheral Blood Stem Cell Collection & Return.

Please note – as detailed in section 8.2.1 and Appendix 7:

<table>
<thead>
<tr>
<th>Specimens for local assessment</th>
<th>Specimens for correlative studies to be sent to central laboratory (see app 8)*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pre-transplant</td>
<td>20ml Blood in EDTA from donor and recipient for assessment of mini-satellite regions</td>
</tr>
</tbody>
</table>

### 7.2.10.1 Myeloablative conditioning regimen

- The following regimen is strongly recommended for patients aged ≤40 years at study entry who are eligible for myeloablative transplantation.
- At the discretion of the transplant centres, cyclophosphamide 60mg/kg on days -3 and -2 is acceptable.
- Local practice for the scheduling of the conditioning regimen may be followed.
- TBI dose should not be less than 13.2Gy.
- T cell depletion is not recommended for unrelated donor SCT. Where T cell depletion is deemed necessary by individual centres, *in-vivo* Alemtuzumab is recommended at 30mg IV days -2 and -1. The dose given should be documented on the relevant CRF.

**Table 7.2.10a - Myeloablative conditioning regimen - preferred option: Etoposide**

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dose</th>
<th>Route of administration</th>
<th>Day –7</th>
<th>Day –6</th>
<th>Day –5</th>
<th>Day –4</th>
<th>Day –3</th>
<th>Day –2</th>
<th>Day –1</th>
<th>Day 0</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fractionated TBI</td>
<td>total dose 1320 cGY in 8 fractions</td>
<td></td>
<td>-7</td>
<td>-6</td>
<td>-5</td>
<td>-4</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Etoposide</td>
<td>60 mg/ kg</td>
<td>IV</td>
<td></td>
<td></td>
<td></td>
<td>-3</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Haematopoetic stem cell infusion</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Table 7.2.10b - Myeloablative conditioning regimen - alternative option: Cyclophosphamide**

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dose</th>
<th>Route of administration</th>
<th>Day –7</th>
<th>Day –6</th>
<th>Day –5</th>
<th>Day –4</th>
<th>Day –3</th>
<th>Day –2</th>
<th>Day –1</th>
<th>Day 0</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fractionated TBI</td>
<td>total dose 1320 cGY in 8 fractions</td>
<td></td>
<td>-7</td>
<td>-6</td>
<td>-5</td>
<td>-4</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cyclophosphamide</td>
<td>60 mg/ kg</td>
<td>IV</td>
<td></td>
<td></td>
<td></td>
<td>-3</td>
<td>-2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Haematopoetic stem cell infusion</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Patients eligible for a myeloablative stem cell transplant will have been randomised between standard dose Palifermin (60micrograms/kg x 6 doses) and collapsed dose Palifermin (180micrograms/kg x 1 dose plus 60micrograms/kg x 3 doses).

### Table 7.2.10c – Palifermin schedule: P1- Standard dose (only for those patients randomised)

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dose</th>
<th>Route of administration</th>
<th>Day -10</th>
<th>Day -9</th>
<th>Day -8</th>
<th>Day -7</th>
<th>Day -6</th>
<th>Day -5</th>
<th>Day -4</th>
<th>Day -3</th>
<th>Day -2</th>
<th>Day -1</th>
<th>Day 0</th>
<th>Day 1</th>
<th>Day 2</th>
<th>Day 3</th>
<th>Day 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Palifermin</td>
<td><strong>P1 - Standard</strong></td>
<td>60 micrograms/kg IV bolus injection</td>
<td>-10</td>
<td>-9</td>
<td>-8</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0</td>
<td>2</td>
<td>4</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Table 7.2.10d – Palifermin schedule: P2-Collapsed doses (only for those patients randomised)

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dose</th>
<th>Route of administration</th>
<th>Day -10</th>
<th>Day -9</th>
<th>Day -8</th>
<th>Day -7</th>
<th>Day -6</th>
<th>Day -5</th>
<th>Day -4</th>
<th>Day -3</th>
<th>Day -2</th>
<th>Day -1</th>
<th>Day 0</th>
<th>Day 1</th>
<th>Day 2</th>
<th>Day 3</th>
<th>Day 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Palifermin</td>
<td><strong>P2 - Collapsed</strong></td>
<td>180 micrograms/kg IV bolus injection</td>
<td>-9</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0</td>
<td>2</td>
<td>4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Palifermin</td>
<td></td>
<td>60 micrograms/kg IV bolus injection</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0</td>
<td>2</td>
<td>4</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

7.2.10.2 Non-myeloablative conditioning therapy

The following regimen should be used for patients aged ≥40 at study entry who are eligible for non-myeloablative transplantation:

### Table 7.2.10e – Non-myeloablative conditioning regimen schedule

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dose</th>
<th>Route of administration</th>
<th>Day -7</th>
<th>Day -6</th>
<th>Day -5</th>
<th>Day -4</th>
<th>Day -3</th>
<th>Day -2</th>
<th>Day -1</th>
<th>Day 0</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fludarabine</td>
<td>30 mg/m²</td>
<td>IV over 1 hour</td>
<td>-7</td>
<td>-6</td>
<td>-5</td>
<td>-4</td>
<td>-3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Melphalan</td>
<td>140 mg/m²</td>
<td>IV</td>
<td>-1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>For recipients of unrelated donor allografts:</td>
<td>-2</td>
<td>-1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alemtuzumab*</td>
<td>30 mg</td>
<td>IV</td>
<td>-2</td>
<td>-1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>For recipients of sibling allografts:</td>
<td>-1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alemtuzumab*</td>
<td>30 mg</td>
<td>IV</td>
<td>-1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Pre-medication with steroids prior to Alemtuzumab is strongly recommended, in addition to antihistamines and paracetamol.

Please note that as patients receiving Reduced Intensity Conditioning regimens DO NOT receive TBI there is a need to maintain appropriate CNS directed therapy. These patients will therefore receive 8 x 3 monthly intrathecal methotrexate injections at a dose of 12.5 mg, for 2 years post transplant starting at 3 months post transplant - see section 7.2.11.

Please note, as detailed in section 8.2.1 and appendix 7:

<table>
<thead>
<tr>
<th>Specimens for local assessment</th>
<th>Specimens for correlative studies to be sent to central laboratory (see app 8)*</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Post-transplant (non-myeloablative only):</strong></td>
<td>20ml peripheral blood in EDTA for chimerism. To be repeated every 3 months.</td>
</tr>
<tr>
<td></td>
<td>3-5 ml Bone marrow in EDTA for MRD assessment. To be repeated every 3 months until 2 years post bone marrow transplant or until relapse.</td>
</tr>
</tbody>
</table>

7.2.10.3 Supportive care during and after transplant

Investigating transplant centres should use local protocols with regard to anti-emetic and anti-infective prophylaxis.

7.2.10.4 Imatinib after transplant

There is no concrete evidence about whether, when, for how long and under what circumstances to give imatinib post allograft. Published data show that when given within the first 2-3 months it is toxic and poorly tolerated and most patients cannot continue with it. Unpublished data from a small randomised study from GMALL in which patients were randomised to receive imatinib either ‘prophylactically’ (ie all patients given the drug beginning at 3 month, regardless of bcr-abl status) or ‘pre-emptively’ (ie only if bcr-ab positive) showed no difference in outcome between the two arms. Some of the patients who were bcr-abl post allograft became negative after starting imatinib. Unsurprisingly, those with persistent bcr-abl from an early time point post allograft did poorly, regardless of whether they received imatinib or not. Those who became positive at later time-points had a better outcome and some had a long term good outcome when starting imatinib at the time of re-appearance of bcr-abl. In summary, it would not be a good idea to start imatinib until at least 3 months post allograft. Thereafter, physicians can pursue a policy of giving it to all of their patients or giving it only to those who are (or become) bcr-abl positive. Both strategies appear to produce the same long term outcome. Both require adherence to regular bcr-abl quantification for best results. There are no data whatsoever to indicate how long to best continue the drug. In UKALL12, it was given within the trial for 2 years but we don’t have data on how many continued a physicians discretion after the two year period nor do we have data on the benefit of continuing in the long term. Hence it might make more sense pragmatically to only start the drug in the presence of a positive bcr-abl signal because a) there are possible side effects and drug interactions and b) once started in a bcr-abl negative patient, stopping decisions will be potentially problematic."
7.2.10.5 Graft versus host disease prophylaxis

Ciclosporin

Ciclosporin will be given as follows: total dose of 3 mg/kg/day I.V. from day -1 to +28. (Local practices for GVHD prophylaxis may be followed). The dose will be adjusted to maintain a therapeutic blood level and the patient will be switched to oral ciclosporin once clinically indicated. Ciclosporin will tapered from 2 months and discontinued at 3 months in the absence of GVHD.

Methotrexate

Short course methotrexate is given as per the original Seattle protocol to patients receiving a myeloablative transplant. Please note; MTX is NOT needed for the non myeloablative regimen

The dosing is as follows:

15 mg/m² day 1 and 10 mg/m² days 3, 6 and 11

We strongly advise that 4 doses of methotrexate should be given as lower doses of methotrexate may result in increased incidences of acute and chronic GVHD.

Moderate mucositis should not prevent full methotrexate dosing and the amount of methotrexate given is a secondary endpoint of the palifermin randomisation.

Dose reductions should occur in renal impairment:

CrCl 61-80 mL/minute: Reduce dose to 75% of usual dose
CrCl 51-60 mL/minute: Reduce dose to 50% of usual dose
CrCl < 50 mL/minute: no methotrexate

Investigators are permitted to give omitted doses of methotrexate when the renal impairment has resolved and can discuss this with the transplant coordinator of the trial.

Dosage adjustment in hepatic impairment:

Bilirubin 50-75 umol/l or AST >180 units: Administer 50% of usual dose
Bilirubin >75 umol/l : no methotrexate

Patients at particular risk of progressive renal or hepatic impairment may require greater reductions in dosage. Discussion with the transplant coordinator of the trial is advised.

Folinic acid rescue may be given as per local policy.

7.2.10.6 Prophylaxis against infectious diseases

All patients should receive prophylaxis against infection with HSV, VZV, fungal organisms and PCP according to local guidelines. CMV monitoring by PCR should be undertaken.

7.2.10.7 Donor lymphocyte infusions (DLI)

Disease and chimerism status will be assessed in all patients as per schedule in correlative studies section post non-myeloablative allogeneic transplant. If needed, DLI will be given in escalating doses at 3 monthly
intervals.

Indications for DLI:

1. mixed chimerism
2. continued or progressive minimal residual disease

DLI at 6 months post transplant.

Doses:

- 6 months: $1 \times 10^6$ T cells/kg
- 9 months: $3 \times 10^6$ T cells/kg
- 12 months: $1 \times 10^7$ T cells/kg
- 15 months: $3 \times 10^7$ T cells/kg
- 18 months: $1 \times 10^8$ T cells/kg

The chimerism status will be assessed 2 months after each infusion as per chimerism monitoring section (7.2.10.7) and correlative science section (8.2.1) and no further infusions will be given if both remission of the immune phenomena and full donor chimerism is achieved. However, if the patient fails to achieve this after the final dose of donor lymphocytes ($1 \times 10^8$ T-cells/kg), this is considered a treatment failure.

Patients in clinical remission with full donor chimerism at 6 months post transplant will not receive DLI. If, at future assessment, there is evidence of either disease relapse OR mixed chimerism, patients may commence DLI as per the above dose schedule.

Chimerism, Minimal Residual Disease and donor leukocyte infusions in patients receiving reduced intensity conditioned alloHSCT

Prior to transplant, 10 ml of EDTA blood will be collected from both the donor and recipient and sent to the central laboratory, to allow the selection of informative PCR primers. .. Whenever unrelated donors are used, centres are encouraged, wherever possible, to store aliquots of donor leukocytes for subsequent donor leukocyte infusions (DLI)

In order to determine how and when these should be used, quantitative, lineage-specific (myeloid + T cell) chimerism will be performed by microsatellite PCR on peripheral blood and minimal residual disease (MRD) will be quantified by Ig/TCR on bone marrow following transplant.

Chimerism-triggered DLI

In the absence of GVHD, immunosuppression will be tapered and discontinued by 3 months and chimerism will be tested at 4 months post transplant. The presence of mixed chimerism ($\leq 95\%$ donor cells in T or myeloid lineages) in the absence of GVHD will lead to initiation of escalated (dose escalation schedule below) from 4 months post transplant. Different initial T cell doses will be used for sibling and unrelated donors.

Three months following the first DLI, chimerism testing will be repeated and the presence of persistent mixed chimerism in the absence of GVHD will trigger the next dose of donor leukocytes. If there is a greater
than 50% reduction in the percentage of recipient cells at 3 months post DLI, then further chimerism testing will be repeated 4 weeks later to allow further time for the establishment of full donor chimerism. Any alteration in the DLI schedule must be discussed with the Transplant Coordinator (Prof David Marks) or Chief Investigator (Dr Adele Fielding). Investigators are encouraged to contact the trial management group as DLI decisions may be affected by patient characteristics or risk factors. Repeat chimerism testing ± DLI will be performed every 3 months until the establishment of full donor chimerism or the development of GVHD.

**MRD-triggered DLI**

MRD will be quantified in bone marrow at 3 monthly intervals post transplant, beginning at 3 months - around the time that the immune suppression has been stopped. If MRD at any quantifiable level is detected, any residual immune suppression on-going should be tapered as rapidly as possible followed by, in the absence of GVHD, commencement of the DLI schedule below, with escalating doses being dependent upon the result of repeat MRD testing. If MRD is detected outside the quantifiable range, repeat testing is recommended in 2 months, if acceptable to the patients and clinician.
7.2.10.8 Multi Lineage Chimerism monitoring:
Peripheral blood samples for determination of the donor or recipient origin of T cells and myeloid cells will be performed centrally, as per correlative science studies section. Results of chimerism analyses will be available within 1 week of the sample. All patients should be followed very carefully until they achieve a high level of donor chimerism (>95%). Subsequent falls in donor chimerism should be confirmed and these patients should be followed carefully, for evidence of relapse especially if peripheral blood counts have fallen or there are symptoms suggestive of leukaemia.

The usual specimen for peripheral blood chimerism is 20 mls of blood in an EDTA (green) tube. Regular monitoring of chimerism by XY FISH in sex-mismatched allografts locally is also encouraged as supporting evidence.

Patients with persistent mixed chimerism or a fall in chimerism, are candidates for immunotherapy at the protocolised doses. Investigators are encouraged to contact the transplant co-ordinator (Professor David Marks) to discuss these patients and immunotherapy decisions.

7.2.10.9 T cell depletion in the unrelated donor myeloablative HSCT setting an alternative protocol for centres committed to T cell depletion.
T cell depletion is not permitted for sibling allografting and T cell depletion is not recommended during full intensity unrelated donor allografting. For those centres committed to T cell depletion, in-vivo CAMPATH 1-H (60mg pretransplant as 2 x 30mg doses) is permissible.

7.2.11 Post-transplant Intrathecal therapy:
For those patients having reduced intensity conditioned transplant, it will be necessary to complete further intrathecal therapy post-transplant. The 8 doses intrathecal methotrexate (12.5mg) which would be given in maintenance should be given post RIC transplant, at 3 monthly intervals over 2 years.

7.3 Management after treatment withdrawal
If a patient withdraws consent or stops trial treatment for any reason e.g. toxicity or lack of efficacy then subsequent treatment will be at the discretion of the treating clinician. In these cases patients remain within the trial for the purposes of follow-up and data analysis according to the treatment option to which they have been allocated.

7.4 Out-of-hours medical care
Medical care, including out-of-hours medical care is the responsibility of the site. Sites must ensure that all patients registered onto the trial receive a copy of the UKALL14 patient card and that the site on-call contact details have been added.
8.0 **Assessments**

8.1 **Assessment time points**

- Information is required for **all** patients at the following time points:
  - Initial diagnosis & pre treatment (pre-registration – section 5.1)
  - Post-induction phase 1 (at count recovery)
  - Post-induction phase 2 (at count recovery)
  - After intensification
  - Annual follow-up after study treatment completion until death

- For patients treated with Consolidation
  - After each cycle of Consolidation

- For patients treated with maintenance:
  - Every 3 months during maintenance

- For **Transplant** recipients:
  - Pre-transplant (section 5.5)
  - Day 100 post transplant
  - Every 3 months for 2 years following transplant
  - Any patients participating in the Palifermin/KGF randomization, Oral Mucositis Daily Questionnaire (OMDQ) to completed daily by all patients during in-patient therapy from day -12 until day 28 or date of discharge (whichever is sooner)

**PLEASE SEE STUDY VISIT SCHEDULE (APPENDIX 11) FOR FURTHER DETAILS**

8.2 **Routine Clinical and Laboratory Assessments during treatment**

  a) Clinical examination will be carried out daily or more often, if the patient is acutely unwell, as part of routine clinical care.

  b) Assessment of performance status ECOG will be carried out before each discrete block of therapy.

  c) Height/Weight & BSA will be assessed as needed to prescribe each block of therapy.

  d) Full blood count/ and other laboratory tests e.g. LFTs, U&Es will be carried out at the clinicians discretion as part of the routine management of acute leukaemia. These tests are usually carried out a minimum of three times weekly during inpatient stays.
### 8.2.1 Schedule of testing for MRD and correlative science testing

<table>
<thead>
<tr>
<th>Specimens for local assessment</th>
<th>Specimens for correlative studies to be sent to central laboratory (see app 8)*</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>At Diagnosis</strong></td>
<td></td>
</tr>
<tr>
<td>Cytogenetics/molecular assessment of BCR-ABL and MLL on bone marrow. A copy of the results should be sent to the Leukaemia Research Cytogenetics Group (LRCG) at Newcastle University. (Please refer to Appendix 6 for details of the LRCG). Tissue typing of patient and any siblings to be carried out. Donor search to be initiated if no matched sibling donor available.</td>
<td>Bone marrow 3-5ml in EDTA (OR peripheral blood 30-50ml in EDTA if WCC &gt; 30x 10^9/l). BCR-ABL status will also be checked.</td>
</tr>
</tbody>
</table>

| **During Phase 1 therapy**    |                                                                                   |
| 5ml peripheral blood in a serum tube (for Asparaginase activity assay and anti-Asparaginase antibodies) taken on d3 or d4 (patients under 40 only) and d18 (immediately prior to doses 1 and 2 of peg-asp) **Not applicable to Philadelphia positive patients.** On the same day (d3 or d4), a 4.5 ml sodium citrate tube should be filled (to the line) to collect plasma. Spin the tube @ 2000G for 5 mins, aliquot serum into 5 eppendorfs and store locally at –80°C if possible or if not, -20°C.***. |                                                                  |

| **At recovery** post Phase 1 | Bone marrow aspirate for remission assessment locally. Same day local FBC to determine peripheral count. | Bone marrow from biopsy: 3-5ml in EDTA for MRD assessment - **Result not reported to sites** (App.7) (IgH/TCR rearrangements for Ph-ALL, BCR-ABL for Ph+ALL) |

| **At recovery** post Phase 2 | Bone marrow aspirate for remission assessment locally. Same day local FBC to determine peripheral count. | Bone marrow from biopsy: 3-5ml in EDTA for MRD assessment. - **Result reported to site within 10 working days of receipt of sample** (App.7) (IgH/TCR rearrangements for Ph-ALL, BCR-ABL for Ph+ALL) |

| **During intensification:** | 5ml peripheral blood in a serum tube (for Asparaginase activity assay and anti-Asparaginase antibodies) taken on d2 and d16 of intensification (immediately prior to doses 3 and 4 of peg-asp). On the same day (d3 or d4), a 4.5 ml sodium citrate tube should be filled (to the line) to collect plasma. Spin the tube @ 2000G for 5 mins, aliquot serum into 5 eppendorfs and store locally at –80°C if possible or if not, -20°C.***. |                                                                  |

| **Pre-transplant**           | 20ml Blood in EDTA from donor and recipient for assessment of mini-satellite regions |                                                                  |

| **Post-transplant (non-myeloablative only):** | 20ml peripheral blood in EDTA for chimerism. To be repeated every 3 months. 3-5 ml Bone marrow in EDTA for MRD assessment. To be repeated every 3 months until 2 years post bone marrow transplant or until relapse. |                                                                  |

| **At Relapse**               | Bone marrow 3-5ml in EDTA (OR peripheral blood 30-50ml in EDTA if WCC > 30x 10^9/l). |                                                                  |

*Please refer to Appendix 7 for guidelines for sending specimens to the central laboratory

** "Recovery" is defined as neutrophils >0.75 x 10^9/l, platelets >75 x 10^9/l.

*** Sites to collect, process and store these samples if possible depending on resources however this is optional.
8.3 Assessments during follow up

All patients will be followed up annually until death.

Follow-up begins when trial treatment is completed, i.e. after the last dose of maintenance therapy has been given. In the case of patients treated by transplantation, precise definition of when treatment becomes follow-up is difficult due to the wide variation in the clinical scenarios. Hence follow-up will be arbitrarily defined to commence 2 years after the date of stem cell infusion, to coincide with the length of maintenance therapy.

a) Clinical examination as necessary (often there are no expected abnormal findings)
b) Full blood count
c) Any other tests as dictated by the patient's clinical condition
d) Assessment of disease status
e) Record of any occurrence of AVN or serious cardiac problems
f) Employment history post treatment of ALL
g) GVHD

At the 2 year follow up appointment (2 years after stopping maintenance/4 years post stem cell infusion), as well as the above annual assessments, patients will also be assessed for late effects of treatment:

a. General Health Questionnaire (GHQ-12) Appendix 12
b. Symptoms of heart failure
c. Echocardiogram
d. Avascular necrosis
e. GVHD
f. Mental Health
g. Fertility
h. Any other cancer diagnosis since ALL diagnosis.
i. Employment history post treatment of ALL

If a patient fails to attend clinic for any visit then the site must make every effort to gain follow up information as requested. If a patient no longer attends clinic at the treating transplant centre (e.g. moves away or is discharged from clinic) it is the duty of the site to inform UCL CTC of where follow up information may be obtained (e.g. GP, alternate transplant centre). Patients will also be consented to follow up through the NHS Information Centre.
9.0 Correlative Science

PLEASE ALSO SEE SECTION 8.2.1 and APPENDICES 7, 8 and 12 FOR FURTHER DETAILS INCLUDING CONTACT NAMES AND ADDRESSES.

Four distinct but inter-related scientific correlative studies are planned, closely integrated with the clinical questions being asked. Minimal residual disease (MRD) testing will be carried out as a matter of course, as an integral part of the risk-stratified treatment allocation. The Adult ALL MRD laboratory at UCL Royal Free Campus, will provide specimen reception, processing and storage facilities and carry out the MRD testing, providing the infrastructure for the duration of the study.

Tests and analyses will be performed in 3 places (a) the central laboratory, UCL Royal Free Campus, London (b) Northern Institute of Cancer Research (NICR), Newcastle University & CRUK-PIMS (c) Medac, Germany.

Data will be ultimately be collated with clinical outcome data held by UCL Cancer Trials Unit.

9.1 Aim 1. To determine the relationship between CD20 on ALL blasts and response to monoclonal antibody therapy

9.1.1 Background

The ability to combine rituximab (antiCD20) with chemotherapy (resulting in considerable improvement in outcome) in the treatment of lymphoma coupled with the expression of CD20 in ALL of B cell precursor-cell type has lead to the introduction of rituximab in the treatment of B cell precursor (BCP) ALL. The expression of CD20 on ALL blasts varies widely (E. Paietta, personal communication) CD20 is less commonly or less highly expressed on B-ALL blasts than some other B cell antigens. However, there is accumulating evidence that it is of prognostic significance.

Upon instituting an investigation into the use of anti-B cell monoclonal antibodies in ALL, the investigators realised that there was no answer to the recurrent question asked in review 'why do you not limit anti-CD20 antibody administration only to those with CD20 positive tumors'. No data in ALL - or other tumour - were available to define the relationship between antigen expression and response and suggest a threshold level for response. Particularly intriguing in this regard is a recent demonstration that the relatively modest expression level of CD20 at diagnosis was often dramatically up-regulated, both in numbers of cells expressing the antigen and levels of expression per cell, following induction chemotherapy. This was shown in vitro to occur on exposure to glucocorticoids, and correlated well with in-vitro rituximab-induced killing. We think this kind of study offers an ideal opportunity to investigate this important issue further.

9.1.2 Plan of investigation

In order to investigate the hypothesis that response to monoclonal antibody therapy may have no clear relation to the density of relevant antigen expression at diagnosis, we plan to investigate the relationship between density of CD20 antigen expression at diagnosis and response to monoclonal antibody therapy in all patients with B-lineage ALL who are participating in the induction randomisation. Flow cytometry will be used to quantify CD20 antigen expression (percentage expression and mean fluorescence intensity MFI) at diagnosis. Correlation between percentage CD20 expression and response to initial therapy (CR rate and
quantitative MRD level after both phases of induction) will be determined for all 4 randomisation groups, the group receiving no monoclonal antibodies serving as a negative control group.

9.2 Aim 2. To determine whether the administration of an anti-B cell monoclonal antibody as part of induction therapy for ALL limits the extent of anti-asparaginase antibody formation and promotes asparagine depletion.

9.2.1 Background
L-asparaginase is arguably one of the most valuable drugs in the treatment of ALL. However, it is associated with numerous toxicities. When these occur early in treatment, therapeutic delays are often generated which can result in compromise of overall therapy. The appropriate dose, preparation and formulation of L-asp remain unresolved. In paediatric practice, pegylated L-asp (peg-asp) is less immunogenic and gives the most appropriate pharmacokinetic and pharmacodynamics but evidence that this agent could be properly used in adults was lacking until a recent CALGB phase II study used peg-asp as part of a multi-agent regimen. Effective asp depletion was achieved in some adults although increasing age was associated with significantly decreased peg-asp doses and less asparagine depletion, furthermore, there was still a significant number of patients who developed of anti-asparaginase antibodies; this correlated with a less successful asparagine depletion. Within the associated clinical study UKALL14, peg-asp will be administered to adults for the first time in a large phase 3 setting.

9.2.2 Plan of Investigation
We hypothesise that the rate of anti-asparaginase antibody formation will be reduced by the co-administration of antiCD20 and that this can result in higher levels of asparaginase activity. We will test this hypothesis by quantifying anti-asparaginase antibody levels and asparaginase activity prior to peg-asp infusion and at time-points specified in section 8.2.2 post peg-asp infusion. The 2-way randomization provides the control groups (antiD20, or neither) necessary to adequately address this question.

9.3 Aim 3. To perform genomic profiling in order to discover and characterise novel prognostic markers and to identify known copy number alterations (CNA).

9.3.1 Background
ALL is a heterogeneous disease at the genetic level and numerous genetic abnormalities have been described which correlate with demographic, clinical and outcome parameters. Karyotype is one of the most important risk factors in adult ALL. Genomic copy number arrays have now revolutionised our understanding of the genetic basis of childhood ALL and have identified novel subgroups which correlate with clinical parameters, genetic subtypes and outcome.CurCurrently, there is very limited genomic information available for adult ALL. In one study, SNP arrays revealed a series of cryptic genomic abnormalities but it was too small to establish any novel subgroups or correlate the findings with clinical parameters or outcome. UKALL14 provides a valuable opportunity to collect diagnostic and remission samples to identify novel CNAs within a large cohort. We will focus on Philadelphia chromosome (Ph) negative BCP-ALL, since T-ALL is better understood at the genetic level and shares a greater homology with paediatric ALL.
9.3.2 Plan of Investigation

We plan to analyse DNA from 400 diagnostic samples using the Affymetrix SNP6.0 array (or later version). We will generate a normal cohort for comparison by analysing DNA from 50 MRD-negative post phase II remission samples. Data from this cohort will be used alongside the publicly available HapMap control dataset to remove copy number variants (CNV), using paired and unpaired normalisation. All labelling and hybridisation procedures will be outsourced to CRUK-PIMS. The raw data files will be returned to the LRCG where it will be processed, stored and analysed using a combination of in-house tools, freeware and commercially available software (e.g. Affymetrix Genotyping Console, dChip, Partek and Nexus). Where necessary, CNAs identified by the SNP arrays will be confirmed using home-grown and commercially available FISH probes. The LRCG has experience analysing large complex datasets and integrating data from different technologies e.g. genomic, gene expression and micro-RNA data.59-61

Using cytogenetic and FISH data generated during the patients diagnostic work-up we will determine whether each novel CNA co-exists with known chromosomal abnormalities. This will allow us to assess whether these novel lesions are likely to represent primary genetic aberrations which might define new biological subgroups or secondary abnormalities which are likely to be cooperating mutations. Running high resolution SNP arrays will reveal novel CNAs and also identify known CNAs which are beyond the detection limits of standard diagnostic technologies (e.g. Ikaros deletions, which have shown to be associated with a poor outcome in childhood ALL and are frequently <85kb).6 Running this array-based project in conjunction with a clinical trial will allow the clinical relevance of these novel and existing genetic lesions to be assessed in a reasonable timeframe. We will investigate the relationship of each CNA with the age, sex, white cell count, immunophenotype and other clinical parameters. Most importantly, we will be able assess their prognostic relevance in the context of a modern treatment protocol and be able to consider a variety of clinically relevant endpoints (e.g. CR status, MRD status, BM and CNS relapse and death). Assuming an overall event rate of 50%, the analysis of 400 patients will give us 80% power to detect a 20% difference in outcome for an abnormality found in 20% patients. This magnitude of effect was observed for cytogenetic subgroups in the previous trial and novel CNAs of this frequency have been discovered in childhood ALL using the same platform. Standard statistical tests will be used and all analyses will be conducted in collaboration with the trial statistician (Dr Sue Richards) as in previous studies.

This project will identify a number of genomic abnormalities whose functional consequence will need to be fully evaluated in order to elucidate their contribution to leukaemogenesis and assess their potential as therapeutic targets. Utilising total RNA extracted from the same diagnostic samples used for the SNP arrays we plan to further investigate different genetic lesions using gene expression arrays (Affymetrix Exon 1.0 ST array) and micro-RNA arrays (Agilent miRNA microarray Rel12.0). These additional scientific studies will require additional funding; however, the LRCG is an excellent position to attract such funding. We have ongoing collaborations within NICR with experts in functional analysis (Dr Olaf Heidenreich), molecular pharmacology (Dr Julie Irving) and molecular carcinogenesis (Dr James Allan). In addition, we are well positioned to take forward any identified therapeutic targets through the CRUK Drug Discovery programme in collaboration with Herbie Newell, Professor of Cancer Therapeutics, NICR and Roger Griffin, Professor of Medicinal Chemistry.
9.4 **Aim 4. To determine whether the speed at which full donor chimerism is achieved in the T - cell compartment correlates with the level of molecularly determined minimal residual disease.**

9.4.1 **Background**

Since the age threshold at which TRM exceeds reduction in relapse risk may be as low as 35 to 40 years old, it is very reasonable to examine non-myeloablative HSCT (previously reported only in retrospective studies) as a way to provide a graft versus leukaemia effect with reduced toxicity in adult ALL and this will be investigated in UKALL14. The success of this approach is likely to be disease burden dependent - absence of MRD at the time of transplant and the speed at which full donor chimerism can be achieved may be of crucial importance. This has never previously been studied. Hence, the main scientific question to be addressed in this correlative study is whether the graft versus leukaemia effect is of sufficient magnitude and appropriate in timescale to deliver an effective anti-leukaemia therapy.

9.4.2 **Planned Investigation**

In order to investigate this question thoroughly, mixed-lineage chimerism analysis will be performed on peripheral blood - fractionated into myeloid, T cell and B cell populations using immunomagnetic beads - at 3, 6, 9, 12, 18 and 24 months post transplant. The degree of donor/recipient chimerism will be assessed with PCR analysis of informative mini-satellite regions. Peripheral blood (20 ml EDTA) must be collected and stored from both the donor and patient prior to the transplant.

For patients receiving DLI as defined in the protocol, the chimerism status will be assessed 2 months after each DLI infusion, until full donor chimerism is obtained.

Minimal residual disease will be assessed at the same time-points, using immunoglobulin gene or T cell receptor gene re-arrangements as identified at diagnosis.

9.5 **Aim 5. Assessment of late effects**

9.5.1 **Aims**

To formally assess the late effects of ALL therapy for all patients on the trial, whether they have received chemotherapy alone or an allograft.

To identify and describe some of the adverse physical and psychosocial consequences of the disease and its treatment.

9.5.2 **Background & Planned Investigations**

A great deal of research has been carried out on the late effects caused by chemotherapy for acute lymphoblastic leukaemia in children. It is well documented that approximately 2 out of every 3 survivors from childhood cancers, including ALL, will suffer at least one late effect. One in four survivors will experience a late effect that is life threatening (1,2).

There are data on late effects of myeloablative transplantation in adults with ALL (EBMT refs), but less research has been done in adult ALL sufferers treated with chemotherapy alone and there are minimal data on the effects of RIC allografting for ALL to date. We presume that the late effect rate in adults will be at least equivalent to that seen in children, if not worse, but we do not know that this is the case. Part of our
role as clinicians is to inform patient choice on the best therapeutic choice available to them. Survival rates are obviously a key part of any such discussions, but increasingly we need to look at the quality of survival offered by available therapies when helping patients consider their options. The aim of this part of the trial is to collect some basic information regarding late effects of diagnosis and treatment of ALL in adults that may inform such discussions with our patients in the future.

Late effects that are known to occur as a consequence of chemotherapy include neurocognitive problems, premature menopause, cardiorespiratory dysfunction, sexual impairment, infertility, chronic fatigue and pain syndromes, and second malignancies. Research shows that many survivors also experience significant negative psychosocial outcomes, including fear of recurrence, poor self-esteem, anxiety and depression, employment and insurance discrimination, and relationship difficulties (5). Historically, survivorship research has sought to identify and address the adverse physical and psychosocial consequences of the disease. An emerging body of evidence suggests that cancer survivors, similar to survivors of other traumatic life events, also experience positive life changes following a cancer diagnosis, and that these positive effects of cancer frequently coexist with the negative (6, 7). Studies in adult cancer survivors have shown that many survivors identify their illness experience as an event that has allowed them to make positive lifestyle changes resulting in higher quality of life scores than the general population (8, 9). We therefore want to use the general health questionnaire-12 (GHQ-12) as part of our screening for treatment related late effects. This is a reliable screening instrument for psychological distress in all clinical groups and can be used for assessing both positive and negative aspects of mental health.

Whilst some late effects may occur after many years eg second malignancies, other effects such as infertility can be assessed at much earlier time points. The aim of this part of the study is to initially assess each patient for late effects 2 years following the end of therapy. This will be 4 years from diagnosis for those having received chemotherapy only whereas it will be less than 3 years from diagnosis in some cases where allografting has been used. This part of the study is in addition to the routine data collected for all transplant patients.

9.6 Schedule of testing for correlative science studies

Please see section 8.2.1 - Schedule of testing for MRD and correlative science (please also see appendices 7, 8 and 12)
10.0 Data Collection & Management

All documents must be available for inspection by the appropriate authorities upon request.

10.1 Completing Forms

The original CRFs must be sent to the UCL CTC and a copy kept at site. All entries must be clear and legible. The use of abbreviations and acronyms must be avoided. The treating clinician is responsible for the accuracy of all data reported in the CRF. All CRFs must be signed off by staff who are listed on the site staff delegation log as performing this duty.

10.2 Corrections

Any corrections must be made by drawing a single line through the incorrect item whilst ensuring that the previous entry is not obscured. Each correction must be dated and initialled. Tippex must not be used.

10.3 Missing Data

To avoid the need for unnecessary data queries CRFs must be checked at site for blank fields before sending to the UCL CTC. When data is unavailable because a measure has not been taken or test not performed, enter “ND” for not done. If a measure was not required at the particular time the form relates to, enter “N/A” for not applicable. When data is unknown enter the value “NK” (only use if every effort has been made).

10.4 Queries

Data arriving at the UCL CTC will be checked for completeness, accuracy and consistency of data. Queries will be sent out sites. When completing a query, attach an amended copy of your case report form and please mail to the UCL CTC. All amendments must be initialled and dated.

10.5 Submission Timelines

UK sites must complete and return CRFs to the UCL CTC within one month of the patient being seen. Sites outside the UK must complete and return CRFs to their country co-ordinating centre within one month of the patient being seen. Country co-ordinating centres must forward all CRFs to the UCL CTC within 5 business days.

10.6 Archiving of Trial Documentation

At the end of the trial, the UCL CTC will archive securely all trial related documentation for 5 years. Arrangements for confidential destruction will then be made. It is the responsibility of PIs to keep all essential documents relating to the trial for a minimum of 5 years after the end of the trial and in accordance with national legislation and for the maximum period of time permitted by the site. Essential documents are those which enable both the conduct of the trial and the quality of the data produced to be evaluated and show whether the site complied with the principles of Good Clinical Practice and all applicable regulatory requirements.
11.0 Pharmacy

Please see separate UKALL14 drug supply document for initial drug supply guidelines, section 7.0 for treatment schedule and appendices 2-4 for full details of IMPs and supporting medications.

11.1 Pharmacy responsibilities

Please see separate UKALL14 drug supply guidelines and Clinical Trial Site Agreement.

11.2 Drug accountability

Accountability for Rituximab, Nelarabine, Palifermin and Pegylated Asparaginase at participating sites is the responsibility of the Principal Investigator, who may delegate this responsibility to the local pharmacist, or other appropriately qualified personnel. The responsible person will ensure that the Rituximab, Nelarabine, Palifermin and Pegylated Asparaginase are used only in accordance with this protocol and that appropriate drug accountability records are maintained.

The trial drugs must not be used outside the context of this protocol. Under no circumstances should the site investigator or other site personnel supply trial drug to other investigators, patients, or clinics, or allow supplies to be used other than directed by this protocol without prior authorisation from the Supplier and notification to the Sponsor.

The site pharmacy must maintain drug accountability records for the 4 drugs listed above including receipt dispensing, returned medication, storage conditions and destruction of returned/unused medication. Sites are permitted to use their own drug accountability systems as long as the required information above is recorded and available to the Sponsor.
12.0 Pharmacovigilance

12.1 Definitions of Adverse Events

The following definitions have been adapted from Directive 2001/20/EC, ICH E2A “Clinical Safety Data Management: Definitions and Standards for Expedited Reporting” and ICH GCP E6:

**Adverse Event (AE)**

Any untoward medical occurrence or effect in a patient treated on a trial protocol, which does not necessarily have a causal relationship with a trial treatment. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with the use of a trial treatment, whether or not related to that trial treatment.

**Adverse Reaction (AR)**

All untoward and unintended responses to a trial treatment related to any dose administered. A causal relationship between a trial treatment and an adverse event is at least a reasonable possibility, i.e. the relationship cannot be ruled out.

**Serious Adverse Event (SAE) or Serious Adverse Reaction (SAR)**

An adverse event or adverse reaction that at any dose:

- Results in death
- Is life threatening (The term “life-threatening” refers to an event in which the subject was at risk of death at the time of the event. It does not refer to an event that hypothetically might have caused death if it were more severe.)
- Requires in-patient hospitalisation or prolongs existing hospitalisation
- Results in persistent or significant or disability/incapacity
- Is a congenital anomaly or birth defect
  Is otherwise medically significant (i.e. important medical events that may not be immediately life-threatening or result in death or hospitalisation but may jeopardise the patient or may require intervention to prevent one of the other outcomes listed above)

**Suspected Unexpected Serious Adverse Reaction (SUSAR)**

A serious adverse reaction, the nature or severity of which is not consistent with the applicable trial treatment information.
12.2 Reporting Procedures

12.2.1 All Adverse Events (AEs)
All adverse events must be recorded in the patient notes. The maximum severity grade of all adverse events that occur between informed consent and 30 days post consolidation (for non transplant patients) or 30 days post transplant (for transplant patients) must be recorded on the trial CRFs. Those meeting the definition of a Serious Adverse Event (SAE) must also be reported to the UCL CTC using the trial specific SAE Report. Also refer to section 12.2.2 (Serious Adverse Events (SAEs)).

Pre-existing conditions do not qualify as adverse events unless they worsen.

12.2.1.1 Overdoses
All accidental or intentional overdoses, whether or not they result in adverse events, must be recorded in the patient notes and CRFs. Overdoses resulting in an adverse event are classified as SAEs and must also be reported to UCL CTC according to SAE reporting procedures. The fact that an overdose has occurred must be clearly stated on the SAE Report. Also refer to section 12.2.2 (Serious Adverse Events (SAEs)).

Sites must inform UCL CTC immediately when an overdose has been identified. Also refer to section 13 (Incident Reporting and Serious Breaches).

12.2.1.2 Adverse Event Term
An adverse event term must be provided for each adverse event, preferably using the term listed in the Common Terminology Criteria for Adverse Events (CTCAE) v4.0 available online at:

12.2.1.3 Severity
Severity for each adverse event must be determined by using the Common Terminology Criteria for Adverse Events (CTCAE) v4.0 as a guideline, wherever possible. The criteria are available online at

In those cases where the CTCAE criteria do not apply, severity should be coded according to the following criteria:
1 = Mild (awareness of sign or symptom, but easily tolerated)
2 = Moderate (discomfort enough to cause interference with normal daily activities)
3 = Severe (inability to perform normal daily activities)
4 = Life threatening (immediate risk of death from the reaction as it occurred)
5 = Fatal (the event resulted in death)
12.2.1.4 Causality

The PI, or other delegated site investigator must perform an evaluation of causality for each adverse event. Causal relationship to the trial treatment must be determined as follows:

- **None**
  
  There is no evidence of any causal relationship.

- **Unlikely**
  
  There is little evidence to suggest a causal relationship (e.g. because the event did not occur within a reasonable time after administration of the trial treatment). There is another reasonable explanation of the event (e.g. the patient’s clinical condition, other concomitant treatments).

- **Possibly**
  
  There is some evidence to suggest a causal relationship (e.g. because the event occurs within a reasonable time after administration of the trial treatment). However, the influence of other factors may have contributed to the event (e.g. the patient’s clinical condition, other concomitant treatments).

- **Probably**
  
  There is evidence to suggest a causal relationship and the influence of other factors is unlikely.

- **Definitely**
  
  There is clear evidence to suggest a causal relationship and other possible contributing factors can be ruled out.

A causal relationship for an event only needs to be assigned to the trial treatment given in the last 30 days, unless the event is thought to be a long term effect of treatment. For example, if a patient receives Rituximab in Phase 1 induction and suffers an AE or SAE during intensification.

12.2.2 Serious Adverse Events (SAEs)

All SAEs that occur between informed consent and 30 days post the last IMP administration, or 30 days post transplant for transplant patients (or after this date if the site investigator feels the event is related to one of the IMPs.) must be submitted to UCL CTC by fax within 1 business day of observing or learning of the event, using the trial specific SAE Report. All sections on the SAE Report must be completed. If the event is not reported within 1 business day to UCL CTC, the circumstances that led to this in the SAE report must be detailed to avoid unnecessary queries.

12.2.2.1 Events which do not Require Immediate Reporting on an SAE Report

The following events do not require immediate reporting on an SAE Report for this trial, but must be recorded in the relevant section(s) of the CRF (please see section 12.2.1)

- Disease progression
- Disease related deaths
- GvHD
- Graft Failure
- Secondary Malignancy
Please note that hospitalisation for elective treatment or palliative care does not qualify as an SAE.

Completed SAE Reports must be faxed within 24 hours of becoming aware of the event, to UCL CTC
Fax: +44 (0)20 7679 9861
12.2.2.3 Adverse Event Reporting Flowchart

1. Adverse event
2. Assign severity grade
3. Investigator to assess causality
   Is the event causally related to the trial treatment?
4. Was the event serious?
   Criteria:
   • Results in death
   • Is life threatening
   • Results in persistent or significant disability/incapacity
   • Requires in-patient hospitalisation or prolongs existing hospitalisation
   • Results in a congenital anomaly or birth defect
   • Is otherwise medically significant
   - Yes
     - Event exempt from requiring submission on an SAE Report? (as stated in protocol)
       - Yes
       - Complete CRF (to be submitted at time point stated in protocol)
       - No
       - Complete SAE Report
         - Fax Report to UCL CTC within 24 hours of becoming aware of the event
   - No
     - Complete SAE Report

Event exempt from requiring submission on an SAE Report? (as stated in protocol)

Yes

No
All SAEs must be followed-up until resolution and until there are no further queries. The PI, or other delegated site investigator must provide follow-up SAE Reports if the SAE had not resolved at the time the initial report was submitted.

12.2.2.5 SAE Processing at UCL CTC

On receipt of the SAE Report, UCL CTC will evaluate the event for seriousness and expectedness to determine whether or not the case qualifies for expedited reporting. Expectedness will be evaluated using the list of expected adverse events in the current SPCs for Rituximab, Oncaspar, Nelarabine and Palifermin. The CI, or their delegate (e.g. a clinical member of the TMG), may be contacted to review the SAE and to perform an evaluation of causality on behalf of UCL CTC. If UCL CTC has considered expectedness difficult to determine, the CI, or their delegate, will be consulted for their opinion at this time.

UCL CTC will submit individual case SAE Reports concerning patients who have received Pegylated Asparaginase, Rituximab, Nelarabine or Palifermin to Medac GbmH, Roche, Glaxosmithkline or Swedish Orphan Biovitrum respectively within 1 business day of becoming aware of the minimum data elements.

UCL CTC will provide Roche with quarterly line listings of SARs related to Rituximab.

12.3 SUSARs

If the event is evaluated as a Suspected Unexpected Serious Adverse Reaction (SUSAR), UCL CTC will submit a report to the applicable regulatory authority within the EEA within 7 calendar days for fatal/life threatening events (with a follow-up report within a further 8 calendar days) and 15 calendar days for all other events.

Where the SUSAR has occurred outside the UK but within the EEA, UCL CTC will enter the case on the EudraVigilance Clinical Trial Module in order to notify the European Medicines Agency and applicable regulatory authorities. Where the SUSAR has occurred within the UK or outside the EEA, UCL CTC will submit the report directly to the MHRA for them to enter the case on the EudraVigilance Clinical Trial Module. UCL CTC will also report all SUSARs originating in the UK to the UK REC.

UCL CTC will also submit the report to country co-ordinating centres/country lead sites (CCCs/CLSs) within 6 calendar days for fatal/life threatening events (with a follow-up report within a further 7 calendar days) and 14 calendar days for all other events. CCCs/CLSs must forward all SUSAR reports to their ethics committee(s), as required, and their regulatory authority (for non-EEA countries only), if applicable, within 1 business day. UCL CTC will ensure that consideration is given where the reporting deadline occurs at a weekend to allow reporting within the required timeframes.
Where there are conflicting evaluations of causal relationship by the site and UCL CTC/CI, both opinions will be reported.

12.4 Safety Monitoring
UCL CTC will provide safety information to the TMG and the IDMC on a periodic basis for review.
Trial safety data will be monitored to identify:
- new adverse reactions to the trial treatment regimen or individual trial treatments;
- a higher incidence in rare adverse events than is stated in the IB/SPC for a trial treatment;
- trial related events that are not considered related to the trial treatment regimen.
Should UCL CTC identify or suspect any issues concerning patient safety at any point throughout the trial, the CI or TMG will be consulted for their opinion.

12.5 Pregnancy
If a female patient or a female partner of a male patient becomes pregnant at any point during the trial, a completed trial specific Pregnancy Report must be submitted to UCL CTC by fax within 24 hours of learning of its occurrence. Consent to report information regarding the pregnancy must be obtained from the pregnant patient/partner. The trial-specific pregnancy monitoring information sheets and informed consent forms for trial patients and the partners of trial patients must be used for this purpose.

All pregnancies must be reported by faxing a completed Pregnancy Report within 24 hours day of becoming aware of the pregnancy to UCL CTC
Fax: +44 (0)20 7679 9861

12.5.1 Pregnancy Follow-Up Reports
All pregnancies must be followed-up until an outcome is determined. Follow-up Pregnancy Reports must be submitted to UCL CTC by fax within 24 hours of learning of the outcome. Reports must include an evaluation of the possible relationship of the trial treatment to the pregnancy outcome.

12.5.2 SAEs During Pregnancy
Any SAE occurring in a pregnant patient must be reported using the trial specific SAE Report, according to SAE reporting procedures. Refer to section 12.2.2 (Serious Adverse Events (SAEs)) for details.

12.5.3 Pregnancy Report Processing at the UCL CTC
UCL CTC will submit all Pregnancy Reports to Medac GmbH, Roche, Glaxosmithkline and Swedish Orphan Biovitrum concerning patients who have been administered the products they supply for the trial within 1 business day.
UCL CTC will submit reports to all relevant regulatory authorities within the EEA, the UK, REC and country co-ordinating centres/country lead sites should the pregnancy outcome meet the definition of a SUSAR. Also refer to section 12.3 (SUSARs).

12.6 Development Safety Update Reports (DSURs)
Safety data obtained from the trial will be included in DSURs that UCL CTC will submit to the MHRA, the UK REC and all CCCs/CLSs. CCCs/CLSs must forward all reports to the regulatory authority and ethics committee(s) in that country, as required, within 1 business day.

UCL CTC will provide Medac GmbH, Roche, Glaxosmithkline and Swedish Orphan Biovitrum with DSURs that include information regarding the products they supply for the trial.
13.0 Incident Reporting and Serious Breaches

13.1 Incident Reporting

Organisations must notify UCL CTC of all deviations from the protocol or GCP immediately. UCL CTC may require a report on the incident(s) and a form will be provided if the organisation does not have an appropriate document (e.g. Trust Incident Form for UK sites).

If site staff are unsure whether a certain occurrence constitutes a deviation from the protocol or GCP, the UCL CTC trial team can be contacted immediately to discuss.

Where the incident has occurred in a site outside the UK, the CCC/CLS in that country must also notify the relevant ethics committee in accordance with local requirements. Where UCL CTC identifies an incident at a site outside the UK, the CCC/CLS in the country where the incident occurred will be informed.

UCL CTC will assess all incidents to see if they meet the definition of a serious breach.

13.2 Serious Breaches

Systematic or persistent non-compliance by a site with GCP and/or the protocol, including failure to report SAEs occurring on trial within the specified timeframe, may be deemed a serious breach.

In cases where potential or actual a serious breach has been identified, UCL CTC will inform the MHRA within 7 calendar days and country co-ordinating centres and/or country lead sites within 6 calendar days of becoming aware of the breach. Country co-ordinating centres and/or country lead sites must forward all reports to the regulatory authority in that country, as required, within 1 business day.

UK sites must have written procedures for notifying the sponsor of serious breaches (MHRA Guidance on the Notification of Serious Breaches, 2009).

UCL CTC will use an organisation’s history of non-compliance to make decisions on future collaborations.
14.0 Withdrawal of patients

In consenting to the trial, patients are consenting to trial treatment, trial follow-up and data collection.

14.1 Withdrawal from Trial Treatment

The site investigator may withdraw a patient from the trial treatment whenever continued participation is no longer in the patient's best interests, but the reasons for doing so must be recorded. Reasons for discontinuing treatment may include:

- Disease progression whilst on therapy
- Unacceptable toxicity
- Intercurrent illness which prevents further trial treatment
- The patient withdraws consent to further trial treatment
- Any alterations in the patient's condition which justifies the discontinuation of treatment in the site investigator's opinion

In these cases patients remain within the trial for the purposes of follow-up and data analysis according to the treatment option to which they have been allocated. If a patient wishes to withdraw from trial treatment, sites should explain the importance of remaining on trial follow-up, or failing this of allowing routine follow-up data to be used for trial purposes.

14.2 Withdrawal of Consent to Data Collection

If a patient explicitly states their wish not to contribute further data to the trial their decision must be respected and recorded on the relevant CRF.

Details should be recorded in the patient's hospital records and no further CRFs must be completed.

14.3 Moving

For patients moving from the area, every effort should be made for the patient to be followed up at another participating trial site and for this new centre to take over the responsibility for the patient, or for follow-up via GP.

14.4 Lost to follow-up

If a patient is lost to follow-up every effort should be made to contact the patient's GP (if consented) to obtain information on the patient's status.

Patients lost to follow up can be tracked via the NHS Information Centre
15.0 Discontinuation/ End of the Trial

15.1 Trial closure
For regulatory purposes the end of the trial will be defined as the end of the follow up phase (2 years after the end of maintenance or 4 years after the date of stem cell infusion for transplant patients) at which point the ‘declaration of end of trial’ form will be submitted to participating regulatory authorities and ethical committees, as required. However, this will be followed by the non-interventional phase of long-term follow-up, which will continue indefinitely after the final patient entered onto the trial has completed trial follow up (2 years after the end of maintenance or 4 years after the date of stem cell infusion for transplant patients).

15.2 Archiving of Trial Documentation
At the end of the trial, the UCL CTC will archive securely all centrally held trial related documentation for 5 years. Arrangements for confidential destruction will then be made. It is the responsibility of the PI’s to keep all data and essential documents relating to the trial held at site, for a minimum of 5 years after the end of the trial and in accordance with national legislation and for the maximum period of time permitted by the site.
If a patient withdraws consent for their data to be used, it will be confidentially destroyed.
All documents must still be available for inspection by the appropriate authorities upon request.

15.3 Early discontinuation of trial
The trial may be stopped before completion upon recommendation of the TSC or IDMC (see section 16 Sites will be informed by UCL CTC in writing of reasons for early closure and actions to be taken with regards to trial patients. Patients should continue to be followed up as per protocol.

15.4 Withdrawal from trial participation by sites
When closing the trial at a site Investigators must inform the UCL CTC in writing with reasons for withdrawal. Follow up as per protocol should continue for all patients recruited into the trial at that site.
If a patient withdraws consent for their data to be used, it will be confidentially destroyed immediately.
16.0 Trial Monitoring and oversight

16.1 Monitoring

UK participating sites and PIs must agree to allow trial-related on-site monitoring, Sponsor audits, and regulatory inspections by providing direct access to source data/documents as required. Patients are informed of this in the patient information sheet and are asked to consent to their medical notes being reviewed by appropriate individualson the consent form.

16.1.1 Central monitoring

Sites will be requested to submit screening logs and staff delegation logs to UCL CTC at the frequency detailed in the trial monitoring plan or on request, and these will be checked for consistency and completeness.

Eligibility of all patients entered in the trial is assessed by the PI, or, if delegated by the PI, other appropriately trained site staff. Checks of the criteria listed on the registration form will be (Registration & Randomisations (B & T) at study entry).

Sites will be required to maintain a log of all patient informed consent forms that have been completed at site (regardless of whether the patient is subsequently registered/randomised to the trial). This log will include details of the versions of informed consent form/patient information sheet used, patient completion of the consent form, the name of the person taking consent, etc. A copy of the log must be submitted to UCL CTC at the frequency detailed in the trial monitoring plan or on request. Also refer to section 4 (Informed Consent).

Copies of completed drug accountability logs will be collected at UCL CTC for all trial patients. Sites will be required to submit logs at the frequency detailed in the trial monitoring plan or on request. A proportion of these will be monitored centrally to ensure completeness and correlation with data captured in the CRF. Also refer to section 11.2 (Drug Accountability).

Sites will be requested to conduct quality control checks of documentation held within the Investigator Site File and Pharmacy Site File at the frequency detailed in the trial monitoring plan. Checklists detailing the current version/date of version controlled documents will be provided for this purpose.

Data received at UCL CTC will be subject to review in accordance with section 10.4 (Queries). Where central monitoring of data and/or documentation submitted by sites indicates that a patient may have been placed at risk (e.g. evidence of an overdose having been administered, indication that dose modifications for an IMP were not observed following an adverse reaction, etc.), the matter will be raised urgently with site staff and escalated as appropriate (refer to section 13 (Incident Reporting and Serious Breaches) and 16.1.2 (‘For cause’ on-site monitoring) for further details).
16.1.2 ‘For Cause’ On-Site Monitoring

On-site monitoring visits may be scheduled where there is evidence or suspicion of non-compliance at a site with important aspect(s) of the trial protocol/GCP requirements. Sites will be sent a letter in advance outlining the reason(s) for the visit. The letter will include a list of the documents that are to be reviewed, interviews that will be conducted, planned inspections of the facilities, who will be performing the visit and when the visit is likely to occur.

16.1.3 Monitoring report

Following any monitoring visit, the monitor/TC will provide a report to the site, which will summarise the documents reviewed, and a statement of findings, deviations, deficiencies, conclusions, actions taken or recommended and actions required. The PI at the site will be responsible for ensuring that monitoring findings are addressed (this may be delegated to an appropriate member of staff).

UCL CTC will assess whether it is appropriate for the site to continue participation in the trial and whether the incident(s) constitute a serious breach. Refer to section 13 (Incident Reporting and Serious Breaches) for details.

16.2 Oversight Committees

16.2.1 Trial Management Group (TMG)

The TMG will include the Chief Investigator, clinicians and experts from relevant specialities and UKALL14 trial staff from UCL CTC (see page 2). The TMG will be responsible for overseeing the trial. The group will meet regularly and will send updates to PI (via newsletters or at Investigator meetings) and to report to the appropriate NCRI Clinical Studies Group.

The TMG will review substantial amendments to the protocol prior to submission to the REC, MHRA and other applicable regulatory authorities. All PIs will be kept informed of substantial amendments through their nominated responsible individuals.

16.2.2 Trial Steering Committee (TSC)

The role of the TSC is to provide overall supervision of the trial. The TSC will review the recommendations of the Independent Data Monitoring Committee and, on consideration of this information, recommend any appropriate amendments/actions for the trial as necessary. The TSC acts on behalf of the funder(s) and Sponsor.

16.2.3 Independent Data Monitoring Committee (IDMC)

The role of the IDMC is to provide independent advice on the data and safety aspects of the trial. Meetings of the Committee will be held periodically to review interim analyses, or as necessary to address any issues. The IDMC is advisory to the (TSC) and can recommend premature closure of the trial to the TSC.

16.2.4 Role of UCL CTC

UCL CTC will be responsible for the day to day coordination and management of the trial and will act as custodian of the data generated on the trial (on behalf of UCL). UCL CTC is responsible for all duties relating to pharmacovigilance which are conducted in accordance with section 12 (Pharmacovigilance).
17.0 Statistics

17.1 Population for analysis
The population for this trial will be adult patients age 25-65 years, inclusive. The primary objective of this study is to compare the event-free survival (EFS) in a phase III trial of patients with B cell precursor ALL receiving either Rituximab in conjunction with chemotherapy to chemotherapy alone. The primary endpoint of the trial is event free survival (EFS) and all analysis for this endpoint will be on an intention to treat basis.

The incidence of cases of ALL within the age range of the trial (25-65 years) in England in the decade between 1997 and 2006 suggests that there will be 150 eligible patients per year in the UK. The aim is to recruit 80% of eligible patients, giving 120 per year. The target overall recruitment is thus 720 patients over 6 years or 840 patients over 7 years. This would give 576 or 672 patients expected to be B lineage-ALL and randomized equally between two treatment arms.
20% of patients are expected to be T lineage, so there will be 144 or 168 T-lineage.

The Trial Steering Committee will assess at the time whether it is feasible and necessary to continue recruitment for the seventh year, blinded to randomised treatment results.

17.2 Analysis of the primary objective(s)
The primary endpoint, EFS, is defined as time from randomization to relapse or to death from any cause. Curves for the comparison of EFS will be produced using the method of Kaplan-Meier and compared using the log-rank test.

Subgroup analyses will be performed in patient groups aged <40 and ≥40 years. If a relationship between CD20 expression and response is found, this will be used to define positive and negative groups for subgroup analysis of EFS by treatment.

Primary objective in patients with B-lineage disease: effect of antibody on EFS
For the evaluation of additional benefit of antibody to chemotherapy in terms of EFS in patients with B cell precursor ALL, the effect of the antibody will be tested at a two-sided significance level of 0.05, using the log rank test using all randomized patients (intention-to-treat analysis).

Primary objective in patients with T lineage disease: effect of nelarabine on EFS
Patients with T-lineage disease enrolled in this study will be randomized between chemotherapy and the combination of Nelarabine and chemotherapy as a phase II study to determine if Nelarabine improves the EFS of patients with T-cell ALL.
17.3 Analysis of secondary objectives

Tolerability of pegylated asparaginase in induction
Cases of hypersensitivity to peg-asparaginase will be recorded, plus changes to Erwinia or withdrawal of asparaginase treatment.

Toxicity of RIC BMT
An early loss of 16% of patients due to induction failure or relapse is expected before transplant can be reached. About 1/3 of patients will have a matched sibling donor and about 1/2 of those without such a donor might be expected to be high risk, giving 2/3 eligible for transplant, of whom about half can be expected to be over 40 years old. Thus 720 or 840 recruited patients would result in 201 or 235 who might receive a reduced intensity conditioned transplant. Based on UKALLXII/E2993 data, some of these will be excluded on the basis of liver function, or other, tests, so we would expect perhaps 150 or 175 to receive the transplant. Currently the treatment related mortality (TRM) of transplant in this age group is over 40%. Unfortunately it would be impractical to randomize between standard and RIC BMT, and thus a historical comparison is necessary and results should be treated with the appropriate caution. It is expected that the reduction in toxicity will be substantial, maybe as much as halved. As there may be an increase in relapses, EFS will be the primary outcome with the current rate of 40% at 3 years post transplant.

Palifermin randomization
In the palifermin study, approximately 150 or 175 patients treated with myeloablative HSCT will be randomized to evaluate the “standard dose” of palifermin vs. a single “collapsed” dose in reducing the incidence of Grades 3 or 4 mouth and throat soreness (MTS) scores. The randomization will be stratified by gender, sibling/MUD donor & precursor-B/T lineage.
Outcome measures are:
1. OMDQ 2. Number of doses of MTX administered 3. Acute GVHD

17.3.1 Efficacy (secondary)
- Secondary outcomes will be
- Overall survival
- Complete remission rate
- Death in complete remission
- Relapse rate (actuarial incidence of relapse, excluding non-remitters and censoring at death in remission)
- Bone marrow relapse rate (actuarial incidence of relapse involving the bone marrow, excluding non-remitters and censoring at relapse at other sites and death in remission)
- Central nervous system (CNS) relapse rate (actuarial incidence of relapse involving the CNS, excluding non-remitters and censoring at relapse of other sites and death in remission)
- For the antibody randomisations only: anti-asparaginase levels and asparaginase activity prior to asparaginase infusions.
• Minimal Residual Disease at the end of Phase 1 Induction (antibody randomisation) or post transplant

17.3.2 Safety
All grade 3 or 4 toxicities will be reported.

17.4 Sample size calculations
Addition of monoclonal antibody to standard induction chemotherapy in patients with precursor B-ALL
The power calculations of the comparisons are made under the assumption that the 3-year EFS of the chemotherapy in this patient population (based on UKALLXII/E2993 data) is approximately 40%. With 576 (or 672 with 7 years accrual) patients randomised, there is 84% (or 89%) power to detect an improvement in 3-year EFS from 40% to 52%.

Addition of Nelarabine to standard induction chemotherapy in patients with precursor T-ALL
With 144 (or 168 with 7 years accrual) patients randomized, we would have over 86% power to detect an improvement in 3-year EFS from 50% to 75%, and about 68% (or 75% with 7 years accrual) power to detect an improvement to 70%, at a two-sided significance level of 0.05.

17.5 Power for analysis of critical secondary variables
Palifermin randomisation
Based on the references from Spielberger et al., and T. Shea et al., we assumed a range of incidence of Grades 3 or 4 MTS scores of 60%, 70% and 80% for the standard dose arm, and 30%, 40% and 50% for the collapsed dose arm, and a two-sided alpha level of 0.05, the table below provides the power for 75 patients per arm.

<table>
<thead>
<tr>
<th></th>
<th>30%</th>
<th>40%</th>
<th>50%</th>
<th>60%</th>
</tr>
</thead>
<tbody>
<tr>
<td>60%</td>
<td>97%</td>
<td>69%</td>
<td>23%</td>
<td>NA</td>
</tr>
<tr>
<td>70%</td>
<td>99%</td>
<td>97%</td>
<td>71%</td>
<td>26%</td>
</tr>
<tr>
<td>80%</td>
<td>99%</td>
<td>99%</td>
<td>99%</td>
<td>84%</td>
</tr>
</tbody>
</table>

The null hypothesis is that the incidence is the same between the standard dose and the collapsed dose arms. The alternative hypothesis is that there is a difference between the two arms. With 75 patients per arm, the study would have at least 69% power to detect a treatment difference of at least 20%.

Since the patients are hospitalized, the MTS evaluation period is relatively short (until discharge or 28 days post-transplant) and the worst score for a patient will be used for the incidence calculation, the sample size loss due to non-compliance and loss to follow up will be small and the resulting power loss will be negligible.
17.6 Interim analysis

Interim analyses of the main endpoints will be supplied approximately annually, in strict confidence, to a data monitoring committee (DMC) starting in the fourth year of recruitment, or when 300 patients have been entered, whichever is the sooner. This will allow 4 or 5 planned interim analyses to be performed before the completion of the trial at 8 years, with the first occurring when about 25% of the expected events have happened. In the light of these interim analyses, the DMC will advise the MRC Leukaemia Steering Committee if, in their view, the randomized comparisons in the trial have provided proof beyond reasonable doubt ($P < 0.001$) that for all or for some types of patient one treatment is clearly indicated or clearly contraindicated.

The main analyses will be performed using standard log-rank methods based on the intention to treat, i.e. all patients believed to be eligible at the time of randomization will be included in the analysis, irrespective of protocol compliance, early relapse, etc. All analyses will assume that there may be some quantitative differences in the size of any treatment effects in different strata, but that there is unlikely to be any qualitative difference (i.e. harm in one group, benefit in another).

Final analyses will be performed when the last patient randomized has been followed up for 2 years, i.e. after all patients have finished their initial treatment.
18.0 Ethical and Regulatory Approvals

In conducting the Trial, the Sponsor, UCL CTC and Sites shall also comply with all laws and statutes, as amended from time to time, applicable to the performance of clinical trials including, but not limited to:

- Applicable Good Clinical Practice requirements as outlined in Directives 2001/20/EC and 2005/28/EC and all laws implementing these in the relevant country(ies), and any amendments thereto and where applicable incorporating elements of ICH Harmonised Tripartite Guideline for Good Clinical Practice (CPMP/ICH/135/95) the Human Rights Act 1998
- the Data Protection Act 1998
- the Freedom of Information Act 2000
- the Human Tissue Act 2004
- the Medicines Act 1968
- the Medicines for Human Use (Clinical Trials) UK Regulations SI 2004/1031, and subsequent amendments
- Good Manufacturing Practice
- the Research Governance Framework for Health and Social Care, issued by the UK Department of Health (Second Edition 2005) or the Scottish Health Department Research Governance Framework for Health and Community Care (Second Edition 2006)

All non-UK sites shall comply with all their local laws and statutes applicable to the performance of clinical trials.

18.1 Ethical Approval

The trial will be conducted in accordance with the World Medical Association the Declaration of Helsinki entitled ‘Ethical Principles for Medical Research Involving Human Subjects’ (1996 version) and in accordance with the terms and conditions of the ethical approval given to the trial.

The trial has received a favourable opinion from the NRES Committee London - Fulham. The UCL CTC will submit Annual Progress Reports to the REC, which will commence one year from the date of ethical approval for the trial.

18.2 Regulatory Approval

A Clinical Trial Authorisation (CTA) has been granted for the trial.

The trial will be conducted at approved trial sites in accordance with the trial protocol and the terms of the CTA granted by the MHRA and other applicable regulatory authorities.

18.3 Site Approvals

The Lead Comprehensive Local Research Network (CLRN) Central and East London Comprehensive Local Research Network has given NHS permission following global governance checks. Local governance checks will be undertaken by local CLRN associated with individual trial sites.
Evidence of approval from the Trust R&D for a trial site must be provided to UCL CTC. Sites will only be activated when all necessary local approvals for the trial have been obtained.

All non-UK sites must provide confirmation of approval of their local institution(s).

18.4 Protocol Amendments
UCL CTC will be responsible for gaining ethical and regulatory approval(s), as appropriate, for amendments made to the protocol and other trial-related documents. Once approved, UCL CTC will ensure that all amended documents are distributed to sites and CLRNs as appropriate.

Site staff will be responsible for acknowledging receipt of documents and for implementing all amendments.

18.5 Patient Confidentiality & DPA
Patient identifiable data, including initials, date of birth, Hospital Number and NHS number will be required for the registration/randomisation process and will be provided to UCL CTC. UCL CTC will preserve patient confidentiality and will not disclose or reproduce any information by which patients could be identified. Data will be stored in a secure manner and UCL CTC trials are registered in accordance with the Data Protection Act 1998 with the Data Protection Officer at UCL.
19.0 Sponsorship and Indemnity

19.1 Sponsor Details:

**Sponsor Name:**  University College London  
**Sponsor Contact:**  Managing Director Research Support Centre

**Telephone:**  +44 (0) 20 3447 9995/2178 (unit admin)  
**Fax:**  +44 (0) 20 3447 9937  
Joint Research Office  
Gower Street  
Address:  London  
WC1E 6BT

19.2 Indemnity:

University College London holds insurance to cover participants for injury caused by their participation in the clinical trial. Participants may be able to claim compensation if they can prove that UCL has been negligent. However, as this clinical trial is being carried out in a hospital, the hospital continues to have a duty of care to the participant of the clinical trial. University College London does not accept liability for any breach in the hospital’s duty of care, or any negligence on the part of hospital employees. This applies whether the hospital is an NHS Trust or not. This does not affect the participant’s right to seek compensation via the non-negligence route.

Participants may also be able to claim compensation for injury caused by participation in this clinical trial without the need to prove negligence on the part of University College London or another party. Participants who sustain injury and wish to make a claim for compensation should do so in writing in the first instance to the Chief Investigator, who will pass the claim to the Sponsor’s Insurers, via the Sponsor’s office.

Hospitals selected to participate in this clinical trial shall provide clinical negligence insurance cover for harm caused by their employees and a copy of the relevant insurance policy or summary shall be provided to University College London, upon request.
**20.0 Publication Policy**

All publications and presentations relating to the trial will be authorised by the TMG. The first publication of the trial results will be in the name of the TMG, if this does not conflict with the journal’s policy. The TMG will form the basis of the writing committee and advise on the nature of publications. If there are named authors, these should include the Chief Investigator, Trial Coordinator, and Statistician involved in the trial. Contributing site investigators in this trial will also be acknowledged. Data from all sites will be analysed together and published as soon as possible. Participating sites may not publish trial results prior to the first publication by the TMG or without prior written consent from the TMG.

The trial data is owned by UCL CTC. Drug companies who have provided grants towards the trial will be permitted to see the draft manuscripts and make comments at least 30 days prior to submission for publication. (to be confirmed)

The Eudract number (2009-012717-22) or the clinicaltrials.gov number once allocated to this trial will be quoted in any publications resulting from this trial.
21.0 References


50. Garderet L, Labopin M, Gorin NC, et al. Patients with acute lymphoblastic leukaemia allografted with a matched unrelated donor may have a lower survival with a peripheral blood stem cell graft compared to bone marrow. Bone Marrow Transplant. 2003;31:23-29.


### Appendix 1: Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>AE</td>
<td>Adverse Event</td>
</tr>
<tr>
<td>ALL</td>
<td>Acute Lymphoblastic Leukemia</td>
</tr>
<tr>
<td>ALT</td>
<td>Alanine transaminase</td>
</tr>
<tr>
<td>ANC</td>
<td>Absolute Neutrophil Count</td>
</tr>
<tr>
<td>AR</td>
<td>Adverse Reaction</td>
</tr>
<tr>
<td>AST</td>
<td>Aspartate aminotransferase</td>
</tr>
<tr>
<td>AVN</td>
<td>Avascular Necrosis</td>
</tr>
<tr>
<td>BMT</td>
<td>Bone Marrow Transplant</td>
</tr>
<tr>
<td>CCC</td>
<td>Country Co-ordinating Centre</td>
</tr>
<tr>
<td>CI</td>
<td>Chief Investigator</td>
</tr>
<tr>
<td>CLS</td>
<td>Country Lead Site</td>
</tr>
<tr>
<td>CMV</td>
<td>Cytomegalovirus</td>
</tr>
<tr>
<td>CNA</td>
<td>Copy Number Alteration</td>
</tr>
<tr>
<td>CNS</td>
<td>Central Nervous System</td>
</tr>
<tr>
<td>CR</td>
<td>Complete response</td>
</tr>
<tr>
<td>CRF</td>
<td>Case Report Form</td>
</tr>
<tr>
<td>CrCl</td>
<td>Creatinine Clearance</td>
</tr>
<tr>
<td>CT</td>
<td>Computerised Tomography</td>
</tr>
<tr>
<td>CTA</td>
<td>Clinical Trial Authorisation</td>
</tr>
<tr>
<td>CTAAC</td>
<td>Clinical Trials Advisory &amp; Awards Committee</td>
</tr>
<tr>
<td>CTCAE</td>
<td>see NCI CTCAE</td>
</tr>
<tr>
<td>CTSA</td>
<td>Clinical Trial Site Agreement</td>
</tr>
<tr>
<td>DFS</td>
<td>Disease Free Survival</td>
</tr>
<tr>
<td>DLI</td>
<td>Donor Lymphocyte Infusion</td>
</tr>
<tr>
<td>DPA</td>
<td>Data Protection Act</td>
</tr>
<tr>
<td>DSUR</td>
<td>Development Safety Update Report</td>
</tr>
<tr>
<td>ECG</td>
<td>Electrocardiogram</td>
</tr>
<tr>
<td>ECOG</td>
<td>Eastern Cooperative Oncology Group</td>
</tr>
<tr>
<td>EDTA</td>
<td>Ethylene Diamine Tetra Acetate</td>
</tr>
<tr>
<td>EFS</td>
<td>Event Free Survival</td>
</tr>
<tr>
<td>EudraCT</td>
<td>European Clinical Trials Database</td>
</tr>
<tr>
<td>FISH</td>
<td>Flourescent In Situ Hybridization</td>
</tr>
<tr>
<td>FBC</td>
<td>Full Blood Count</td>
</tr>
<tr>
<td>G-CSF</td>
<td>Granulocyte Colony Stimulating Factor</td>
</tr>
<tr>
<td>GVHD</td>
<td>Graft versus Host Disease</td>
</tr>
<tr>
<td>GFR</td>
<td>Glomerular Filtration Rate</td>
</tr>
<tr>
<td>GVL</td>
<td>Graft versus Lymphoma</td>
</tr>
<tr>
<td>HSCT</td>
<td>Hematopoietic Stem Cell Transplantation</td>
</tr>
</tbody>
</table>
TRM  Transplant Related Mortality
TMF  Trial Master File
TMG  Trial Management Group
TSC  Trial Steering Committee
UCL CTC  CR UK and UCL Cancer Trials Centre
U&E  Urea and Electrolyte
ULN  Upper Limit of Normal
VZV  Varicella Zoster Virus
WBC  White Blood Cells
WCC  White Cell Count
Appendix 2: IMP Information

It is recommended that sites follow local guidelines for dose adjustments for obese patients.

**Rituximab (Mabthera)**

**Formulation and storage**

<table>
<thead>
<tr>
<th>Chemical Name:</th>
<th>Rituximab</th>
</tr>
</thead>
<tbody>
<tr>
<td>Other Names:</td>
<td>Mabthera®</td>
</tr>
<tr>
<td>Physical Characteristics:</td>
<td>Concentrate for solution for infusion. Clear, colourless liquid</td>
</tr>
</tbody>
</table>

**Description**

Rituximab is a genetically engineered chimeric mouse/human monoclonal antibody representing a glycosylated immunoglobulin with human IgG1 constant regions and murine light-chain and heavy-chain variable region sequences. The antibody is produced by mammalian (Chinese hamster ovary) cell suspension culture and purified by affinity chromatography and ion exchange, including specific viral inactivation and removal procedures.

Rituximab is supplied as a clear, colourless liquid. It is a concentrate for solution for infusion. Rituximab comes in 500mg and 100mg vials containing concentrate for solution for infusion. Each solution contains 10mg/ml of rituximab.

Rituximab should be stored in a refrigerator (2 °C – 8 °C). Keep the container in the outer carton in order to protect from light.

The prepared infusion solution of Rituximab is physically and chemically stable for 24 hours at 2 °C - 8 °C and subsequently 12 hours at room temperature.

Please refer to the SmPC for more information.

**Administration**

Aseptically withdraw the necessary amount of MabThera, and dilute to a calculated concentration of 1 to 4 mg/ml rituximab into an infusion bag containing sterile, pyrogen-free sodium chloride 9 mg/ml (0.9 %) solution for injection or 5 % Glucose in water. For mixing the solution, gently invert the bag in order to avoid foaming. Care must be taken to ensure the sterility of prepared solutions. Since the medicinal product does not contain any anti-microbial preservative or bacteriostatic agents, aseptic technique must be observed.

Parenteral medicinal products should be inspected visually for particulate matter and discoloration prior to administration. Any unused product or waste material should be disposed of in accordance with local requirements.

The prepared Rituximab solution should be administered as an intravenous infusion through a dedicated line. It should not be administered as an intravenous push or bolus.
Rituximab infusions should be administered under the close supervision of an experienced physician, and in an environment where full resuscitation facilities are immediately available. Premedication consisting of an anti-pyretic and an antihistaminic, e.g. paracetamol and diphenhydramine, should always be administered before each infusion of Rituximab. Premedication with glucocorticoids should also be considered.

The recommended initial rate for infusion is 50 mg/hr; after the first 30 minutes, it can be escalated in 50 mg/hr increments every 30 minutes, to a maximum of 400 mg/hr.

Subsequent doses of MabThera can be infused at an initial rate of 100 mg/hr, and increased by 100 mg/hr increments at 30 minutes intervals, to a maximum of 400 mg/hr.

For second and subsequent doses, it is acceptable to give Rituximab according to the escalated infusion protocol- to give 20% of the infusion over 30 minutes, with the remaining 80% given over an hour.

Patients should be closely monitored for the onset of cytokine release syndrome. Patients who develop evidence of severe reactions, especially severe dyspnoea, bronchospasm or hypoxia should have the infusion interrupted immediately. Patients should be evaluated for evidence of tumour lysis syndrome including appropriate laboratory tests and, for pulmonary infiltration, with a chest x-ray. In all patients, the infusion should not be restarted until complete resolution of all symptoms, and normalisation of laboratory values and chest x-ray findings. At this time, the infusion can be initially resumed at not more than one-half the previous rate. If the same severe adverse reactions occur for a second time, the decision to stop the treatment should be seriously considered on a case by case basis.

Mild or moderate infusion-related reactions usually respond to a reduction in the rate of infusion. The infusion rate may be increased upon improvement of symptoms.

A dose of 375mg/m² should be given by IV on days 3,10,17 & 24 of Phase 1 Induction Therapy.
Pegylated Asparaginase

**Formulation and storage**

<table>
<thead>
<tr>
<th>Chemical Name:</th>
<th>Pegylated asparaginase</th>
</tr>
</thead>
<tbody>
<tr>
<td>Other Names:</td>
<td>Pegaspargase, Oncaspar®</td>
</tr>
<tr>
<td>Physical Characteristics:</td>
<td>Solution for injection</td>
</tr>
</tbody>
</table>

**Description**

Oncaspar® is a medicinal product (cytostatic agent) which lowers the L-asparaginase level in the tumour cells so that the protein synthesis in these cells is inhibited.

**Administration**

When administered intravenously Oncaspar® should be given over a period of 1-2 hours in 100ml sodium chloride 0.9% or glucose 5% into a free flowing infusion.

Oncaspar® is available in packs with:

1 vial (type I glass) containing 5 ml ready-to-use solution for injection [N1] (German labelling) or
1 vial (type I glass) containing 5 ml ready-to-use solution for injection [N1] (German-English labelling).

Not all pack sizes may be marketed.

1 vial contains 3750 I.U. pegasparagase (equivalent to 750 I.U./ml), in a clear colourless phosphate-buffered sodium chloride solution, pH 7.3.

Oncaspar should be stored in a refrigerator (2°C – 8°C), and should not be frozen or shaken. Discard any drug that remains unused. Do not use if the solution is cloudy or a precipitate has formed.

Please refer to the SmPC for more information.
**Nelarabine (Atriance)**

**Formulation and storage**

<table>
<thead>
<tr>
<th>Chemical Name:</th>
<th>((2R,3S,4R,5R)-2-(2\text{-amino-6-methoxy-purin-9-yl})-5-(\text{hydroxymethyl})\text{oxolane-3,4-diol})</th>
</tr>
</thead>
<tbody>
<tr>
<td>Other Names:</td>
<td>Nelarabine, Atriance</td>
</tr>
<tr>
<td>Physical Characteristics:</td>
<td>Solution for injection, Clear, colourless liquid</td>
</tr>
</tbody>
</table>

**Description**

Nelarabine is a purine analogue and is provided as a clear, colourless 5mg/ml solution for infusion. Each ml contains 5mg of nelarabine and each vial contains 250mg of nelarabine. This medicinal product does not require any special storage conditions. Nelarabine is stable for up to 8 hours at up to 30°C once the vial is opened. Please refer to the SmPC for more information.

**Administration**

Nelarabine is for intravenous use only and must only be administered under the supervision of a physician experienced in the use of cytotoxic agents. Nelarabine is not diluted prior to administration. The appropriate dose of nelarabine is transferred into polyvinylchloride (PVC) or ethyl vinyl acetate (EVA) infusion bags or glass containers and administered as a two-hour infusion in adult patients.

A dose of 1.5grams/m² should be given by IV on days 1, 3 & 5 following Phase 2 induction treatment.

**Neurological adverse events**

Severe neurological events have been reported with the use of Nelarabine. These events have included altered mental states including severe somnolence, central nervous system effects including convulsions, and peripheral neuropathy ranging from numbness and paresthesias to motor weakness and paralysis. There have also been reports of events associated with demyelination, and ascending peripheral neuropathies similar in appearance to Guillain-Barré Syndrome.

Full recovery from these events has not always occurred with cessation of Nelarabine. Therefore, close monitoring for neurological events is strongly recommended, and Nelarabine must be discontinued at the first sign of neurological events of NCI common Toxicity Grade 2 or greater.
**Palifermin (Kepivance)**

*Formulation and storage*

<table>
<thead>
<tr>
<th>Chemical Name:</th>
<th>Palifermin</th>
</tr>
</thead>
<tbody>
<tr>
<td>Other Names:</td>
<td>Kepivance</td>
</tr>
<tr>
<td>Physical Characteristics:</td>
<td>Solution for injection.</td>
</tr>
</tbody>
</table>

**Description**

Palifermin is a human keratinocyte growth factor (KGF), produced by recombinant DNA technology in *Escherichia coli*. It is provided in a vial with 6.25mg of powder for solution for injection. Each vial contains 6.25 mg of palifermin. Reconstituted Kepivance contains 5 mg/ml of palifermin.

Palifermin should be stored in the original package to protect from light in a fridge (2°C - 8°C). Once reconstituted it can be stored in a fridge (2°C - 8°C), protected from light, for 24 hours.

**Administration**

The standard dosage of Kepivance is 60 micrograms/kg/day, administered as an intravenous bolus injection for three consecutive days before and three consecutive days after myeloablative therapy for a total of six doses (see below). Kepivance should not be administered subcutaneously due to poor local tolerability.

In the collapsed dose schedule the the 1st 3 doses at 60mcg/kg are replaced by one 180mcg/kg dose as an intravenous bolus (see below).

Reconstituted Kepivance should not be left at room temperature for more than one hour, and should be protected from light. Prior to administration, visually inspect the solution for discolouration and particulate matter before administration.

**STANDARD DOSE SCHEDULE:**

A dose of 60micrograms/kg should be given by IV bolus injection on days -10, -9 -8 and, 0, 2 & 4.

**COLLAPSED DOSE SCHEDULE:**

A dose of 180micrograms/kg should be given by IV bolus injection on day -9 and a dose of 60 micrograms/kg should be given on days 0, 2 & 4.
Appendix 3: Non-IMP General Drug information

This appendix is intended as a guide for the administration of non-IMPs in the UKALL14 trial. Those centres with a firm local policy which differs in administration detail (but not dose) from the information provided below may follow their local guidelines.

Body surface area should be calculated according to the Dubois formula:

\[
\text{Body Surface Area (m)} = 0.007184 \times (\text{patient height in cm})^{0.725} \times (\text{patient weight in kg})^{0.425}
\]

Body surface area should be recalculated after each cycle of chemotherapy and with any major weight change.

It is recommended that sites follow local guidelines for dose adjustments for obese patients.

**Drugs used in Induction**

**Cyclophosphamide**

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Powder for solution for injection. A white crystalline powder contained in clear glass injection vials.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Storage</td>
<td>Do not store above 25°C. Store in original container. After reconstitution (for either intravenous or oral administration), store at 2 - 8°C and protect from light.</td>
</tr>
<tr>
<td>Administration</td>
<td>A dose of 1000mg/m² to be given in 250ml sodium chloride 0.9% over 30mins. Give 125 mls/m²/hour of Dextrose/ Saline for 30 minutes before cyclophosphamide and for 3.5 hours afterwards i.e 4 hours in total. Do not add potassium. Mesna is not needed.</td>
</tr>
</tbody>
</table>

**Cytarabine**

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Clear, colourless solution for injection.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Storage</td>
<td>Do not store above 25°C. Keep container in the outer carton.</td>
</tr>
<tr>
<td>Administration</td>
<td>A dose of 75mg/m² to be given at a concentration of 20mg/ml in syringe by slow IV bolus or by IV infusion depending on local practice.</td>
</tr>
</tbody>
</table>

**Dexamethasone**

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Each tablet contains 2mg Dexamethasone PhEur.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Storage</td>
<td>Store below 25°C protected from light.</td>
</tr>
<tr>
<td>Administration</td>
<td>10mg/m² to be given orally in one dose with breakfast.</td>
</tr>
</tbody>
</table>

**Daunorubicin**

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Vial containing a red lyophilised powder for intravenous administration following reconstitution in water for injections and dilution with saline. Each vial contains 21.4 mg Daunorubicin hydrochloride (equivalent to 20 mg as base).</th>
</tr>
</thead>
<tbody>
<tr>
<td>Storage</td>
<td>Daunorubicin vials should be stored below 25°C, protected from light. After reconstitution Daunorubicin should be stored at 2 - 8°C, protected from light.</td>
</tr>
<tr>
<td>Administration</td>
<td>30mg/m² dose to be diluted in sodium chloride 0.9% to give final concentration of 1mg/ml and inject over 20 mins into side arm of freely running intravenous infusion of sodium chloride 0.9%. Alternatively the Daunorubicin may be added to a 100ml minibag of sodium chloride 0.9% and this solution infused over 20 minutes into the side arm of a freely running infusion of sodium chloride 0.9%. Take care to avoid extravasation.</td>
</tr>
</tbody>
</table>
### Imatinib

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Glivec® 100 mg film-coated tablets &amp; Glivec® 400 mg film-coated tablets</th>
</tr>
</thead>
<tbody>
<tr>
<td>Storage</td>
<td>Do not store above 30°C. Store in the original package in order to protect from moisture.</td>
</tr>
<tr>
<td>Administration</td>
<td>The prescribed dose should be administered orally with a meal and a large glass of water to minimise the risk of gastrointestinal irritations. Doses of 400 mg or 600 mg should be administered once daily. For patients unable to swallow the film-coated tablets, the tablets may be dispersed in a glass of mineral water or apple juice. The required number of tablets should be placed in the appropriate volume of beverage (approximately 50 ml for a 100 mg tablet, and 200 ml for a 400 mg tablet) and stirred with a spoon. The suspension should be administered immediately after complete disintegration of the tablet(s).</td>
</tr>
</tbody>
</table>

### Methotrexate

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Methotrexate 2.5mg/ml for intrathecal use</th>
</tr>
</thead>
<tbody>
<tr>
<td>Storage</td>
<td>See relevant SPC</td>
</tr>
<tr>
<td>Administration</td>
<td>12.5mg to be given intrathecally, ensure national guidance on the safe administration of intrathecal chemotherapy is followed (Department of Health).</td>
</tr>
</tbody>
</table>

### Vincristine

<table>
<thead>
<tr>
<th>Formulation</th>
<th>A sterile, colourless solution for injection. Each 1 ml contains 1.0 mg of vincristine sulphate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Storage</td>
<td>Store at 2 - 8°C. Keep container in the outer carton.</td>
</tr>
<tr>
<td>Administration</td>
<td>Ensure NPSA guidance for using Vinca Alkaloid minibags is followed (reference NPSA/2008/RRR 004. When vinca alkaloids are prescribed, dispensed or administered in adult and adolescent units:</td>
</tr>
<tr>
<td></td>
<td>• Doses in syringes should no longer be used.</td>
</tr>
<tr>
<td></td>
<td>• The prescribed dose should be supplied from the hospital pharmacy ready to administer in a 50ml minibag of sodium chloride 0.9%.</td>
</tr>
<tr>
<td></td>
<td>• The following warning should be prominently displayed on the label of ALL vinca alkaloid doses ‘For Intravenous Use Only - Fatal If Administered by Other Routes’.</td>
</tr>
<tr>
<td></td>
<td>• The vinca minibag should be infused intravenously over 5 - 10 minutes and the patient closely monitored for signs of extravasation. Incidents of extravasation should be reported and shared via the National Extravasation Information Service (<a href="http://www.extravasation.org.uk">www.extravasation.org.uk</a>).</td>
</tr>
</tbody>
</table>

### Mercaptopurine

<table>
<thead>
<tr>
<th>Formulation</th>
<th>50mg tablets containing 50mg of Mercaptopurine</th>
</tr>
</thead>
<tbody>
<tr>
<td>Storage</td>
<td>Store below 25ºC. Keep the bottle tightly closed.</td>
</tr>
<tr>
<td>Administration</td>
<td>60 mg/m² orally taken once daily at the same time each day, should be administered at least 1 hour before or 3 hours after food or milk</td>
</tr>
</tbody>
</table>
### Drugs used in Intensification

<table>
<thead>
<tr>
<th><strong>Imatinib</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Formulation</strong></td>
</tr>
<tr>
<td><strong>Storage</strong></td>
</tr>
<tr>
<td><strong>Administration</strong></td>
</tr>
</tbody>
</table>

### Methotrexate - HIGH DOSE

| **Formulation** | 1g or 5g vials |
| **Storage** | As per relevant SPC |
| **Administration** | 3g/m² to be given by IV infusion (see Appendix 15 for high dose Methotrexate guidelines) |

### Drugs used in Consolidation

#### Cyclophosphamide

| **Formulation** | Powder for solution for injection. A white crystalline powder contained in clear glass injection vials. |
| **Storage** | Do not store above 25°C. Store in original container. After reconstitution (for either intravenous or oral administration), store at 2 - 8°C and protect from light. |
| **Administration** | A dose of 650mg/m² given at a concentration of 20mg/ml in syringe by IV bolus |

#### Cytarabine

| **Formulation** | Clear, colourless solution for injection. |
| **Storage** | Do not store above 25°C. Keep container in the outer carton. |
| **Administration** | A dose of 75mg/m² to be given at a concentration of 20mg/ml in syringe by slow IV bolus or by IV depending on local practice. |

#### Daunorubicin

| **Formulation** | Vial containing a red lyophilised powder for intravenous administration following reconstitution in water for injections and dilution with saline. Each vial contains 21.4 mg Daunorubicin hydrochloride (equivalent to 20 mg as base). |
| **Storage** | Daunorubicin vials should be stored below 25°C, protected from light. After reconstitution Daunorubicin should be stored at 2 - 8°C, protected from light. |
| **Administration** | 25mg/m² dose to be diluted in sodium chloride 0.9% to give final concentration of 1mg/ml and inject over 20 mins into side arm of freely running intravenous infusion of sodium chloride 0.9%. Alternatively the Daunorubicin may be added to a 100ml minibag of sodium chloride 0.9% and this solution infused over 20 minutes into the side arm of a freely running infusion of sodium chloride 0.9%. Take care to avoid extravasation. |

#### Dexamethasone

| **Formulation** | Each tablet contains 2.0mg Dexamethasone PhEur. |
| **Storage** | Store below 25°C protected from light. |
| **Administration** | 10mg/m² to be given orally in one dose after breakfast. |

#### Etoposide: HIGH DOSE
<table>
<thead>
<tr>
<th>Formulation</th>
<th>Concentrate for solution for infusion (to dilute).</th>
</tr>
</thead>
<tbody>
<tr>
<td>Storage</td>
<td>Store below 25° C, protected from light (keep vials in the outer carton). Do not freeze. Diluted solutions: Do not store the diluted product in a refrigerator (2 – 8 °C) as this might cause precipitation. Solutions showing any sign of precipitation should not be used.</td>
</tr>
<tr>
<td>Administration</td>
<td>Concentrate for solution for infusion 20 mg/ml must be diluted prior to use with either 5 % dextrose in water, or 0.9 % sodium chloride solution to give a final concentration of 0.2 to 0.4 mg/ml. (or as recommended by manufacturer). Give over at least 30 minutes.</td>
</tr>
</tbody>
</table>

**Imatinib**

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Glivec® 100 mg film-coated tablets &amp; Glivec® 400 mg film-coated tablets</th>
</tr>
</thead>
<tbody>
<tr>
<td>Storage</td>
<td>Do not store above 30°C. Store in the original package in order to protect from moisture.</td>
</tr>
<tr>
<td>Administration</td>
<td>The prescribed dose should be administered orally with a meal and a large glass of water to minimise the risk of gastrointestinal irritations. Doses of 400 mg or 600 mg should be administered once daily. For patients unable to swallow the film-coated tablets, the tablets may be dispersed in a glass of mineral water or apple juice. The required number of tablets should be placed in the appropriate volume of beverage (approximately 50 ml for a 100 mg tablet, and 200 ml for a 400 mg tablet) and stirred with a spoon. The suspension should be administered immediately after complete disintegration of the tablet(s).</td>
</tr>
</tbody>
</table>

**Methotrexate**

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Methotrexate 2.5mg/ml for intrathecal use</th>
</tr>
</thead>
<tbody>
<tr>
<td>Storage</td>
<td>See relevant SmPc</td>
</tr>
<tr>
<td>Administration</td>
<td>12.5mg to be given intrathecally, ensure national guidance on the safe administration of intrathecal chemotherapy is followed (Department of Health).</td>
</tr>
</tbody>
</table>

**Vincristine**

<table>
<thead>
<tr>
<th>Formulation</th>
<th>A sterile, colourless solution for injection. Each 1 ml contains 1.0 mg of vincristine sulphate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Storage</td>
<td>Store at 2 - 8°C. Keep container in the outer carton.</td>
</tr>
</tbody>
</table>
| Administration | Ensure NPSA guidance for using Vinca Alkaloid minibags is followed (reference NPSA/2008/RRR 004. When vinca alkaloids are prescribed, dispensed or administered in adult and adolescent units:  
  - Doses in syringes should no longer be used.  
  - The prescribed dose should be supplied from the hospital pharmacy ready to administer in a 50ml minibag of sodium chloride 0.9%.  
  - The following warning should be prominently displayed on the label of ALL vinca alkaloid doses ‘For Intravenous Use Only – Fatal If Administered by Other Routes’.  
  - The vinca minibag should be infused intravenously over 5 - 10 minutes and the patient closely monitored for signs of extravasation. Incidents of extravasation should be reported and shared via the National Extravasation Information Service (www.extravasation.org.uk). |

**Mercaptopurine**

<table>
<thead>
<tr>
<th>Formulation</th>
<th>50mg tablets containing 50mg of -Mercaptopurine</th>
</tr>
</thead>
<tbody>
<tr>
<td>Storage</td>
<td>Store below 25ºC. Keep the bottle tightly closed.</td>
</tr>
<tr>
<td>Administration</td>
<td>60 mg/m² aken once daily at the same time each day, should be administered at least 1 hour before or 3 hours after food or milk</td>
</tr>
</tbody>
</table>

**Drugs used in Maintenance**

- Methotrexate oral
<table>
<thead>
<tr>
<th>Formulation</th>
<th>2.5mg tablets</th>
</tr>
</thead>
<tbody>
<tr>
<td>Storage</td>
<td>As per relevant SPC</td>
</tr>
<tr>
<td>Administration</td>
<td>20mg/m² to be given orally once a week</td>
</tr>
</tbody>
</table>

**Methotrexate IV**

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Injection</th>
</tr>
</thead>
<tbody>
<tr>
<td>Storage</td>
<td>As per relevant SPC</td>
</tr>
<tr>
<td>Administration</td>
<td>20mg/m² to be given intravenously once a week (as IV bolus or infusion)</td>
</tr>
</tbody>
</table>

**Prednisolone**

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Enteric coated Tablet</th>
</tr>
</thead>
<tbody>
<tr>
<td>Storage</td>
<td>As per relevant SPC</td>
</tr>
<tr>
<td>Administration</td>
<td>60mg/m² by mouth in the morning for 5 days every three months</td>
</tr>
</tbody>
</table>

**Vincristine**

<table>
<thead>
<tr>
<th>Formulation</th>
<th>A sterile, colourless solution for injection. Each 1 ml contains 1.0 mg of vincristine sulphate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Storage</td>
<td>Store at 2 - 8°C. Keep container in the outer carton.</td>
</tr>
<tr>
<td>Administration</td>
<td>Ensure NPSA guidance for using Vinca Alkaloid minibags is followed (reference NPSA/2008/RRR 004. When vinca alkaloids are prescribed, dispensed or administered in adult and adolescent units:</td>
</tr>
<tr>
<td></td>
<td>• Doses in syringes should no longer be used.</td>
</tr>
<tr>
<td></td>
<td>• The prescribed dose should be supplied from the hospital pharmacy ready to administer in a 50ml minibag of sodium chloride 0.9%.</td>
</tr>
<tr>
<td></td>
<td>• The following warning should be prominently displayed on the label of ALL vinca alkaloid doses ‘For Intravenous Use Only – Fatal If Administered by Other Routes’.</td>
</tr>
<tr>
<td></td>
<td>The vinca minibag should be infused intravenously over 5 - 10 minutes and the patient closely monitored for signs of extravasation. Incidents of extravasation should be reported and shared via the National Extravasation Information Service (<a href="http://www.extravasation.org.uk">www.extravasation.org.uk</a>).</td>
</tr>
</tbody>
</table>

**Mercaptopurine**

<table>
<thead>
<tr>
<th>Formulation</th>
<th>50mg tablets containing 50mg of Mercaptopurine</th>
</tr>
</thead>
<tbody>
<tr>
<td>Storage</td>
<td>Store below 25ºC. Keep the bottle tightly closed.</td>
</tr>
<tr>
<td>Administration</td>
<td>75 mg/m² orally aken once daily at the same time each day, should be administered at least 1 hour before or 3 hours after food or milk.</td>
</tr>
</tbody>
</table>

Appendix 3 continued on next page
Drugs used in transplant conditioning regimens

### Alemtuzumab

<table>
<thead>
<tr>
<th><strong>Formulation</strong></th>
<th>MabCampath 30 mg/ml concentrate for solution for infusion</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Storage</strong></td>
<td>Store in a refrigerator (2°C-8°C).&lt;br&gt;Do not freeze.&lt;br&gt;Store in the original package in order to protect from light.&lt;br&gt;Alemtuzumab should be used within 8 hours after dilution. Solutions may be stored at 15°C-30°C or refrigerated. This can only be accepted if preparation of the solution takes place under strictly aseptic conditions and the solution is protected from light.</td>
</tr>
<tr>
<td><strong>Administration</strong></td>
<td>The required amount of the vial contents should be added to 100 ml of sodium chloride 9 mg/ml (0.9%) solution for infusion or glucose (5%) solution for infusion. The bag should be inverted gently to mix the solution. Care should be taken to ensure the sterility of the prepared solution particularly as it contains no antimicrobial preservatives.&lt;br&gt;All doses should be administered by intravenous infusion over approximately 2 hours.&lt;br&gt;Patients should be premedicated with oral or intravenous steroids, an appropriate antihistamine and analgesic 30-60 minutes prior to each alemtuzumab infusion</td>
</tr>
</tbody>
</table>

### Cyclophosphamide: HIGH DOSE

<table>
<thead>
<tr>
<th><strong>Formulation</strong></th>
<th>Powder for solution for injection. A white crystalline powder contained in clear glass injection vials.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Storage</strong></td>
<td>Do not store above 25°C. Store in original container.&lt;br&gt;After reconstitution (for either intravenous or oral administration), store at 2 - 8°C and protect from light.</td>
</tr>
<tr>
<td><strong>Administration</strong></td>
<td>A dose of 60mg/kg to be given, as 20mg/ml cyclophosphamide in sodium chloride 0.9% in empty ethyl vinyl acetate (EVA) bag over 2 hours</td>
</tr>
</tbody>
</table>

### Etoposide:

<table>
<thead>
<tr>
<th><strong>Formulation</strong></th>
<th>Concentrate for solution for infusion (100mg in 5ml vials)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Storage</strong></td>
<td>Room temperature</td>
</tr>
<tr>
<td><strong>Administration</strong></td>
<td>60mg/kg To be given undiluted via central venous catheter over approx 4 hours. Use polyethylene or polyethylene lined line – new line for each syringe, primed with saline. Do not flush line, disconnect at source and use new line for each syringe. An extra 2ml Etoposide is supplied in each syringe to account for Etoposide lost in line.&lt;br&gt;Ensure anti-emetics are prescribed. Ensure patient remains well hydrated.&lt;br&gt;Patient must have a baseline ECG before starting the infusion and be coupled to a cardiac monitor throughout. Regular recordings of pulse and blood pressure should be made throughout the infusion, which can be slowed if necessary. Maintenance of blood pressure using fluid support or colloids may be necessary</td>
</tr>
</tbody>
</table>
### Fludarabine

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Fludara 50mg powder for solution for injection or infusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Storage</td>
<td>See relevant SPC</td>
</tr>
<tr>
<td>Administration</td>
<td>Fludara should be prepared for parenteral use by aseptically adding sterile water for injection. When reconstituted with 2 ml of sterile water for injection, the powder should fully dissolve in 15 seconds or less. Each ml of the resulting solution will contain 25 mg of fludarabine phosphate, 25 mg of mannitol, and sodium hydroxide (to adjust the pH to 7.7). The pH range for the final product is 7.2 - 8.2.</td>
</tr>
<tr>
<td>Dilution</td>
<td>The required dose (calculated on the basis of the patient's body surface) is drawn up into a syringe. For intravenous bolus injection this dose is further diluted in 10 ml sodium chloride 9mg/ml (0.9%). Alternatively, for infusion, the required dose may be diluted in 100 ml sodium chloride 9mg/ml (0.9%) and infused over approximately 30 minutes.</td>
</tr>
</tbody>
</table>

### Melphalan

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Freeze-dried powder for injection.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Storage</td>
<td>Store below 30°C, Protect from light &amp; Do not refrigerate.</td>
</tr>
<tr>
<td>Administration</td>
<td>For intravenous administration, Melphalan Injection solution may be administered diluted in an infusion bag. Melphalan is not compatible with infusion solutions containing dextrose and it is recommended that only sodium chloride intravenous infusion 0.9% w/v is used. When further diluted in an infusion solution, Melphalan has reduced stability and the rate of degradation increases rapidly with rise in temperature. If Melphalan is infused at a room temperature of approximately 25°C, the total time from preparation of the injection solution to the completion of infusion should not exceed 1.5 hours. Should any visible turbidity or crystallisation appear in the reconstituted or diluted solutions, the preparation must be discarded. Hydration and forced diuresis is recommended but not mandatory-please follow your local practice.</td>
</tr>
</tbody>
</table>

Please check relevant Summary Product Characteristics for brand of drug used for storage, special precautions and contraindications, interactions, undesirable effects and stability information.
Appendix 4: Dose modifications for toxicity

Steroids
Hypertension: Steroid should not be reduced. Sodium restriction and anti-hypertensives should be employed in an effort to control hypertension.
Malignant Hypertension: Reduce dose 33%. Sodium restriction and anti-hypertensive drugs may also be utilised.
Hyperglycemia: Steroids should not be reduced if the patient develops clinical signs of diabetes. Rather, insulin therapy should be employed to control the blood glucose level such that symptoms and signs are minimal.
Pancreatitis: Do not modify dose.
Psychosis: Administer half dosage of steroid.
Suspected steroid-induced myopathy: Measure CPK with isoenzymes, consider EMG studies.
Avascular necrosis: Contact CI or clinical coordinators if AVN develops before Maintenance therapy has begun. Omit further steroids if AVN develops during maintenance.
Varicella Zoster: Steroids should be held during active infection except during Induction (Discuss with coordinators). They should not be held during incubation period following exposure to Varicella.
Severe Dexamethasone intolerance - change to Prednisolone 40 mg/m².

Vincristine
Seizures: Hold 1 dose, then reinstitute.
Severe foot drop, paresis or ileus: Hold dose(s); institute aggressive regimen to treat constipation (except enemas if neutropenic), if present. When symptoms abate, resume at 1.0 mg/m²; escalate to full dose as tolerated.
Jaw pain: Treat with analgesics; do not modify Vincristine dose.
Hyperbilirubinemia: Withhold if total bilirubin > 50. Administer 50% of dose if total bilirubin 25 - 50. Do not alter dose for abnormal transaminases.

Asparaginase
Anaphylaxis or anaphylactoid reactions: PEG-asparaginase should be discontinued if the patient develops a Grade 2 - 4 toxicity. Send blood samples to the Adult ALL MRD laboratory for asparaginase antibodies and change to Erwinase (appendix 14).
Symptomatic pancreatitis: Discontinue L-asparaginase in the presence of symptomatic pancreatitis documented by an elevated serum amylase or lipase level or ultrasonographic abnormalities. Do not give further doses if there is a prior history of asparaginase induced pancreatitis.
Hyperglycaemia: Do not modify dose. Administer Insulin as required.
Ketoacidosis: Hold L-Asparaginase until blood glucose can be regulated with insulin.
Coagulopathy: When significant symptomatic coagulopathy occurs, withhold L-asparaginase until resolved. Routine clotting screens are not recommended. Coagulopathy without bleeding is not an indication to withhold L-asparaginase.
Liver Dysfunction: Check LFTs only if patient jaundiced. Withhold if total bilirubin > 50. Do not alter dose for abnormal transaminases.

**Anthracyclines (Daunorubicin)**

Hyperbilirubinemia: If total bilirubin > 120 omit dose; if > 90 but < 120 give 25% of dose. If > 50 but < 90 give 50% of dose, and if < 50 give full dose. Check LFTs only if patient jaundiced. Do not alter dose for abnormal transaminases.

**Intrathecal Methotrexate**

Any significant neurotoxicity not due to lumbar puncture syndrome (low opening pressure, slow CSF flow, orthostatic symptoms) should be reported.

Systemic toxicity: The dosage for Intrathecal Methotrexate will not be reduced for systemic toxicity (myelosuppression, mucositis, etc).

Viral, bacterial or fungal meningitis: Omit until resolved.

Encephalopathy attributed to intrathecal Methotrexate: see appendix.

**Oral Methotrexate**

Mucositis: For grade 2 mucositis of over 3 days duration, decrease MTX dose by 30%. For grade 3-4, mucositis, withhold MTX until resolved; resume at 50% of the previously attained dose and subsequently escalate to 75% to 100% dose at 10 day intervals provided grade 3-4 toxicity does not recur. Consider culturing lesions for herpes simplex if mucositis persists or recurs.

Liver: Check LFT’s only if patient jaundiced. If bilirubin is >50 micromoles/L omit MTX until it is less than 20 micromoles/L, and then restart at half of the previously attained dose. Escalate from 50% to 75% to 100% dose at 10-day intervals provided hyperbilirubinaemia does not recur. Do not modify dosage for elevated aminotransferases.

Kidney (Grade 3-4): Omit MTX until grade 0 toxicity (ie completely resolved). Resume at 100% of the previously attained dose and continue at 10-day intervals.

**Intravenous Methotrexate**

PLEASE SEE APPENDIX 15

**Cyclophosphamide**

Prior history of gross haematuria or microscopic haematuria: Hydrate at 125 ml/m²/hr for 24 hours after dose and use Mesna 360 mg/m² pre, and 4, 7, 11 hours post dose.

Acute Fluid retention: Treat with Frusemide and saline; do not modify dose.

**Cytarabine**

Hyperbilirubinaemia: if total bilirubin > 120 omit dose; if > 90 but < 120 give 25% of dose. If > 50 but < 90 give 50% of dose, and if < 50 give full dose. Check LFT’s only if patient jaundiced. Do not alter dose for abnormal transaminases.
**Mercaptopurine**

Hyperbilirubinaemia: If bilirubin >50micromol/l omit mercaptopurine until it is less than 20micromol/l and then restart at half the previously attained dose. Escalate from 50% to 75% to 100% dose at 10-day intervals provided hyperbilirubinaemia does not recur. Do not modify dosage for elevated aminotransferases.

**Nelarabine**

Nelarabine must be discontinued at the first sign of neurological events of National Cancer Institute Common Terminology Criteria Adverse Event (NCI CTCAE) grade 2 or greater. Delaying subsequent dosing is an option for other toxicities, including haematological toxicity.

**Renal Impairment**

Nelarabine has not been studied in individuals with renal impairment. Nelarabine and 9-β-D-arabinofuranosylguanine (ara-G) are partially renally excreted (see section 5.2 — Renal impairment). There are insufficient data to support a dose adjustment recommendation for patients with a renal clearance of creatinin CrCl less than 50 ml/min. Patients with renal impairment must be closely monitored for toxicities when treated with nelarabine.

**Hepatic Impairment**

Nelarabine has not been studied in patients with hepatic impairment. These patients should be treated with caution.

Patients receiving nelarabine are recommended to receive intravenous hydration according to standard medical practice for the management of hyperuricemia in patients at risk of tumour lysis syndrome. For patients at risk of hyperuricemia, the use of allopurinol should be considered.
Appendix 5: Assessment of GVHD

Graft Versus Host Disease (GVHD) arises due to reactivity of cytotoxic T lymphocytes against recipient cells, through both HLA- and minor histo-incompatibility between the donor and the recipient. After the transplant the reaction usually requires 10 or more days for priming and proliferation of T cells to occur.

GVHD is divided into two forms, each of which tend to produce distinct clinical syndromes:

- Acute GVHD: <100 days post transplant (grades I to IV)
- Chronic GVHD: >100 days post transplant (limited or extensive)

Organ involvement for GVHD should be staged using the criteria outlined in the tables below. Biopsy of each organ site at diagnosis or major change in disease activity will be performed unless clinical circumstances make it impossible.

**Acute GVHD**

Acute graft versus host disease predominantly affects three organs, either singly or together:

- Skin - maculopapular rash, erythema, desquamation
- Gastrointestinal tract - nausea, vomiting, diarrhoea
- Liver - raised alkaline phosphatase, bilirubin, later hepatitis

### Glucksberg criteria for assessment of Acute GVHD: \(\text{Table A}\)

<table>
<thead>
<tr>
<th>Stage</th>
<th>Skin</th>
<th>Liver</th>
<th>Gut</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>rash &lt;25% body</td>
<td>bilirubin 35 - 50 uM/l</td>
<td>Diarrhoea &lt;1 l/day</td>
</tr>
<tr>
<td>2</td>
<td>rash 25-50% body</td>
<td>bilirubin 51-100 uM/l</td>
<td>Diarrhoea 1-1.5 l/day</td>
</tr>
<tr>
<td>3</td>
<td>rash &gt;50% body</td>
<td>bilirubin 101-250 uM/l</td>
<td>Diarrhoea &gt;1.5 l/day</td>
</tr>
<tr>
<td>4</td>
<td>desquamation or bullae</td>
<td>bilirubin &gt;250 uM/l</td>
<td>Pain or ileus</td>
</tr>
</tbody>
</table>

### Glucksberg criteria for assessment of Acute GVHD: \(\text{Table B}\)

<table>
<thead>
<tr>
<th>Grade</th>
<th>Skin stage</th>
<th>Liver stage</th>
<th>Gut stage</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>1-2</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>II</td>
<td>1-3</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>III</td>
<td>2-3</td>
<td>2-3</td>
<td>2-3</td>
</tr>
<tr>
<td>IV</td>
<td>2-4</td>
<td>2-4</td>
<td>2-4</td>
</tr>
</tbody>
</table>
**Chronic GVHD**

Classification scheme for chronic GVHD (Shulman et al.):

| **Limited** |  
| --- | --- |
| Either or both: |  
| 1. Localised skin involvement |  
| 2. Hepatic dysfunction due to chronic GVHD |

| **Extensive** |  
| --- | --- |
| Either: |  
| 1. Generalised skin involvement; or |  
| 2. Localised skin involvement and/or hepatic dysfunction due to chronic GVHD, plus: |  
| a. Liver histology showing chronic aggressive hepatitis, bridging necrosis or cirrhosis; or |  
| b. Involvement of eye: Schirmer’s test with less than 5mm wetting; or |  
| c. Involvement of minor salivary glands or oral mucosa demonstrated on labial biopsy; or |  
| d. Involvement of any other target organ |
Appendix 6: Cytogenetic Definitions and Detection Strategy

Definition and detection of high risk abnormalities

It is essential that conventional G-banded cytogenetics analysis is performed on all trial patients. In addition, FISH or RT-PCR to detect high risk cytogenetic abnormalities will be necessary in all patients with a normal karyotype or failed cytogenetics.

The four cytogenetic subgroups which will be treated as high risk in UKALL14 are:

- Philadelphia chromosome / t(9;22)(q34;q11)/BCR-ABL1
- t(4;11)(q21;q23) / MLL-AFF1
  - NB AFF1 was previously known as AF4 and MLLT2
- low hypodiploidy / near-triploidy (Ho-Tr)
- complex karyotype (CK).

Philadelphia chromosome / t(9;22)(q34;q11)/BCR-ABL1

Patients with Philadelphia positive ALL will receive imatinib in induction in UKALL14 and therefore all patients must be identified as quickly as possible. All patients must be screened by FISH using a dual-colour dual-fusion translocation probe or RT-PCR using standard primers.

t(4;11)(q21;q23) / MLL-AF4:

This translocation is readily detectable by conventional cytogenetics but patients with a normal karyotype or failed cytogenetics must be screened using either RT-PCR using standard primers or the following FISH strategy:

- FISH with a MLL dual colour break apart probe.
- Patients with a MLL split signal pattern should be screened using an appropriate AF4 dual colour break apart probe, unless a t(4;11) is visible cytogenetically. Currently, no AF4 probe is commercially available. Thus we advise the use of a home-grown dual-colour probe comprising the tiling path clones RP11-397E7 and RP11-476C8 which cover the 5’ and 3’ portions of the gene respectively. For further advice please contact the LRCG (see below). If necessary the LRCG will undertake this specific FISH test centrally.

Low hypodiploidy (30-39 chromosomes) / near-triploidy (60-78 chromosomes) (Ho-Tr):

This cytogenetic subgroup comprises two related entities a low hypodiploid clone and its “doubled” near-triploid counterpart [Charrin et al (2004) Blood 104:2444]. Although both entities are usually detectable by conventional cytogenetics occasionally just one is visible. In cases where only the near-triploid clone is visible there may be some confusion with high hyperdiploidy if the karyotype has 60-65 chromosomes. Distinction between the two subgroups can be made on the basis of chromosomes gained and the proportion of tetrasomic chromosomes. In particular, near-triploidy karyotypes in this subgroup are usually
tetrasomic for chromosomes 1, 6, 11 and 18, and are almost always disomic for chromosomes 3, 7 and 15. If there is any doubt in classifying patients please contact the LRCG (see contact details below).

Patients with a normal karyotype or failed cytogenetics should be screened for Ho-Tr using one of the following techniques:

- Flow cytometry to determine the DNA content of the blast cells – cases with Ho-Tr typically display two aneuploid peaks – low hypodiploid (0.7-0.9) and near-triploid (1.4-1.6).
- FISH using the Chromoprobe Multiprobe-I System (CytoCell, www.cytocell.com) or equivalent, which allows the simultaneous enumeration of all chromosomes on a single slide.
- FISH using selected centromeric probes. Defining precise chromosomes to test is difficult as the key feature of this subgroup is the modal chromosome number of the karyotype rather than the gain or loss of any individual chromosome or sets of chromosomes. However, characteristic chromosomes include 1, 6, 11 and 18 which are usually disomic and tetrasomic and 3, 7 and 15 which are usually monosomic and disomic in the low hypodiploid and near-triploid clones respectively.

Complex karyotype (CK):
The definition of a complex karyotype is five or more chromosomal abnormalities in the absence of an established translocation (e.g. t(1;19)(q23;p13), t(11;19)(q23;p13), t(12;21)(p13;q22)/ETV6-RUNX1 etc.) or ploidy subgroup (e.g. low hypodiploidy / near-triploidy, high hyperdiploidy, tetraploidy). Detection is by conventional cytogenetics only. If there is any doubt in classifying patients please contact the LRCG (see contact details below).

Contact details for Leukaemia Research Cytogenetics Group (LRCG)
Dr Anthony V Moorman, 0191 282 1323, anthony.moorman@ncl.ac.uk
Professor Christine J Harrison, 0191 282 1320, christine.harrison@ncl.ac.uk
Ms Claire Schwab, 0191 282 1324, claire.schwab@ncl.ac.uk

Northern Institute for Cancer Research, Level 5, Sir James Spence Institute, Royal Victoria Infirmary, Queen Victoria Road, Newcastle upon Tyne, NE1 4LP
tel: 0191 282 1324 | fax: 0191 282 1326
Appendix 7: Adult ALL MRD Laboratory and trial schedule

The laboratory will quantify MRD by immunoglobulin/T cell receptor generic rearrangements for Ph- ALL and by BCR-ABL quantification for Ph+ ALL.

The Royal Free MRD Lab will be required to charge for MRD Analysis. This will be a standard cost of £3,200 per patient. A reduced fee of £200 will be charged if a marker is not identified. A price list is available upon request.

Request forms

These will be provided by our laboratory. They have been designed to provide sufficient information for each patient to be reliably identified and for MRD results to be correctly interpreted for reporting. It is important that you let us know the blast percentage in the marrow as we need this to interpret the result. It is important to let us know as much immunophenotyping information as you have available, since it assists us to set up the correct MRD marker panel. Please send a Sample Request Form with all samples that are sent to the Royal Free MRD Lab for MRD Analysis and Correlative Science Testing.

MRD sample Collection and Transport

At diagnosis
2 - 5mls of bone marrow from all adults with suspected leukaemia should be placed into EDTA. In patients with peripheral white counts greater than 30 x10⁹/litre, 10 - 20 mls of blood collected into EDTA is also acceptable at diagnosis. Please note that peripheral blood is of no value as an MRD sample at other time points.

Follow Up Samples
5mls of bone marrow should be placed into EDTA at the following timepoints. (Please note peripheral blood is NOT an acceptable alternative for follow-up specimens.)

Samples required: Absolute (taken as standard practice)
Bone Marrow sample following Phase 1 therapy (this is for the secondary end-point of the antibody randomisations and will not be reported)
Bone Marrow sample following Phase 2 induction therapy (this is for the risk stratification and will be reported within 10 working days of specimen receipt to sites. The report will be sent to the Randomising Clinician and a copy sent to UCL CTC who will confirm the patient’s risk status.)

If the MRD result is not available (failed or specimen not sent) patient should be considered standard risk in absence of any other high risk features.

Bone Marrow sample following bone marrow transplant and then at 3 monthly intervals until 2 years post bone marrow transplant or until relapse.
At relapse: We hope that relapse will be infrequent, but if it does occur, we would be pleased to receive a specimen of bone marrow (3-5ml, in EDTA) so that we can identify whether or not the relapse has originated, or not, from the Ig-TCR confirmed clone which we have been using as an MRD marker.

**Transport**

All samples should be packaged appropriately using local packaging and should be sent by courier or by 1st class post to arrive the same day or overnight to the following address:

**Minimal Residual Disease Laboratory**

(URGENT: FAO Lena Rai, Aditi Dey, Bella Patel or Adele Fielding UKALL14 STUDY SAMPLE)

Department of Haematology

Royal Free Campus

UCL School of Medicine

Rowland Hill St

London NW3 2PF

The package should be clearly marked on the outside as "URGENT, FEASIBILITY STUDY SAMPLE"

**Weekend and Bank Holiday Shipments**

For samples taken on a Friday, please store in a fridge until Monday and send via courier or 1st class post.

For samples taken before a Bank Holiday weekend, please store the sample in a fridge until the next working day and send via courier or 1st class post.

**Sample processing**

On receipt of bone marrow aspirates, the MRD laboratory will assign the patient and the sample a unique number according to the standard operating procedure. Cell counts will be recorded and DNA extracted within 48 hours of receipt of the sample. A minimum of 10 micrograms of DNA is required at diagnosis and 5 micrograms for follow-up samples.

**UK MRD Network of Laboratories**

MRD monitoring for this study will be undertaken at the Royal Free Hospital headed by Dr Adele Fielding. This laboratory has recently joined the UK network of MRD laboratories. This network was conceived for the purpose of MRD monitoring for the current UK childhood trial (UKALL 2003) as such it has demonstrated a robust framework for providing quality assured results.

The UK MRD network acts as a virtual single laboratory using a standard operating procedure and centrally distributed reagents to measure MRD by the Real time quantitative (RQ PCR) Allele Specific Oligonucleotide (ASO) PCR method. This technique is considered to be the most widely applicable and sensitive approach to MRD detection in ALL. The network is co-ordinated by clinical and scientific leads based at Bristol Children's Hospital (Dr J Hancock to co-ordinate) and headed by a Steering committee chaired by Professor Nicholas
Cross. It participates in national and European External Quality Assurance schemes under Professor J Van Dongen's direction.

**Funding**

The Royal Free MRD Laboratory will be required to charge participating centres for MRD testing as it has been deemed by CR-UK as an 'excess NHS treatment cost'.
Appendix 8: Donor Peripheral Blood Stem Cell Collection & Return

The donor will be given G-CSF 10 micrograms/kg/day s.c. from day -4 to day 0. Mononuclear cells will be collected by leucapheresis on days 0 and +1. If sufficient cells are harvested on day 0 no further collection is required. The leucapheresis product will be assessed for nucleated cell count, CD34 content and NK and T cell subset content.

NB: It is mandatory to assess the leucapheresis product for nucleated cell count and CD34. Evaluation of other cell subset content (NK cells, T cells) is desirable but it is at the centre’s discretion.

A minimum dose of $2 \times 10^6$ CD34+ cells/kg will be returned to the patient on Day 0 of the transplant. The target dose for returned cells is $> 4 \times 10^6$ CD34+ cells/kg.

G-CSF 5 micrograms/kg s.c. (or 300 micrograms Filgrastim) will be given to the patient from day +6 until neutrophils $> 1 \times 10^9$/l on 2 consecutive days.

Chugai Pharma UK will provide a 25% retrospective reimbursement in stock for rHuG-CSF (Lenograstim) used within the study period.

Please contact medicalaffairs@chugai-pharm.co.uk with regards to making a claim.

Granocyte is available at NHS contract prices through AAH Hospital Service Telephone 0845 607 6699.

Please refer to the SpC for Lenograstim: www.medicines.org.uk
## Appendix 9: Haematopoietic Cell Transplantation-Specific Comorbidity Index

Comorbidity index = sum of scores defined in table below

<table>
<thead>
<tr>
<th>Comorbidity</th>
<th>Definitions</th>
<th>Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arrhythmia</td>
<td>Atrial fibrillation or flutter, sick sinus syndrome, or ventricular arrhythmias</td>
<td>1</td>
</tr>
<tr>
<td>Cardiac</td>
<td>Coronary artery disease*, congestive heart failure, myocardial infarction, or EF≤50%</td>
<td>1</td>
</tr>
<tr>
<td>Inflammatory bowel disease</td>
<td>Crohn’s disease or ulcerative colitis</td>
<td>1</td>
</tr>
<tr>
<td>Diabetes</td>
<td>Requiring treatment with insulin or oral hypoglycaemic, but not controlled with diet alone</td>
<td>1</td>
</tr>
<tr>
<td>Cerebrovascular disease</td>
<td>Transient ischaemic attacks or cerebrovascular accident</td>
<td>1</td>
</tr>
<tr>
<td>Psychiatric disturbance</td>
<td>Depression/anxiety requiring psychiatric consult and/or treatment at the time of transplant</td>
<td>1</td>
</tr>
<tr>
<td>Hepatic (mild)</td>
<td>Chronic hepatitis, bilirubin&gt;ULN to 1.5xULN, or AST/ALT&gt;ULN to 2.5xULN</td>
<td></td>
</tr>
<tr>
<td>Obesity</td>
<td>BMI&gt;35 for adults or with BMI-for-age percentile of ≥95th percentile for children</td>
<td>1</td>
</tr>
<tr>
<td>Infection</td>
<td>Documented infection or fever of unknown aetiology requiring anti-microbial treatment before, during and after the start of conditioning regimen</td>
<td>1</td>
</tr>
<tr>
<td>Rheumatological</td>
<td>SLE, RA, polymyositis, mixed CTD and polymyalgia rheumatica</td>
<td>2</td>
</tr>
<tr>
<td>Peptic ulcer</td>
<td>Requiring treatment</td>
<td>2</td>
</tr>
<tr>
<td>Renal (moderate/severe)</td>
<td>Serum creatinine&gt;2mg/dL†, on dialysis or prior to renal transplantation</td>
<td>2</td>
</tr>
<tr>
<td>Pulmonary (moderate)</td>
<td>DLCO and/or FEV1 66-80% or dyspnœa on slight activity</td>
<td>2</td>
</tr>
<tr>
<td>Prior solid tumour</td>
<td>Treated at any point in the patients history, excluding non-melanoma skin cancer</td>
<td>3</td>
</tr>
<tr>
<td>Heart valve disease</td>
<td>Except asymptomatic mitral valve prolapse</td>
<td>3</td>
</tr>
<tr>
<td>Pulmonary (severe)</td>
<td>DLCO and/or FEV1 ≤65% or dyspnœa at rest or requiring oxygen</td>
<td>3</td>
</tr>
<tr>
<td>Hepatic (moderate/severe)</td>
<td>Liver cirrhosis, bilirubin&gt;1.5xULN, or AST/ALT&gt; 2.5xULN</td>
<td>3</td>
</tr>
</tbody>
</table>


* one or more vessel coronary artery stenoses requiring medical treatment, stent or bypass graft.

† to convert creatinine from mg/dL to μmol/L, multiply by 88.4
## Appendix 10: ECOG performance status

<table>
<thead>
<tr>
<th>Score</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>Asymptomatic and fully active</td>
</tr>
<tr>
<td>1</td>
<td>Symptomatic; fully ambulatory; restricted physically strenuous activity</td>
</tr>
<tr>
<td>2</td>
<td>Symptomatic; ambulatory; capable of self-care; more than 50 percent of waking hours are spent out of bed</td>
</tr>
<tr>
<td>3</td>
<td>Symptomatic; capable of limited self care; spends more than 50 percent of time in bed but not bedridden.</td>
</tr>
<tr>
<td>4</td>
<td>Completely disabled; no self-care; bedridden</td>
</tr>
</tbody>
</table>
## Appendix 11: Schedule of Assessments (including testing for MRD & Correlative Science)

### Table 12.1a: Treatment & Follow up (for Non Transplant patients)

<table>
<thead>
<tr>
<th>Timing</th>
<th>Registration</th>
<th>During Phase 1 treatment (d8 or d4 and d18)</th>
<th>Upon recovery from Phase 1 induction</th>
<th>Upon recovery from Phase 2 induction</th>
<th>During intensification (d2 and d16)</th>
<th>After intensification</th>
<th>After Cycle 1 consolidation</th>
<th>After Cycle 2 consolidation</th>
<th>Before Cycle 3 consolidation</th>
<th>After Cycle 3 consolidation</th>
<th>After Cycle 4 consolidation</th>
<th>During maintenance therapy (every 3 months)</th>
<th>Annual Follow up (until patient death)</th>
<th>2 year follow up appointment</th>
<th>At Relapse</th>
</tr>
</thead>
<tbody>
<tr>
<td>Informed consent</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Full medical history &amp; physical examination</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Height, Weight, &amp; BSA</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ECOG Status</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FBC</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Biochemistry</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bone marrow aspirate &amp; trephine (SENT TO MRD LAB @ ROYAL FREE)</td>
<td>X²</td>
<td>X²</td>
<td>X²</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pregnancy test</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Confirmation of disease diagnosis</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cytogenetics</td>
<td>X³</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lumbar puncture</td>
<td>X³</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Peripheral blood sample- for asparaginase activity (SENT TO MRD LAB @ ROYAL FREE)</td>
<td>X³</td>
<td>X³</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Plasma collected – for asparaginase coagulation activity Stored locally at -80°C (or if not possible, -20°C)</td>
<td>X³</td>
<td>X³</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Assessment of disease status</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Echocardiogram</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>General Health Questionnaire (GHQ-12)</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Late Effects of Treatment Assessment</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Record of AVN or serious cardiac problems</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

1= Bone marrow 3-5ml in EDTA (OR peripheral blood 30-50ml in EDTA if WCC > 30x10⁹/l). (Please see protocol section 8.2.1 & Appendix 7)
2= Bone marrow from biopsy: 3-5ml in EDTA for MRD assessment. (Please see protocol section 8.2.1 & Appendix 7)
3= Cytogenetics/molecular assessment of BCR-ABL and MLL on bone marrow. A copy of the results should be sent to the Leukemia Research Group. (Please see Appendix 6)
4= Lumbar puncture is not required at diagnosis except in the case of suspected central nervous system involvement. (Please see protocol section 5.1)
5= 5ml peripheral blood in a sodium citrate tube (for Asparaginase activity assay and anti-Asparaginase antibodies). (Please see protocol section 8.2.1 & Appendix 7)
6= 4.5ml sample in a sodium citrate tube (filled to the line) (Please see protocol section 8.2.1)
### Table 12.1b Transplant & Follow up (for transplant patients)

Transplant patients should follow the schedule of assessments on the previous page for Phase I & II treatment, and for intensification and at relapse, if applicable.

<table>
<thead>
<tr>
<th>Timing</th>
<th>Pre-Transplant</th>
<th>100 days Assessment</th>
<th>3 monthly assessments for 2 years following transplant</th>
<th>Annual Follow up (until patient death)</th>
<th>2 year follow up appointment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Assessment</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Full medical history &amp; physical examination</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ECOG Status &amp; Karnofsky Performance Status</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Co morbidity Index</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Full blood count with differential</td>
<td>X</td>
<td></td>
<td></td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Biochemistry (including LDH) &amp; assessment of liver and renal function</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pregnancy test, Microbial Titres, Urinalysis &amp; clotting screen (including PT/APTT)</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bone marrow aspirate &amp; trephine (SENT TO MRD LAB @ ROYAL FREE)</td>
<td>X</td>
<td></td>
<td></td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Assessment of cardiac &amp; pulmonary function</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Peripheral blood sample- mini satellite regions (SENT TO MRD LAB @ ROYAL FREE)</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chimerism studies (SENT TO MRD LAB @ ROYAL FREE)</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GVHD Assessment</td>
<td>X</td>
<td></td>
<td></td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Donor Lymphocyte Infusion</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical examination (as necessary)</td>
<td>X</td>
<td></td>
<td></td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Assessment of disease status</td>
<td>X</td>
<td></td>
<td></td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Oral Mucositis Daily Questionnaire (OMDQ)</td>
<td>X</td>
<td></td>
<td></td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Employment status</td>
<td>X</td>
<td></td>
<td></td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Record of AVN or serious cardiac problems</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Echocardiogram</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>General Health Questionnaire (GHQ-12)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Late Effects of Treatment Assessment</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
</tbody>
</table>

1= 3-5ml Bone Marrow in EDTA for MRD assessment. FOR NON MYELOABLATIVE TRANSPLANT PATIENTS ONLY.
2= 20ml blood in EDTA from donor and recipient for assessment of mini-satellite regions
3= 20ml peripheral blood in EDTA for chimerism. FOR NON MYELOABLATIVE TRANSPLANT PATIENTS ONLY.
4= For patients participating in the Palifermin randomisation, ODMQ to be completed daily by all patients during in-patient therapy
Appendix 12: General Health Questionnaire (GHQ-12)

General Health Questionnaire

Name..........................................................

We want to know how your health has been in general over the last few weeks. Please read the questions below and each of the four possible answers. Circle the response that best applies to you. Thank you for answering all the questions.

Have you recently:

1. been able to concentrate on what you’re doing?

   better than usual    same as usual    less than usual    much less than usual
   (0)                  (1)              (2)                (3)

2. lost much sleep over worry?

   Not at all       no more than usual    rather more than usual    much more than usual

3. felt that you are playing a useful part in things?

   more so than usual    same as usual    less so than usual    much less than usual

4. felt capable of making decisions about things?

   more so than usual    same as usual    less than usual    much less than usual

5. felt constantly under strain?

   Not at all       no more than usual    rather more than usual    much more than usual

6. felt you couldn’t overcome your difficulties?

   Not at all       no more than usual    rather more than usual    much more than usual
7. been able to enjoy your normal day to day activities?
more so than usual same as usual less so than usual much less than usual

8. been able to face up to your problems?
more so than usual same as usual less so than usual much less than usual

9. been feeling unhappy or depressed?
not at all no more than usual rather more than usual much more than usual

10. been losing confidence in yourself?
not at all no more than usual rather more than usual much more than usual

11. been thinking of yourself as a worthless person?
not at all no more than usual rather more than usual much more than usual

12. been feeling reasonably happy, all things considered?
more so than usual same as usual less so than usual much less than usual

General Health Questionnaire Scoring

Scoring – Likert Scale 0, 1, 2, 3 from left to right.
12 items, 0 to 3 each item
Score range 0 to 36.
Scores vary by study population. Scores about 11-12 typical.
Score >15 evidence of distress
Score >20 suggests severe problems and psychological distress
Appendix 13:  Oral Mucositis Daily Questionnaire

1. How would you rate your OVERALL HEALTH during the LAST 24 HOURS? (circle one number)
   ![Rating Scale]

2. During the LAST 24 HOURS, how much MOUTH AND THROAT SORENESS did you have? (circle one number)
   - No soreness ———— 0
   - A little soreness ———— 1
   - Moderate soreness ———— 2
   - Quite a lot of soreness ———— 3
   - Extreme soreness ———— 4
   
   If you circled 0, please skip to question 5

3. During the LAST 24 HOURS, how much did MOUTH AND THROAT SORENESS limit you in each of the following activities? (circle one number)
   - Swallowing ———— Not Limited
   - Drinking ———— Limited A Little
   - Eating ———— Limited Some
   - Talking ———— Limited A Lot
   - Sleeping ———— Unable To Do
     ![Limited Activities Table]

4. On a scale of 1 to 10, how would you rate your OVERALL MOUTH AND THROAT SORENESS during the LAST 24 HOURS? (circle one number)
   ![Soreness Scale]

5. During the LAST 24 HOURS, how much DIARRHEA did you have? (circle one number)
   - No diarrhea ———— 0
   - A little diarrhea ———— 1
   - Moderate diarrhea ———— 2
   - Quite a lot of diarrhea ———— 3
   - Severe diarrhea ———— 4
   
   If you circled 0, STOP here

6. On a scale of 1 to 10, how would you rate your OVERALL DIARRHEA during the LAST 24 HOURS? (circle one number)
   ![Diarrhea Scale]
Appendix 14: Guidance on Use of Erwinia Asparaginase (Erwinase®) in patients with systemic reactions to Pegylated-Asparaginase.

1. A licensed preparation of Erwinia Asparaginase (Erwinase®) is now available, thus providing an effective alternative for patients with hypersensitivity to E.Coli Asparaginase.

2. Erwinase® will be marketed and distributed by EUSA Pharma.

3. Erwinase® should be used in place of Pegylated E. Coli Asparaginase in the following circumstances:
   • Systemic hypersensitivity reactions to n Pegylated E.Coli Asparaginase (Oncaspar). This includes patients with generalised rash with or without anaphylactic symptoms, but not those with only local pain or redness at the site of injection.
   • Patients with previously documented systemic reactions to Pegylated E.Coli Asparaginase should receive Erwinase® in any remaining Asparaginase containing courses.

4. Each dose of Pegylated Asparaginase (Oncaspar) should be replaced with 6 doses of 20,000 Units/m² Erwinase® given on Mondays, Wednesdays and Fridays. (or this could be 6 doses q 48 hours if preferred)

5. Erwinase® should be administered by intra-muscular injection. The individual dose may be split between two injection sites if injection volume more than 4ml.

6. Please notify the trials office of patients switching to Erwinase®.

Chemical name - Erwinia L-asparaginase

Other names - ERWINASE®, Crisantaspase (Asparaginase from Erwinia chrysanthemi; Erwinia L-asparaginase)

Formulation - 10,000 Units/vial, Lyophilisate for solution for injection, White lyophilised powder in a vial.

Special warnings and precautions for use

Warnings: Anaphylactic reactions have been observed after the use of Erwinase. Facilities should be made available for management of an anaphylactic reaction, should it occur, during administration. Careful observation is required on re-exposure to L-asparaginase after any time interval, which may increase the risk of anaphylactic reactions occurring.

Careful monitoring before and during therapy is necessary:
• Serum amylose, lipase and/or insulin levels should be monitored to exclude hyperglycaemia and severe pancreatitis. Hyperglycaemia may be treated with insulin, if needed.
• Routine clotting screening may be performed before treatment initiation. If significant symptomatic coagulopathy occurs withhold L-asparaginase treatment until resolved then continue according to protocol.
• Hepatic function tests should be monitored regularly during therapy.

Storage - Store at 2-8°C

Administration - The contents of each vial should be reconstituted in 1 ml to 2 ml of sodium chloride (0.9%) solution for injection. Slowly add the reconstitution solution against the inner vial wall, do not squirt
directly onto or into the powder. Allow the contents to dissolve by gentle mixing or swirling maintaining the vial in an upright position. Avoid froth formation due to excessive or vigorous shaking.

The solution should be clear without any visible particles. Fine crystalline or thread-like wisps of protein aggregates may be visible if shaking is excessive. If there are any visible particles or protein aggregates present the reconstituted solution should be rejected.

The solution should be administered within 15 minutes of reconstitution. If a delay of more than 15 minutes between reconstitution and administration is unavoidable, the solution should be withdrawn into a glass or polypropylene syringe for the period of the delay. The solution should be used within 8 hours.

Give by intra-muscular injection, if the volume is over 4ml the individual dose may be split between two injection sites.

See also SPC at www.medicines.org.uk
Appendix 15: Guideline for the administration of Intravenous High-Dose Methotrexate

Regimen for administration of high-dose methotrexate

NOTE: The guidance for administration of high dose methotrexate is a detailed suggestion for trial participants to follow. It contains all the necessary information to give the drug safely. However, those centres who have a firm local policy in place which differs in administration detail (but not dose) from the suggestions put forward here can administer high dose methotrexate within UKALL14 according to their local policies.

One week before admission for the 1st methotrexate infusion the Creatine Clearance (measured according to local practice) should be determined. The initial Creatinine Clearance before starting methotrexate should ideally be > 100 mls/minute.

Patients with a clearance between 80-100 mls / minute before the first dose of High Dose Methotrexate MUST have a measured Creatinine clearance (24 urine collection) BEFORE the second dose and dose adjustments (as above ) made if the result is less than 80 mls /minute.

Also repeat Creatinine Clearance before the 2nd infusion if there is delayed methotrexate excretion after the first course.

Based on a dose of 3g/m² of Methotrexate and renal function pre-treatment use Dose reductions as follows:

<table>
<thead>
<tr>
<th>CrCl(ml/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>&gt; 80 mls/min</td>
<td>100%</td>
</tr>
<tr>
<td>50-80 mls/min</td>
<td>50 %</td>
</tr>
<tr>
<td>&lt;50 mls/min</td>
<td>0 %</td>
</tr>
</tbody>
</table>

Pre Cycle 2

<table>
<thead>
<tr>
<th>CrCl(ml/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>&gt; 50 mls/min</td>
<td>100%</td>
</tr>
<tr>
<td>&lt;50 mls/min</td>
<td>0 %</td>
</tr>
</tbody>
</table>

Consult the TMG if in any doubt regarding the high dose methotrexate.

METICULOUS ATTENTION SHOULD BE PAID AT ALL TIMES TO CHANGES IN CREATININE CLEARANCE DURING THE HIGH DOSE METHOTREXATE PHASE. (BOTH WITHIN AND BETWEEN EACH COURSE OF METHOTREXATE).

On admission for each methotrexate infusion, measure:

- Serum creatinine
- Bilirubin and AST or ALT
- Plasma sodium and potassium
- FBC
Guidelines for dosing high dose methotrexate in Liver impairment

<table>
<thead>
<tr>
<th>Bilirubin (micromol/L)</th>
<th>AST</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;50</td>
<td>And &lt; 180</td>
<td>100%</td>
</tr>
<tr>
<td>51-85</td>
<td>Or &gt; 180</td>
<td>75%</td>
</tr>
<tr>
<td>&gt; 85</td>
<td></td>
<td>Contraindicated</td>
</tr>
</tbody>
</table>

It is expected that patients receiving high dose methotrexate will develop hypertransaminasemia and occasionally hyperbilirubinemia. These elevations can last up to 2 weeks following the methotrexate infusion and are not considered toxicities requiring discontinuation of repeated administration of methotrexate. Persistent hyperbilirubinemia and/or grade 3-4 hypertransaminasemia for longer than 3 weeks should result in discontinuation of the drug. Dose reduce, particularly in patients with concomitantly impaired renal function. The drug is contraindicated in severe hepatic impairment.

**Pre-hydration** - For at least 6 hours prior to the commencement of the intravenous methotrexate.

**Hydration fluid** - 1 litre dextrose saline to which has been added 50 mmol sodium bicarbonate and 20 mmol potassium chloride.

**Infusion rate** - 125 ml/m²/hour.

**Check urine pH** - Adjust the sodium bicarbonate concentration to maintain the urinary pH between 7 and 8 (i.e. alkaline). A urinary pH of 7.5 or greater must be achieved before starting the methotrexate infusion. Alternating bags of sodium chloride 0.9% and glucose 5% is acceptable.

**HIGH-DOSE METHOTREXATE INFUSION**

**Methotrexate dose**

Methotrexate 3 g/m² with:
- 10% (i.e. 300 mg/m²) given over 1 hour (loading dose) in 200 mls sodium chloride 0.9%
- 90% (i.e. 2700 mg/m²) given over next 23 hours in 1 litre sodium chloride 0.9%

**NOTE:** The infusion of methotrexate must always stop at 24 hours even if not completed for any reason.

**FOLIC ACID RESCUE MUST START AT 36 HOURS FROM THE START OF METHOTREXATE.**

The first dose of folic acid (to be given at 36 hours after the start of methotrexate infusion) must be written up at the time of prescribing the methotrexate infusion.

**Dosage of folic acid:**

At 36 hours: Give 15 mg/m² iv.

36-48 hours: Give 15 mg/m² iv every 3 hours.

From then on: Give doses as per table below until methotrexate level is less than 0.1micromol/litre.

**Monitoring of plasma methotrexate levels following infusion.**

Times given are from time 0 (time of starting intravenous methotrexate infusion). The following plasma samples are required for patient’s safe rescue with folic acid: 48 hours, 72 hours, and then every 24 hours until methotrexate level is less than 0.1micromol/litre

**Table for the calculation of folic acid rescue on the basis of MTX plasma levels.**

<table>
<thead>
<tr>
<th>Time after starting MTX</th>
<th>MTX plasma concentration (micromol/litre)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>&lt;0.1</td>
</tr>
<tr>
<td>48h</td>
<td>None</td>
</tr>
</tbody>
</table>
Notes

a  No extra folinic acid is required provided MTX levels are below 0.1 micromol/litre at 48h.
b  Dose and schedule of folinic acid: q6h = every 6 hours.
c  At time points after 120h folinic acid administration should be continued as recommended for 120h.

Hydration regimen during and after completion of intravenous methotrexate infusion

Continue to infuse at a rate of 125 ml/m²/hour for a minimum of 48 hours after start of methotrexate with:
1L dextrose saline containing 50 mmol of sodium bicarbonate and 20 mmol potassium chloride.
Alternating bags of sodium chloride 0.9% and glucose 5% is acceptable.
Continue to ensure that urinary pH is above 7 by adjusting sodium bicarbonate dose.

After 48 hours from the start of the intravenous methotrexate, ENSURE a combined oral and/or intravenous intake greater than 3 litres/m²/24 hours until plasma methotrexate levels<0.1 micromols/litre.

Check fluid balance at regular intervals (at least 4-hourly) through each day, taking early action if fluid overload occurs by giving furosemide if the urine output falls below 400 ml/m² in any given 4-hour period.

Other investigations during folinic acid rescue:
Daily Creatinine, sodium and potassium.
Alternate days Bilirubin, AST, ALT, albumin, full blood count.

These investigations should also be checked at least twice during the week following the first and second methotrexate infusion to detect any toxicity that might occur.

Conversion table for methotrexate levels expressed in different units

<table>
<thead>
<tr>
<th>Molar (M)</th>
<th>μmol/l</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 x 10⁻³</td>
<td>1013.0</td>
</tr>
<tr>
<td>2 x 10⁻⁴</td>
<td>202.0</td>
</tr>
<tr>
<td>1 x 10⁻⁴</td>
<td>101.0</td>
</tr>
<tr>
<td>2 x 10⁻⁵</td>
<td>20.0</td>
</tr>
<tr>
<td>1 x 10⁻⁵</td>
<td>10.1</td>
</tr>
<tr>
<td>2 x 10⁻⁶</td>
<td>2.0</td>
</tr>
<tr>
<td>1 x 10⁻⁶</td>
<td>1.01</td>
</tr>
<tr>
<td>2 x 10⁻⁷</td>
<td>0.2</td>
</tr>
<tr>
<td>1 x 10⁻⁷</td>
<td>0.10</td>
</tr>
</tbody>
</table>

Drug interactions

Drugs which compromise renal function eg. aminoglycosides and cisplatin can decrease clearance of methotrexate and lead to systemic toxicity. Avoid concurrent use of Non steroidal anti inflammatories (NSAI�s) including salicylates and sulphonamides.

Large doses of penicillin may interfere with the active renal tubular secretion of methotrexate.

It is recommended that prophylactic co-trimoxazole be stopped one week before high dose MTX therapy, until maintenance therapy starts.
### Appendix 16- Karnofsky Performance Status

#### Karnofsky Performance Status Scale Definitions Rating (%) Criteria

<table>
<thead>
<tr>
<th>Rating</th>
<th>Criteria</th>
<th>Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>100</td>
<td>Normal no complaints; no evidence of disease.</td>
<td>100</td>
</tr>
<tr>
<td>90</td>
<td>Able to carry on normal activity; minor signs or symptoms of disease.</td>
<td>90</td>
</tr>
<tr>
<td>80</td>
<td>Normal activity with effort; some signs or symptoms of disease.</td>
<td>80</td>
</tr>
<tr>
<td>70</td>
<td>Cares for self; unable to carry on normal activity or to do active work.</td>
<td>70</td>
</tr>
<tr>
<td>60</td>
<td>Requires occasional assistance, but is able to care for most of his personal needs.</td>
<td>60</td>
</tr>
<tr>
<td>50</td>
<td>Requires considerable assistance and frequent medical care.</td>
<td>50</td>
</tr>
<tr>
<td>40</td>
<td>Disabled; requires special care and assistance.</td>
<td>40</td>
</tr>
<tr>
<td>30</td>
<td>Severely disabled; hospital admission is indicated although death not imminent.</td>
<td>30</td>
</tr>
<tr>
<td>20</td>
<td>Very sick; hospital admission necessary; active supportive treatment necessary.</td>
<td>20</td>
</tr>
<tr>
<td>10</td>
<td>Moribund; fatal processes progressing rapidly.</td>
<td>10</td>
</tr>
<tr>
<td>0</td>
<td>Dead</td>
<td>0</td>
</tr>
</tbody>
</table>
## Appendix 17: Protocol Version History

<table>
<thead>
<tr>
<th>Version no.</th>
<th>Date</th>
<th>Amendment no.</th>
<th>Section (no./ title)</th>
<th>Summary of main changes from previous version.</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.0</td>
<td>11nov09</td>
<td>n/a</td>
<td>n/a</td>
<td>n/a</td>
</tr>
<tr>
<td>2.0</td>
<td>17may10</td>
<td>2</td>
<td></td>
<td>Change to Palifermin Dosing Schedule. Guidance added for following local policy for non IMP appendix, MTX appendix. Other minor administrative changes.</td>
</tr>
<tr>
<td>3.0</td>
<td>18aug10</td>
<td>19.08.2010</td>
<td></td>
<td>Removal of Epratuzumab. Other minor administrative changes.</td>
</tr>
<tr>
<td>4.0</td>
<td>24.04.12</td>
<td>24.04.12</td>
<td></td>
<td>Urgent Safety Measure to amend the doses of Daunorubicin and Pegylated Asparaginase.</td>
</tr>
<tr>
<td>5.0</td>
<td>20.07.12</td>
<td>03.08.12</td>
<td></td>
<td>The age range was amended to include patients aged between 19-24 (Philadelphia Positive patients only) An additional blood sample (4.5ml) is to be collected for further analysis. Other minor administrative changes throughout.</td>
</tr>
</tbody>
</table>